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HIV infection and AIDS
The first cases of the acquired immunodeficiency syndrome (AIDS) were described 
in homosexual men in the United States in 1981 (1;2). In 1983, the human immuno-
deficiency virus I (HIV-1), a retrovirus which belongs to the subfamily of lentire-
troviruses, was identified as the causative agent of AIDS (3;4). The virus infects 
CD4 cells of the human immune system, which are used as host cells for virus 
replication. These CD4 lymphocytes are eventually destroyed which causes 
immuno deficiency (5). HIV-2 is another retrovirus, mostly prevalent in West-Africa, 
but appears to be less pathogenic as compared to HIV-1 (6).
Transmission of HIV can be caused by unprotected sexual intercourse, blood 
 transfusion of HIV-infected blood, intravenous drug use with contaminated needles, 
and by infection from mother-to-child during pregnancy, delivery and breast-
 feeding.
Since the recognition of AIDS in 1981 over 25 million people were killed, making it 
one of the most destructive epidemics in history. It is estimated that by the end of 
2006 about 39.5 million people worldwide were living with HIV: 37.2 million adults 
(17.7 million women) and 2.3 million children. In 2006, 4.3 million people were newly 
infected and 2.9 million patients died from AIDS (7). So, the pandemic is still sprea-
ding and there is a clear need for worldwide intensifying and optimising of HIV-
prevention and treatment. This thesis deals with optimisation of Clinical 
 pharmacology of ritonavir-boosted antiretroviral regimens in HIV-treatment.
Antiretroviral agents
In 1987, the first drug to treat HIV and AIDS was introduced: zidovudine, a 
 nucleoside reverse transcriptase inhibitor (8). The introduction of protease 
 inhibitors in 1996 meant a turnaround in the treatment of HIV/AIDS. Thereafter, 
combinations of antiretroviral drugs from different antiretroviral drug classes were 
used to treat HIV-infected patients.
Now, there are four main classes of antiretroviral agents available: nucleoside 
reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase 
 inhibitors (NNRTIs), protease inhibitors (PIs), and fusion or entry inhibitors (Table 1). 
Each of the drug classes attack the virus in a different way. 
Current guidelines for the treatment of HIV/AIDS recommend the combination of at 
least three different antiretroviral agents in a highly active antiretroviral therapy 
(HAART) regimen. Two nucleoside reverse transcriptase inhibitors should be given 
in combination with either a non-nucleoside reverse transcriptase inhibitor or a 
protease inhibitor. The use of HAART is associated with a decline in morbidity and 
mortality in HIV-infected patients (9). 
Nucleoside and nucleotide reverse transcriptase inhibitors
Nucleoside reverse transcriptase inhibitors are prodrugs and must be metabolized 
intracellularly by kinases to exert their activity. Nucleoside reverse transcriptase 
inhibitors undergo intracellular phosphorylation to form active dideoxynucleoside 
Table 1  Overview of worldwide licensed antiretroviral agents 
NRTIs NNRTIs PIs Fusion Inhibitors
Abacavir Delavirdine Atazanavir Enfuvirtide
Didanosine Efavirenz Darunavir 
Emtricitabine Nevirapine Fosamprenavir  
Lamivudine  Indinavir 
Tenofovir  Lopinavir 
Stavudine  Nelfinavir 
Zalcitabine  Ritonavir 
Zidovudine  Saquinavir 
  Tipranavir 
NRTIs: nucleoside reverse transcriptase inhibitors; NNRTIs: non-nucleoside reverse 
transcriptase inhibitors; PIs: protease inhibitors
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analog triphosphates. These active triphosphates compete with the cell’s 
endogenous deoxynucleoside triphosphates for binding to reverse transcriptase. 
Hereby, nucleoside reverse transcriptase inhibitors inhibit the replication of HIV 
(10). In 2001, the first nucleotide analogue, tenofovir, was approved by the Food 
and Drug Association (FDA) of the United States. The difference between 
nucleoside analogues and tenofovir is, that nucleoside analogues must be 
tri-phosphorylated while tenofovir, which already possesses one phosphonate 
group, must be di-phosphorylated intracellularly to exert its activity (11-13). 
Non-nucleoside reverse transcriptase inhibitors
Non-nucleoside reverse transcriptase inhibitors induce allosteric changes in the 
reverse transcriptase of HIV-1, because of which this enzyme is incapable of 
converting viral RNA to DNA. Unlike nucleoside reverse transcriptase inhibitors, 
non-nucleoside reverse transcriptase inhibitors do not require sequential 
phosphorylation to elicit antiretroviral activity (13;14).
Protease inhibitors
Protease inhibitors are inhibitors of the protein HIV-protease. They prevent cleavage 
of gag and gag-pol protein precursors in infected CD4 cells. Thus, by inhibiting 
HIV-protease, protease inhibitors block the maturation and reproduction of nascent 
virions (15). Since the licensing of indinavir, ritonavir and saquinavir in 1996, several 
other protease inhibitors have been developed and introduced (8;13).
Fusion or entry inhibitors
Enfuvirtide is the first approved drug of a new class of antiretroviral agents, the 
fusion inhibitors. Enfuvirtide was approved in 2003 (16). It is a synthetic peptide 
which binds to the HIV-glycoprotein 41 (gp41), blocking fusion of the viral and 
cellular membranes (13;17). Enfuvirtide needs to be administered subcutaneously 
(16).
Trias of patient, drug and virus
For antiretroviral therapy to be effective three parameters are important: the patient, 
the drug and the virus (18).
Treatment outcomes are not only dependent on the potency of the given regimen, 
but also on the tolerability and on the adherence of the patients to the chosen 
regimens. It has been estimated that compliance must be over 95% for all 
antiretroviral drugs to maintain durable suppression of HIV in more than 80% of 
patients (19-21). Therefore, adherence is considered equal in importance to the 
potency of the regimen.
Another important parameter is the antiretroviral drug itself and its plasma drug 
concentration. Even when patients are adherent, drug concentrations can differ 
inter-individually, because of differences in patients’ pharmacokinetics. For protease 
inhibitors and non-nucleoside reverse transcriptase inhibitors target trough 
concentrations have been determined (22). In the Netherlands, therapeutic drug 
monitoring (TDM) is used routinely to determine whether the plasma drug 
concentrations are within the therapeutic window. Depending on the measured 
plasma drug concentrations, dose adjustments are advised, so TDM is used as an 
aid to optimise response to antiretroviral drugs (23).
The final parameter is the virus. HIV can become resistant to certain drugs if the 
virus is not adequately suppressed during virological failure or non-adherence. 
The occurrence of resistance is associated with specific mutations in viral genes. 
The occurrence of resistance may limit the treatment options for a patient, while 
cross-resistance exists between antiretroviral agents within drug classes.
Ritonavir-boosted antiretroviral regimens as 
central theme of this thesis
This thesis handles about protease inhibitors and about ritonavir, especially. 
Protease inhibitors have contributed markedly to the improvement in HIV progression 
and prognosis for HIV-infected patients by their effects on viral replication and 
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immune reconstitution. However, early studies reported 40-60% virological failure 
rates after one year of protease inhibitor-containing antiretroviral therapy (24). 
Part of the failure in viral suppression can be explained by poor adherence as a 
result of pharmacokinetic limitations of the protease inhibitors. As single agents, 
protease inhibitors have several pharmacokinetic limitations, which includes a 
short half-life, therefore requiring frequent dosing and a high pill burden. Moreover, 
they have a modest and variable bioavailability which is influenced by food. Several 
protease inhibitors, such as saquinavir, nelfinavir, lopinavir (capsules), atazanavir, 
tipranavir (13), and darunavir (25), have to be taken with food to increase exposure. 
Other factors which can cause subtherapeutic plasma levels resulting in virological 
failure are: extensive first pass metabolism by the cytochrome P450 system (mainly 
by CYP 3A4 and 3A5), high protein binding, variable efflux by P-glycoprotein and 
interaction with other therapies (24;26).
The use of protease inhibitors is associated with several adverse events. 
Furthermore, because protease inhibitors have a small therapeutic window, 
toxicities can occur as a result of high plasma concentrations. The most commonly 
occurring adverse events of the currently licensed protease inhibitors are described 
in Table 2.
The clinical efficacy of triple antiretroviral drug combinations, including a protease 
inhibitor have been convincingly demonstrated during the recent years with long 
Table 2  General characteristics of protease inhibitors (13;25) 
Generic name Usual dosage Food effect Major adverse effects Additional comments
Atazanavir 400mg QD or   Take with food and avoid antacids  Hyperbilirubinaemia, rash, prolongation  Lowest risk of hyperlipidemia among protease
 300mg QD + 100mg RTV QD to increase bioavailability of PR interval, gastrointestinal inhibitors; Avoid proton pump inhibitors; Use only
 in treatment-experienced patients    boosted ATV if taking tenofovir
Darunavir 600mg BID + 100mg RTV BID Take with meals Gastrointestinal, headache, dizziness, 
   hypertriglyceridaemia, anorexia, insomnia 
Fosamprenavir 700mg BID + 100mg RTV BID or With or without food Rash, gastrointestinal, hyperglycaemia, 
 1400mg QD + 200mg RTV QD  headache, hepatotoxicity
Indinavir 800mg TID or   Unboosted on empty stomach; Nephrolithiasis, hyperbilirubinaemia,  
 400/600/800mg BID + 100mg RTV BID Booster with or without food gastrointestinal, insulin resistance, 
   hyperglycaemia, hyperlipidemia, hepatotoxicity
Lopinavir/ritonavir 400/100mg BID or 800/200mg QD Take with meals Gastrointestinal, hyperlipidemia, elevated 
   transaminases, hyperglycaemia, hepatotoxicity 
Nelfinavir 750mg TID or 1250mg BID Take with meals Gastrointestinal, hyperglycaemia, hyperlipidemia,  Has an active metabolite (M8); Cannot be reliably 
   hepatotoxicity boosted by RTV
Ritonavir 600mg BID when used as sole PI Take with meals Gastrointestinal, paresthesia, taste perversion,  Most potent CYP450 inhibitor; Currently only used for 
   hyperlipidemia, hyperglycaemia, hepatotoxicity its pharmacokinetic enhancement properties
Saquinavir (SGC) 1200mg TID or   Take with fatty snacks or meal Gastrointestinal, hepatotoxicity, hyperglycaemia
 1000mg BID + 100mg RTV BID   
Tipranavir 500mg BID + 200mg RTV BID Take with food Hepatotoxicity, rash, hyperlipidemia,  Cannot be combined with many other protease 
  Bioavailability increased with high-fat meal  hyperglycaemia, gastrointestinal inhibitors
ATV: atazanavir; BID: twice daily; CYP450: cytochrome P450; PI: protease inhibitor; QD: once daily;  
RTV: ritonavir; SGC: soft gel capsules; TID: three times daily
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periods of follow-up (24;27). Nowadays, also double boosted protease inhibitors 
(two protease inhibitors in combination with ritonavir), are successfully used in 
heavily-pretreated HIV-infected patients (26).
An overview of the general characteristics of the currently available protease 
inhibitors is shown in Table 2.
Ritonavir as booster
After licensing, ritonavir was used solely administered in a dose of 600 mg twice 
daily (BID), but was the least well tolerated protease inhibitor, with nausea, diarrhea, 
taste alterations, and paresthesia as commonly reported adverse events (28;29). 
Lower dosages appeared to be much better tolerated than the approved dose. 
Ritonavir is a potent inhibitor of CYP3A4 and was chosen as a pharmacokinetic 
enhancer (in other words: as booster) to increase drug concentrations of other 
protease inhibitors (30). The lowest dosage of ritonavir necessary to achieve the 
booster effect is mostly 100 mg BID. Co-administration of low-dose ritonavir in a 
low dose of 100-200 mg once daily (QD) or BID, as a booster, has been successfully 
adopted as a strategy to improve the pharmacokinetic profile of protease inhibitors. 
This has become standard of care in the therapeutic management of HIV-infection. 
The advantages of boosting include raising protease inhibitors’ trough 
concentrations, diminishing interpatient variability, prolonging drug half-life to allow 
twice-daily and possibly once-daily dosing, and diminishing food requirements 
and tablet volume. In addition, increases in drug exposure may potentially enable 
inhibition of the virus in the presence of reduced sensitivity (30). 
So nowadays, most protease inhibitors (saquinavir, indinavir, lopinavir, fosam-
prenavir, atazanavir, tipranavir and darunavir) are used in combination with ritonavir 
to increase the exposure of the co-administered protease inhibitor. By inhibition of 
the enzyme CYP3A4 ritonavir increases the area under the concentration-time 
curve (AUC) of other protease inhibitors enormously. For example, co-administration 
of 400 mg of lopinavir and 50 mg of ritonavir increased the area under the lopinavir 
plasma concentration-time curve by 77-fold in healthy volunteers (31).
Below the following three objectives of this thesis are discussed: ritonavir and 
once-daily dosing; ritonavir and drug-drug interactions; and ritonavir and 
resistance.
1. Ritonavir and once-daily dosing
As described above, a disadvantage of the treatment with protease inhibitors is the 
high pill burden. Moreover, protease inhibitors have a short half-life, because of 
which they were initially dosed twice or thrice daily. Adherence plays an important 
role in the success of the antiretroviral regimen, as shown previously. The 
complexity of the dosage regimen and a high pill burden are very important factors 
in adherence to a HAART regimen. Simplification of the HAART regimen into a 
once-daily regimen will probably increase adherence. Several studies showed that 
once-daily regimens improve adherence, while maintaining virological efficacy 
(32;33). Chapter 1 describes the pharmacokinetics of a once-daily regimen of 
lopinavir/ritonavir in HIV-1-infected children. Chapter 2 focuses on the virological 
effect and safety of once-daily dosing of lopinavir/ritonavir in HIV-infected children 
during a 12-month follow up. In Chapters 1 and 2, it is determined whether the 
boosting effect of ritonavir is potent enough to assure therapeutic exposure to 
lopinavir during the 24-hour dosing interval in children. 
2. Ritonavir and drug-drug interactions
Since the introduction of protease inhibitors and HAART regimens, HIV-infection 
has changed from a fatal to a chronic disease resulting in a decrease in morbidity 
and mortality. HIV-infected patients nowadays are living longer than before the 
introduction of HAART and treatment of co-morbidity and (long-term) adverse 
events are becoming more important issues. Therapeutic treatment of co-morbid 
diseases or adverse events may complicate the treatment of HIV-infection, because 
of the occurrence of drug-drug interactions. 
Co-morbid diseases such as seizure disorders (34;35), neuropathic pain (34-37) 
and depression (38) occur frequently in HIV-infected patients and need to be 
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treated to increase the quality of life. HIV-infected patients may have an increased 
risk for the development of depression, due to social stigmatization, loss of friends 
to HIV disease, isolation of social support, and other factors. The lifetime prevalence 
of depression in HIV-infected patients has been estimated at 22-45% (reviewed by 
(38)) which is higher than for the general, non-infected population (13-20%). As a 
result frequent use of antidepressants occurs in HIV-infected patients. Furthermore, 
seizure disorders may complicate HIV disease, either as a direct result of HIV or as 
a manifestation of a secondary opportunistic infection (34;35). Retrospective 
studies estimate that 11% to 17% of HIV-infected patients will have seizures 
sometime during their course. Finally, symptomatic neuropathies occur in 
approximately 10% to 15% of HIV-1-infected patients overall and pathological 
evidence of peripheral nerve involvement is present in virtually all end-stage AIDS 
patients. Distal sensory polyneuropathy (DSP) is the most common among HIV-1-
associated neuropathies (39). Approximately one-third of the patients with HIV/
AIDS have DSP, characterized by pain, numbness and burning primarily in the soles 
and dorsum of the feet (36;37).
An example of a frequently occurring adverse event when using protease inhibitors, 
is the development of hyperlipidemia (40), which is reported to be associated with 
an increased risk of myocardial infarction (41).
Ritonavir is a potent inhibitor of cytochrome P450 (CYP450) enzymes and inhibits 
CYP3A4, CYP2D6, CYP2C9, CYP2C19 and others, when given in a high dosage of 
400-600 mg BID (28;29). When used in a high dose, ritonavir is also expected to 
induce glucuronidation (42;43). Furthermore, ritonavir is a substrate for CYP3A4 
and a minor one for CYP2D6 (28;29). Because ritonavir is extensively metabolized 
and affects CYP450 liver enzymes and glucuronidation, it is an important objective 
for drug-drug interactions. Most trials have studied the effects of high dose 
ritonavir, but the effect of low dose ritonavir is less well-studied.
Based on the above, we investigated the potential drug-drug-interactions of 
ritonavir-boosted protease inhibitors with lamotrigine (Chapter 4) and paroxetine 
(Chapter 5), used for epilepsy/neuropathic pain and depression, respectively. 
We investigated the combination of lopinavir/ritonavir and lamotrigine because the 
latter undergoes biotransformation by hepatic glucuronidation by UDP-glucuronyl-
transferases, with the 2N-glucuronide as the principal metabolite (44). 
As mentioned previously, high dose ritonavir can induce glucuronidation of other 
medications, but for low dose ritonavir there are no clear data available about the 
influence on glucuronidation. For a combination of fosamprenavir/ritonavir and 
paroxetine was chosen, because the Summary of Product Characteristics of 
Norvir® (ritonavir) (28) states that concomitant use of CYP2D6 substrates (such as 
paroxetine) and ritonavir is not allowed unless the risk and benefit of this 
combination is evaluated. The effect of low dose ritonavir on paroxetine had not 
been established.
In Chapter 3, the lipid-lowering effect of rosuvastatin in hyperlipidaemic HIV-1-
infected patients on lopinavir/ritonavir and the pharmacokinetics of the combination 
of lopinavir/ritonavir and rosuvastatin were studied. We have chosen to perform this 
study because hyperlipidemia can be treated with statins, but the concomitant use 
of statins with protease inhibitors has been hampered by the occurrence of drug-
drug interactions. Most statins are metabolized by cytochrome P450, while protease 
inhibitors are strong inhibitors of this enzyme. Rosuvastatin is a new statin which is 
not metabolized by this enzyme and is therefore expected not be subject to a drug-
drug interaction with lopinavir/ritonavir. The concomitant use of rosuvastatin with 
lopinavir/ritonavir had not been investigated previously. 
3. Ritonavir and resistance
The emergence of resistance and broad cross-resistance of the human 
immunodeficiency virus to protease inhibitors is a significant barrier to successful 
long-term suppression of viral replication (45-47). The development of resistance to 
protease inhibitors is considered as a gradual increase in the inhibitory concentration 
needed to suppress viral replication. The effectivity of protease inhibitors could 
therefore be dependent on the drug plasma levels in relation to the level of resistance 
of the virus (48;49). The concept of the inhibitory quotient has recently been 
introduced in the treatment of HIV-infected patients (48;50-53). This concept utilizes 
the idea that development of resistance is a relative phenomenon, and that 
increased drug concentrations of antiretroviral agents can overcome resistance of 
the HIV-virus, as long as the drug concentrations remain clinically acceptable. 
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The Genotypic Inhibitory Quotient (GIQ) is expressed as the ratio of the plasma 
trough concentration of an antiretroviral agent and the number of relevant protease 
mutations and is a predictive marker of response to HIV-treatment (52;54;55). The 
GIQ might be a helpful tool in setting individual target drug plasma levels for a 
virological response to treatment.
Chapter 6 describes a retrospective study to determine the association of the GIQ 
of lopinavir with virological response and to determine a cut-off value for the 
GIQ. In Chapter 7, the implementation of GIQ for fosamprenavir in patient care is 
discussed.
Objectives of this thesis
This thesis presents studies that were undertaken to optimise the Clinical 
pharmacology of ritonavir-boosted antiretroviral regimens in HIV-treatment. 
This thesis can be divided in three parts which each assess important issues 
concerning ritonavir-boosted regimens. In Part I, once-daily dosing for simplification 
of antiretroviral therapy is described. Part II deals with pharmacokinetic drug-drug 
interaction studies and Part III focuses on the newly introduced GIQ concept which 
combines data on resistance and drug concentration. Finally, a General Discussion 
is presented.
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Chapter 1
Pharmacokinetics of a once-daily 
regimen of lopinavir/ritonavir in 
HIV-1-infected children
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Abstract
Introduction
Lopinavir is an HIV protease inhibitor that is co-formulated with ritonavir. The approved 
pediatric dose is 230/57.5 mg/m2 twice daily. Once-daily dosing may offer an 
advantage to adherence. We studied the pharmacokinetics of lopinavir/ritonavir in 
a once-daily regimen in HIV-1-infected children.
Methods
HIV-1-infected children on stable antiretroviral therapy with a viral load <50 copies/
mL for at least 6 months received lopinavir/ritonavir 460/115 mg/m2 once daily with 
zidovudine and lamivudine. Blood samples were collected at 0, 2, 4, 6, 8, 12, 18 
and 24 hours after observed intake during steady state. Target level for lopinavir 
Cmin was 1.0 mg/L, based on in vitro IC50 data.
Results
Nineteen HIV-1-infected children with a median (range) age of 4.5 (1.4 – 12.9) years, 
were enrolled. The median (interquartile range) dose of lopinavir was 456 (444 – 
477) mg/m2. The mean (standard deviation) AUC0-24, Cmax and Cmin of lopinavir were 
149.8 ± 58.8 h*mg/L, 10.77 ± 2.90 mg/L and 2.88 ± 3.74 mg/L respectively. These 
values are comparable to data observed in adults using lopinavir/ritonavir 
800/200mg once daily. In 10/19 (53%) children Cmin was considered to be too low 
(<1.0 mg/L). Younger children more often experienced subtherapeutic trough 
levels.
Conclusion
Our findings indicate that 460/115 mg/m2 lopinavir/ritonavir once daily leads to 
mean pharmacokinetic parameters comparable to data of 800/200 mg lopinavir/
ritonavir once daily in adults, although the variability observed in the trough levels 
is much higher in children. Further research, especially in young children, is 
necessary to determine whether a higher dosage of lopinavir/ritonavir once daily 
must be given to reach the target level for Cmin. 
Introduction
Lopinavir/ritonavir is one of the most widely-used HIV protease inhibitors. In 
combination with two nucleoside reverse transcriptase inhibitors (NRTIs), lopinavir/
ritonavir is considered to be one of the most potent antiretroviral agents, and is 
often selected as a first choice when a protease inhibitor is needed. Lopinavir/
ritonavir is approved for adults in a dosage of 400/100 mg twice daily (1). This 
combination has shown to be effective and resulted in a good virological response 
up to 4 years in treatment-naive patients. At week 204, 70% (70 of 100) of the anti-
retroviral (ARV)-naive HIV-infected patients (intention-to-treat analysis) had HIV-1 
RNA levels <50 copies/mL (2).
The U.S. Food and Drug Administration (FDA) also approved lopinavir/ritonavir for 
use in HIV-1-infected children older than 6 months of age and the European 
Medicines Agency (EMEA) from 2 years of age and older. The licensed pediatric 
dosage of lopinavir/ritonavir is 230/57.5 mg/m2 twice daily (1). A recent study 
showed a good virological response in ARV-naive and ARV-experienced children 
after 48 weeks of therapy (3). The proportions of subjects with HIV-RNA <400 
copies/mL using an intention-to-treat analysis were 84% (37 of 44) for ARV-naive 
subjects and 75% (42 of 56) for ARV-experienced subjects.
Treatment outcomes are not only dependent on the potency of the given regimen, 
but also on the tolerability and on the adherence of the patients to the chosen 
regimen. It has been estimated that more than 95% of all highly active antiretroviral 
therapy (HAART) must be taken to maintain durable suppression of HIV in more 
than 80% of patients (4). Therefore, adherence is considered equal in importance 
to the potency of the regimen. The complexity of the dosage regimen is a very 
important factor in adherence to a HAART regimen. Simplification of the HAART 
regimen will probably increase adherence. Once-daily regimens show improvements 
in adherence and tolerability, while maintaining virological efficacy (5;6). 
For lopinavir/ritonavir, simplification to once-daily dosing would also be more 
convenient for another reason: lopinavir/ritonavir has to be taken with food to 
improve the absorption of lopinavir (1;7;8). With a once-daily regimen it is easier to 
select a single time point during the day to secure intake with food. 
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Data from a recent randomized clinical trial in antiretroviral-naive HIV-1-infected 
adults showed that lopinavir/ritonavir taken once daily in a dosage of 800/200 mg 
has similar antiretroviral and immunological activity to twice-daily lopinavir/ritonavir, 
used in the same total daily dose, each combined with twice-daily NRTIs (9). Once-
daily dosing of lopinavir/ritonavir was recently approved for therapy-naive adults by 
the FDA.
To our knowledge no data is available about a once-daily regimen of lopinavir/
ritonavir in HIV-infected children. Therefore, this study was designed to explore the 
pharmacokinetics, tolerability and efficacy of a once-daily dosage regimen of 
lopinavir/ritonavir and two NRTIs in PI-experienced children. This article describes 
the pharmacokinetics of lopinavir/ritonavir over the course of a 24-hour period. 
Clinical follow-up of these children is ongoing and will be reported elsewhere.
Materials and Methods
Study design
The sampling of the 24-hour pharmacokinetic curves for this multiple-dose, open-
label, single-centre, phase IV-trial was conducted between July 2003 and January 
2005 in the Sophia Children’s Hospital which is part of the Erasmus Medical Centre, 
Rotterdam, the Netherlands. The study was designed to examine the 
pharmacokinetics of lopinavir/ritonavir when administered once daily in HIV-1-
infected children.
Study population
Patients had to be between 6 months and 18 years of age on the day of the first 
dosing and had plasma HIV RNA levels <50 copies/mL while on antiretroviral 
therapy for at least 6 months. We have chosen to include patients with an 
undetectable viral load on HAART, because this suggests that adherence is good 
enough to provide an optimal virological response and that patients endure 
antiretroviral medication. Patients who had a history of hypersensitivity to lopinavir/
ritonavir or chemically related compounds or excipients, or who had a relevant 
history that might interfered with drug absorption, distribution, metabolism or 
excretion were excluded from participation. Other exclusion criteria were: results of 
biochemistry, hematology and urinalysis testing showing grade III (severe adverse 
events) /IV (potentially life-threatening) abnormalities based on the Toxicity Tables 
for Grading Severity of Pediatric Adverse Experiences (≥ 3 months of age) 
developed by the National Institute of Health/Division of AIDS (USA, April 2004), 
participation in a drug trial 60 days prior to the first dose, febrile illness within 3 
days before the first dose and prior virological failure with documented resistance 
to lopinavir (more than 2 mutations selected from amino acid positions 10, 20, 24, 
46, 53, 54, 63, 71, 82, 84 and 90). Pregnant girls and patients using concomitant 
medication that could interfere with the pharmacokinetics of lopinavir/ritonavir, 
such as alprazolam, astemizole, bepridil, cisapride, dexamethasone, 
dihydroergotamine, disulfiram, phenytoin, flecainide, lovastatin, midazolam, 
primozide, propafenone, repaglinide, rifampin, rifabutin, St. John’s Wort, terfenadine, 
trazodone, triazolam and zolpidem were excluded as well. 
For all patients written informed consent, approved by the medical ethical 
committee of the Erasmus MC, was given by patients’ parents or legal caregivers. 
Study drug and dosing
Patients received lopinavir/ritonavir, either as capsules (133 mg lopinavir and 33 mg 
ritonavir per capsule) or as oral syrup (containing 80 mg/mL of lopinavir and 20 
mg/mL of ritonavir) in a dose of 460/115 mg/m2 taken once daily. This dose was 
similar to the total daily dose of the registered BID dosage regimen of lopinavir/
ritonavir in HIV-infected children. In addition to the lopinavir/ritonavir treatment the 
children also received 2 NRTIs. The selection of the NRTIs was at the discretion of 
the investigator.
Safety assessments and pharmacokinetic sampling
Plasma samples were collected at day 14 for pharmacokinetic analysis of lopinavir 
and ritonavir over the course of a 24-hour period. Plasma samples were collected 
just before and 2, 4, 6, 8, 12, 18 and 24 hours after drug intake (8 samples). 
If admission on the hospital ward was not possible, the sample to be taken 18 hours 
after dosing was skipped. 
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Bioanalysis of lopinavir and ritonavir concentrations in plasma
Plasma samples of lopinavir and ritonavir were analyzed at the Department of 
Clinical Pharmacy, Radboud University Nijmegen Medical Centre. The Department 
of Clinical Pharmacy has established an HPLC assay for lopinavir and ritonavir, 
which has been published previously (10).
A target trough concentration of 1.0 mg/L was selected based on in vitro IC50 data 
(0.07 mg/L) corrected for protein binding and a plasma trough level that should be 
at least 15 times higher than the IC50 for optimal response to a lopinavir containing 
regimen (15 x 0.07 = 1.0 mg/L). Based on this calculation the proposed minimum 
lopinavir trough level for PI-naive patients is 1.0 mg/L (11;12).
Pharmacokinetic analysis
Pharmacokinetic analyses of plasma lopinavir concentration-time data were 
conducted using non-compartmental methods (13). The plasma peak level (Cmax) 
and the plasma trough level (Cmin) were determined. Trough samples drawn before 
the end of the dosing interval were extrapolated to a 24-hour dosing interval. The 
area under the plasma concentration-time curve during a 24-hour dosing interval 
(AUC0-24) was calculated using the log-linear trapezoidal method. Relative apparent 
oral clearance (Cl/kg *F) was calculated as dose (mg)/AUC0-24*weight (kg). Time to 
Cmax was determined visually from the pharmacokinetic concentration-time curve. 
To determine the terminal half-life (t1/2), the elimination coefficient (Kel) was 
calculated as slope of the terminal phase of the log-transformed plasma 
concentration-time curve of lopinavir divided by ln10. The slope was determined by 
linear regression of at least 3 time points of the log-transformed plasma 
concentration-time curve. T1/2 was derived by dividing ln2 by Kel.
Sample size and statistical analysis
This study was a pilot study primarily initiated to determine the pharmacokinetics 
of once-daily dosing of lopinavir/ritonavir in HIV-1-infected children. A total of 
approximately 20 children is generally accepted to be sufficient for estimation of 
interpatient variability.
Statistical evaluations were carried out using SPSS® for Windows, version 12.0.1 
[SPSS Inc, Chicago, IL, USA, 1989-2003]. 
Results
Baseline patient characteristics
Nineteen PI-experienced HIV-1-infected children were enrolled in the trial, 10 boys 
and 9 girls. Median age of the children was 4.5 (IQR: 3.0 - 10.0) years. The children 
had a median body surface area (interquartile range (IQR)) of 0.76 (0.58 - 1.08) m2. 
They received 456 (444 - 477) mg lopinavir per m2, which was an absolute dose of 
lopinavir of 399 (264 - 533) mg. All patients used zidovudine and lamivudine as 
backbone NRTIs. None of the included patients had ever experienced virological 
failure. Baseline characteristics are listed in Table 1.
Pharmacokinetics
All patients used lopinavir/ritonavir in the calculated dose for at least 14 days 
without interruption before pharmacokinetic sampling. Lopinavir/ritonavir was taken 
with a moderate fat containing morning meal. Ten young patients (between 1.4 - 4.5 
years of age; one child was 7.4 years of age) used lopinavir/ritonavir as syrup and 
nine older patients (between 4.4 - 12.9 years of age) as soft capsules.
Eighteen patients were admitted on the hospital ward, so complete pharmacokinetic 
curves were drawn. One patient skipped the 18-hour sample of the pharmacokinetic 
curve. Data of all 19 patients were used for data analysis. None of the children was 
suspected of non-adherence or lack of steady state during the sampling of the 
pharmacokinetic curves. Information about adherence was gathered by asking 
questions about adherence during the visit using a standardized questionnaire. 
Children and parents were asked about missed doses and time of intake during the 
last 3 days and 3 months. No other objective methods of monitoring adherence 
(e.g. pill count, pharmacy records) were done.
The t1/2 and clearance could be calculated for only 16 patients, because 3 patients 
had an abnormal pharmacokinetic curve. For the first patient the Cmax appeared at 
the beginning of the curve and the curve continued almost horizontal, so it seemed 
that absorption was equal to elimination. We compared this curve to the pharmaco-
kinetic curve of twice-daily dosing of lopinavir/ritonavir, which was previously 
recorded in this child; both curves had similar characteristics. The pharmacokinetic 
curves of the second and third patient had several peaks and the plasma levels 
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increased during the entire dosage interval; consequently, the half-life and 
clearance could not be calculated.
Median (interquartile range) AUC0-24, Cmax and Cmin in the once-daily dosing regimen 
of lopinavir in the children were 140.6 (100.7 - 215.3) h*mg/L, 11.55 (8.68 - 13.14) 
mg/L and 0.65 (0.29 - 4.24) mg/L, respectively. The median clearance (Cl/kg*F) 
(IQR) of lopinavir in the HIV-1-infected children was 0.14 (0.09 - 0.17) L/kg*h (n=16). 
The pharmacokinetic parameters of lopinavir and ritonavir are summarized in Table 
2. We have chosen to show mean values in this table, since this allows a better 
comparison with the results of similar trials.
Mean lopinavir AUC0-24 and Cmax in once-daily dosing in children were somewhat 
lower than the results from studies of once-daily lopinavir/ritonavir in adults (9;14) 
The mean Cmin was similar, but the variation in Cmin was much higher in children. 
Compared to data of twice-daily dosing of lopinavir/ritonavir (230/57.5 mg/m2 BID) 
in HIV-infected children (3), Tmax was about twice as high and Cmax somewhat higher 
in once-daily dosing of lopinavir/ritonavir. The AUC0-24 and t1/2 were similar to twice-
Table 1  Patient baseline characteristics of the total population (N=19)  
and of the children with subtherapeutic (N=10) and therapeutic  
trough levels (N=9) 
 Total population Subtherapeutic Cmin Therapeutic Cmin
 N=19 N=10 N=9
Age (years) (median (IQR)) 4.5 (3.0 - 10.0)  3.9 (1.9 – 10.1) 5.9 (3.4 – 9.0)
Gender (female, male) 9, 10 5, 5 4, 5
Height (cm) (median (IQR)) 109 (93 - 128) 101 (82 – 130) 110 (97 – 135)
Weight (kg) (median (IQR)) 19.8 (13.6 - 30.0)  17.5 (11.0 – 25.7) 20.0 (14.7 – 35.0)
Body surface area (m2)  0.76 (0.58 - 1.08) 0.70 (0.50 – 0.96) 0.78 (0.63 – 1.14)
(median (IQR)) 
Ethnicity (N (%)):
African 12 (63%) 8 (80%) 4 (45%)
Caucasian 1 (5%) - 1 (11%)
Mixed Caucasian and other 4 (21%) 2 (20%) 2 (22%)
Other 2 (11%) - 2 (22%)
Antiretroviral therapy at baseline (N (%)):
Zidovudine, lamivudine,  15 (79%) 8 (80%) 7 (78%)
lopinavir/ritonavir (BID)
Zidovudine, lamivudine,  3 (16%) 2 (20%) 1 (11%)
indinavir/ritonavir
Zidovudine, lamivudine,  1 (5%) - 1 (11%)
nelfinavir 
Time on HAART (months,  24 (12 - 81) 21 (12 - 30) 27 (14 - 78)
median (range))   
Lopinavir dose (mg/m2)  456 (444 - 477) 459 (442 – 487) 456 (444 - 470)
(median (IQR))   
Absolute lopinavir dose (mg) 399 (264 - 533) 343 (238 - 438) 400 (284 - 533)
(median (IQR))    
Table 2  Pharmacokinetic parameters of lopinavir and ritonavir (Mean (SD))  
in 19 HIV-1-infected children using 460/115 mg/m2 lopinavir/ritonavir  
QD compared to adult data and to data of twice-daily lopinavir/ritonavir  
in children 
   Lopinavir/ritonavir regimen
Pharmacokinetic 460/115 mg/m2 800/200 mg 800/200 mg 230/57.5
parameters QD in children  QD in adults QD in adults mg/m2 BID
 (N=19)  (N=17) (9) (N=20) (14) in children
     (N=12) (3)
 Mean ± SD    Mean ± SD Mean ± SD Mean ± SD
 ritonavir lopinavir lopinavir lopinavir lopinavir
AUC0-n (h*mg/L) 8.1 ± 4.3 149.8 ± 58.8 164.9 ± 67.5 197.9 ± 64.5 72.6 ± 31.1
Cmax (mg/L) 0.84 ± 0.58 10.77 ± 2.90 10.94 ± 2.81 12.94 ± 4.47 8.16 ± 2.94
Tmax (h) 7.8 ± 4.6 8.4 ± 5.7 6.6 ± 2.8 5.5 ± 2.7 3.8 ± 1.6
Cmin (mg/L) 0.10 ± 0.13 2.88 ± 3.74 2.46 ± 2.63 2.94 ± 2.48 3.35 ± 2.14
T1/2 (h) 4.5 ± 1.8
 a 7.2 ± 9.2 a - 9.1 ± 8.3 5.8 ± 3.0
a  N = 16
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daily dosing in children, but the mean Cmin in once-daily lopinavir/ritonavir was 
somewhat lower with a higher variation compared to twice-daily dosing in HIV-
infected children: 2.88 ± 3.74 mg/L and 3.35 ± 2.14 mg/L respectively. 
For 4 children, 12-hour pharmacokinetic lopinavir curves were available, previously 
drawn before the trial while these patients were using lopinavir/ritonavir BID in the 
same total daily dose as during our trial. In all 4 children, the AUCs were comparable 
for once- and twice-daily dosing (N=2) or higher for the once-daily dosing of 
lopinavir/ritonavir (N=2). In two children, lopinavir Cmin was >1.0 mg/L for once- 
and twice-daily dosing; 1 patient had lopinavir trough levels <1.0 mg/L in both 
regimens and 1 patient had a Cmin <1.0 mg/L during once-daily dosing and a 
therapeutic Cmin during twice-daily dosing.
In our trial, a high interindividual variability in pharmacokinetic curves and plasma 
trough levels of lopinavir was seen in the enrolled children. As shown in Table 2, the 
variability in AUC0-24 and Cmax of lopinavir after once-daily dosing in children is 
comparable to the variability in the pharmacokinetic parameters of once-daily 
dosing of lopinavir/ritonavir in adults, but the variability in the Cmin after once-daily 
dosing in children is much higher than in adults.
Figure 1 shows the individual pharmacokinetic plasma concentration-time curves, 
as well as the median curve of the patients (n=19).
Compared to twice-daily dosing of ritonavir in adults (8), the mean Cmin and AUC0-24 
are somewhat lower and the Cmax is somewhat higher in once-daily dosing of 
lopinavir/ritonavir in children. In the trial of Eron et al. (9) in adults, AUC0-24 values 
of ritonavir of once- and twice-daily dosing were relatively similar. The mean 
ritonavir Cmin was about 50-60% lower and the Cmax was somewhat higher in once-
daily dosing than after twice-daily dosing. 
In 10/19 (53%) HIV-1-infected children the lopinavir Cmin was <1.0 mg/L and 
therefore considered to be too low. Table 1 shows the difference in baseline 
characteristics of the patients with therapeutic and with subtherapeutic trough 
levels (<1.0 mg/L). It appeared that younger children more often experience sub-
therapeutic trough levels. Five of the 7 (71%) children younger than 3.5 years had 
subtherapeutic trough levels compared to 5/12 (42%) in the group of children older 
than 3.5 years, although a non-parametric test showed no significant difference 
(Fisher’s Exact Test, p=0.35). Other patient characteristics, such as gender, 
weight, height, body surface area, time on HAART and therapy at baseline do not 
seem to have an effect on the trough levels. The percentage of African children in 
the group with subtherapeutic trough levels is higher than in the group with 
therapeutic levels, but the number of children with a different ethnicity than African 
is too low to draw conclusions on the effect of ethnicity on the trough levels.
Figure 1  Individual pharmacokinetic curves and median pharmacokinetic 
  curve of lopinavir in HIV-1-infected children using 460/115 mg/m2  
lopinavir/ritonavir QD, N=19 
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Discussion
In 19 HIV-1-infected children a dosage of 460/115 mg/m2 lopinavir/ritonavir resulted 
in mean AUC0-24, Cmax, and Cmin comparable to historical data of lopinavir/ritonavir 
800/200 mg QD in adults (9;14). An important observation is that the variation in 
trough levels is much higher in children than in adults. It appeared that younger 
children more often had subtherapeutic trough levels than older children, although 
the difference is not significant. A higher dosage of lopinavir/ritonavir may be 
necessary in very young children to achieve the target level for Cmin.
Data from the above mentioned randomized clinical trial (9) in antiretroviral-naive 
HIV-infected adults taking lopinavir/ritonavir once daily in a dosage of 800/200 mg 
or twice daily in the same total daily dose showed that there were no significant 
differences between treatment groups in Cmax and AUC0-24. Cmin values were 
significantly lower with once-daily therapy. A similar trial in adults showed that QD 
administration of lopinavir/ritonavir results in an exposure to lopinavir that is on 
average similar to BID administration with the exception of a somewhat lower Cmin. 
In 30% (6/20) of the patients the Cmin was below the target threshold of 1.0 mg/L (14).
In our trial, we only included children stable on HAART with an undetectable viral 
load, because this suggests that adherence is high enough to have a good 
virological response and that patients were tolerating antiretroviral medication. 
None of the patients had ever experienced virological failure. Therefore, we think 
that these data are also applicable to PI-naive patients. We expect that pharma-
cokinetic parameters will be similar in both groups.
The choice of the target level of 1.0 mg/L is theoretical, but is commonly used for 
lopinavir in PI-naive patients (11). Data on the virological response must show if this 
target level is high enough to cause a good virological response. We expect that 
plasma levels above the target level will give a good virological response because 
of the results of a recently conducted randomized clinical trial in antiretroviral-naive 
HIV-infected adult patients. Data from that trial indicate that lopinavir/ritonavir taken 
once daily in a dosage of 800/200 mg had similar antiretroviral and immunological 
activity compared to twice-daily lopinavir/ritonavir, used in the same total daily 
dose, each combined with twice-daily NRTIs. Both regimens resulted in about 75% 
of all patients attaining a plasma HIV-RNA level of <50 copies/mL at 48 weeks (9). 
We expect that the target level for lopinavir Cmin of 1.0 mg/L also can be used for 
PI-experienced patients who have not experienced virological failure on previous 
PI-regimens and most likely not have many relevant PI-mutations. Therefore, we 
have only included patients without prior virological failure with documented 
resistance to lopinavir (more than 2 mutations selected from amino acid positions 
10, 20, 24, 46, 53, 54, 63, 71, 82, 84 and 90).
In our trial, Cmin was <1.0 mg/L in 10/19 (53%) HIV-1-infected children and therefore 
considered to be too low. It appeared that younger children more often had 
subtherapeutic trough levels. Five of the 7 (71%) children younger than 3.5 years 
had subtherapeutic trough levels compared to 5/12 (42%) in the group of children 
older than 3.5 years, although this did not reach statistical significance, probably 
due to the low number of children in each age group. 
Ten young children received lopinavir/ritonavir syrup and nine older children 
lopinavir/ritonavir soft capsules. Kaletra® soft capsules and liquid have shown to be 
bio-equivalent under non fasting conditions (moderate fat meal) (1;7). Therefore, it 
is not likely that the lower lopinavir levels in younger children could be explained by 
difference in used formulations, because all children took their medication with a 
moderate fat meal. If there would be an effect of the formulation on the lopinavir 
plasma levels, there probably would be higher levels in younger children receiving 
syrup, while the effect of food on bioavailability is greater for the liquid than for the 
soft capsule formulation (8).
It is known that the pharmacokinetics in children change depending on age. 
Several age-related factors, including gastric emptying time, intestinal transit time 
and gastrointestinal motility, influence the absorption of drugs in pediatric patients. 
Total body water, tissue binding, hepatic enzyme activity, glomerular filtration and 
tubular secretory capacity are also changing during childhood (15;16). All these 
factors may affect the pharmacokinetics of lopinavir/ritonavir. Therefore, a possible 
explanation for the trough levels below the target level and large variability is that 
the metabolism and absorption in very young children change continuously. 
Nelfinavir also shows a high interindividual variability in children. Administration of 
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nelfinavir resulted in lower AUCs and lower trough levels in small and young 
children (17;18). 
Because of the large interindividual variability in plasma levels in this trial, we 
recommend therapeutic drug monitoring of lopinavir/ritonavir in the investigated 
once-daily regimen.
Data about the efficacy and tolerability of the investigated dose regimen and the 
effect of dose increment on the lopinavir trough levels will be described as soon as 
the 1-year follow up of all of the included children is completed. These data will 
provide more information about adverse events and virological response.
In conclusion, the findings of this trial indicate that the investigated dosage of 
460/115 mg/m2 QD of lopinavir/ritonavir in this population leads to mean pharma-
cokinetic parameters comparable to pharmacokinetic data of 800/200 mg of 
lopinavir/ritonavir QD in adults, although the variability in the trough levels is much 
higher in children. In 10/19 (53%) HIV-1-infected children the dosage of 460/115 
mg/m2 QD of lopinavir/ritonavir resulted in trough levels below the chosen target 
level of 1.0 mg/L. Further research in young children is necessary to determine 
whether a higher dosage of lopinavir/ritonavir QD must be given to reach the target 
level for Cmin or a more frequent dosing interval of lopinavir/ritonavir is required. 
Regarding the high interindividual variability in plasma levels, especially in Cmin, 
therapeutic drug monitoring may help to determine if dosage adjustments are 
necessary. The results of virological response are needed to determine whether the 
once-daily regimen of 460/115 mg/m2 of lopinavir/ritonavir is effective in HIV-1-
infected children.
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Abstract
Objectives
To show the possibility of a once-daily protease inhibitor (PI)-based highly active 
antiretroviral therapy (HAART) regimen consisting of lopinavir/ritonavir and 2 nucle-
oside reverse transcriptase inhibitors (NRTIs) for HIV-infected children based on 
pharmacokinetics, effectiveness, tolerability and acceptability in order to improve 
adherence and convenience. 
Methods
HIV-infected children on stable antiretroviral therapy (ART) with HIV-1 RNA <50 
copies/ml received lopinavir/ritonavir 460/115 mg/m2 once-daily with zidovudine 
and lamivudine twice-daily. Dose increase of lopinavir/ritonavir took place if Cmin 
was <1.0 mg/L. After 6 months zidovudine and lamivudine were replaced by 
abacavir and lamivudine once-daily. Follow-up included HIV-1-RNA , lymphocyte 
counts, biochemistry, haematology, TDM, adverse event monitoring, and 
acceptability questionnaires.
Results
19 HIV-infected children (median age: 4.5 years) completed at least 12 months of 
follow-up. The studied regimen provided continued viral suppression and immuno-
logical benefit and was well tolerated. Intake with a substantial meal was important 
to obtain lopinavir plasma levels above target level with once-daily dosed lopinavir/
ritonavir. Significantly more children ≤ 3.5 years needed 600/150 mg/m2 lopinavir/
ritonavir to obtain Cmin >1.0 mg/L compared to older children. Patients preferred 
once-daily intake and reported less interference with daily life.
Conclusions
Simplification with once-daily lopinavir/ritonavir, abacavir and lamivudine was safe 
and effective in PI-pre-treated HIV-1 infected children with an undetectable viral load. 
Children ≤ 3.5 years needed a higher lopinavir/ritonavir dose of 600/150 mg/m2. 
Further research is needed to evaluate this higher dose in young children and the 
efficacy of a once-daily dosed lopinavir/ritonavir-based regimen in antiretroviral 
naive and PI-resistant children. 
Introduction
In adults with HIV-infection the trend has been to simplify antiretroviral therapy to 
once-daily regimens in order to improve adherence. Studies suggest patients’ 
preference for compact once-daily regimens, providing that efficacy and tolerability 
are similar to twice-daily regimens (1-3). An increasing number of antiretroviral 
drugs have been approved for once-daily use in adults. However, in children most 
drugs are still being prescribed twice daily, because pediatric pharmacokinetic 
data for once-daily dosing are lacking (4). A once-daily dosing schedule may also 
offer an advantage to convenience and adherence in children. 
Lopinavir is an HIV protease inhibitor (PI) that is co-formulated with ritonavir. 
In adults antiretroviral activity of lopinavir/ritonavir is similar in a once-daily versus 
twice-daily dosed regimen (5-7). The once a day dose of 800/200 mg is only 
approved for use in naive subjects, in the USA, Canada and some countries in Latin 
America (5;6). Lopinavir/ritonavir is virologically very effective and well-tolerated 
when dosed twice daily in children (8). The current pediatric approved dose for 
lopinavir/ritonavir is 230/57.5 mg/m2 twice daily (9).
We recently presented pharmacokinetic data on the pediatric daily dose of 460/115 
mg/m2 taken once-daily (QD) (10). This dose results in mean pharmacokinetic 
parameters comparable to pharmacokinetic data of 800/200 mg of lopinavir/
ritonavir QD in adults, although the inter-individual variability observed in plasma 
trough levels (Cmin) is much higher in children. In 10/19 (53%) HIV-1-infected 
children the dosage of 460/115 mg/m2 QD of lopinavir/ritonavir resulted in Cmin 
below the chosen target level of 1.0 mg/L.
In order to create a truly once-daily highly active antiretroviral therapy (HAART) 
regimen and benefit from its advantages the nucleoside reverse transcriptase 
inhibitor (NRTI) backbone should also be dosed once daily and at the same time 
the anchor drug is taken. In this respect only a few options are available for 
children. For lamivudine and abacavir it has been shown that the pharmacokinetic 
parameters and antiviral activity for once-daily dosing are not inferior to twice-daily 
dosing in children (11;12).
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Here, we present data on pharmacokinetics following dose-adjustments, 
effectiveness, tolerability and acceptability of the first once-daily protease inhibitor-
based HAART regimen for HIV-infected children: lopinavir/ritonavir, abacavir and 
lamivudine. 
Methods
Study design
This prospective, multiple-dose, open-label, single-centre, phase IV pilot study was 
conducted between July 2003 and January 2006 in the Sophia Children’s Hospital 
which is part of the Erasmus MC, Rotterdam, the Netherlands. Some of the patients 
were in shared care with the Radboud University Nijmegen Medical Centre, 
Nijmegen, The Netherlands. The study was designed to examine the pharma-
cokinetics of lopinavir/ritonavir when administered once daily in HIV-1-infected 
children and secondarily to evaluate the tolerability and efficacy of lopinavir/
ritonavir when administered once daily in combination with NRTIs.
Study population
Patients were between 6 months and 18 years of age on the day of the first dosing 
and had plasma HIV-1-RNA levels <50 copies/ml while on HAART for at least 6 
months. We have chosen to include patients with an undetectable viral load, to 
select for subjects that were adherent to their current regimen. Patients who had a 
history of hypersensitivity to lopinavir/ritonavir or chemically related compounds or 
excipients, or a relevant history that might interfere with drug absorption, 
distribution, metabolism or excretion were excluded. Other exclusion criteria were: 
(a) results of biochemistry, hematology and urine analysis testing showing grade III 
(severe adverse events) /IV (potentially life-threatening) abnormalities based on the 
Toxicity Tables for Grading Severity of Pediatric Adverse Experiences (≥3 months 
of age) developed by the National Institute of Health/Division of AIDS (USA, April 
2004), (b) participation in a drug trial 60 days prior to the first dose, (c) febrile 
illness within 3 days before the first dose and (d) prior virological failure with 
documented resistance to lopinavir (more than 2 mutations selected from 10, 20, 
24, 46, 53, 54, 63, 71, 82, 84 and 90), (d) pregnancy and (e) use of concomitant 
medication that interfered with lopinavir/ritonavir pharmacokinetics (13). 
For all patients written informed consent, which was approved by the medical 
ethical committee of the Erasmus MC, was given by patients’ parents or legal 
caregivers. 
Study drug and dosing
Patients received lopinavir/ritonavir, either as capsules (133 mg lopinavir and 33 mg 
ritonavir per capsule) or as oral solution (containing 80 mg/mL of lopinavir and 20 
mg/mL of ritonavir) at an initial dose of 460/115 mg/m2 taken once daily with food. 
NRTIs used at baseline were continued throughout the first 6 months of the follow-
up period in order to be able to study the effects of the once-daily lopinavir/ritonavir 
dosing schedule first. At month 6 the NRTIs were changed to abacavir (16mg/kg 
QD) and lamivudine (8mg/kg QD) to allow for once-daily dosing of the entire 
HAART regimen.
Safety and efficacy assessments and pharmacokinetic sampling
Patients were screened within 4 weeks prior to the first dose. Follow-up was 
planned at days 14 and 28 and at month 2, 3, 6, 9 and 12 after initiation of treatment. 
At every visit virological, immunological and biochemical parameters and adverse 
events were assessed. Quantification of plasma HIV-1 RNA was performed using 
Amplicor Ampli Prep (Roche Diagnostics, Bazel, Switzerland) with a lower detection 
limit of 50 copies/ml. A virologic blip was defined as a plasma HIV-1 RNA between 
>50 copies/ml at one visit and <50 copies/ml on the previous and subsequent 
visit. Virological failure was defined as a plasma HIV-1 RNA >50 copies/ml at ≥ 2 
subsequent visits. In case of virological failure a genotypic resistance test was 
performed. Lymphocyte subsets were analyzed with the FACSCount System 
(Becton Dickinson Immunocytometry Systems, San Jose, CA, USA). Because 
absolute CD4 cell counts are age related, CD4-cell counts as percentage of age 
reference values were calculated. Hereto the patient’s individual values were 
divided by the median of the age-specific reference values for T-cell subpopulations 
at that time-point (14-16). At month 7 an extra clinic visit and laboratory check up 
were scheduled to check for abacavir hypersensitivity reaction and for early 
detection of virological failure following once-daily dosing of abacavir and 
lamivudine. 
Plasma samples were collected at day 14 for pharmacokinetic analysis of lopinavir/
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ritonavir over the course of a 24-hour period. They were collected just before and 
2, 4, 6, 8, 12, 18 and 24 hours after drug intake. If the results of the lopinavir plasma 
levels were <1.0 mgl/L and the lopinavir/ritonavir dose had to be increased, the 
24-hour pharmacokinetic sampling was repeated two weeks later. When this was not 
possible for the patient only a Cmin was drawn 24 hours after intake. This procedure 
was repeated until the lopinavir Cmin was above the target level. 
Bioanalysis of lopinavir and ritonavir concentrations in plasma
Plasma samples of lopinavir and ritonavir were analyzed at the Department of Clinical 
Pharmacy, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands, 
by an established HPLC assay, which has been published previously (17).
A lopinavir target trough concentration of 1.0 mg/L was selected based on in vitro 
IC50 data (0.07 mg/L) corrected for protein binding and a plasma trough levels that 
should be at least 15 times higher than the IC50 for optimal response to a lopinavir-
containing regimen in PI-naive patients (15 x 0.07 = 1.0 mg/L) (18;19).
If the trough level of the pharmacokinetic curve was below 1.0 mg/L, the lopinavir/
ritonavir dose was increased by 33% (to 600/150 mg/m2), which is the normal dose 
increment for adults on a twice-daily regimen of lopinavir/ritonavir.
Pharmacokinetic analyses of plasma lopinavir concentration-time data were conducted 
using non-compartmental methods (20).
Acceptability Questionnaires
Acceptability of the once-daily versus twice-daily regimen was assessed at 
baseline and month 12 by questionnaires which were completed during the study 
visit and with the help of the nurse if required. Structured questions were asked 
about difficulties taking and remembering drugs, administration with food, overall 
preference for twice- or once-daily dosing, and interference of HAART with 
everyday life. 
Sample size and statistical analysis
This study was a pilot study primarily initiated to determine the pharmacokinetics 
of once-daily dosing of lopinavir/ritonavir in HIV-1-infected children. A total of about 
20 children is generally accepted to be sufficient for estimation of interpatient 
variability. This trial was not powered to demonstrate differences in efficacy or 
tolerability in comparison to historical data. Therefore, the measurement of efficacy 
and tolerability was a secondary objective of this trial.
Statistical evaluations were carried out using SPSS® for Windows, version 12.0.1 
[SPSS Inc, Chicago, IL, USA, 1989-2003]. 
Table 1 Patient baseline characteristics 
Median age, years (IQR) 4.5 (3.0 – 10.0) 
Gender (female, male) 9, 10
Median height, cm (IQR) 109 (93 – 128)
Median weight, kg (IQR) 19.8 (13.6 – 30.0)
Median body surface area, m2 (IQR) 0.76 (0.58 - 1.08)
Ethnicity (N (%))
African 12 (63%)
Caucasian 1 (5%)
Mixed Caucasian and other 4 (21%)
Other 2 (11%) 
Antiretroviral therapy at baseline (N (%))
Zidovudine + lamivudine + LPV/r (twice daily) 15 (79%)
Zidovudine + lamivudine + IDV/r 3 (16%)
Zidovudine + lamivudine + NFV 1 (5%) 
Median time on HAART, months (range) 24 (12 - 81)
HIV-1 RNA at baseline (N)
< 500 copies/ml 19
< 50 copies/ml 17 
CD4 T- cells, median (IQR)
absolute counts (106 cells/ml) 1340 (920-1620)
% of age specific reference values 104% (74%-122%)
IQR= interquartile range, IDV/r: indinavir/ritonavir, LPV/r: lopinavir/ritonavir, NFV: nelfinavir
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Results
Baseline patient characteristics 
Between July 2003 and January 2005, 19 PI-experienced HIV-1-infected children, 
10 boys and 9 girls, were screened and subsequently enrolled in the trial. Median 
age of the children was 4.5 years (IQR: 3.0 - 10.0). Ten patients took lopinavir/
ritonavir as a liquid formulation and 9 patients as soft gel capsules. All patients 
used zidovudine and lamivudine as backbone NRTIs. None of the included patients 
had ever experienced virological failure. CD4 cell counts were normal for age. 
Baseline characteristics are listed in Table 1.
Pharmacokinetics
Pharmacokinetic data of lopinavir/ritonavir 460/115 mg/m2 are reported in a 
previous publication. Figure 2 shows the median concentration time curves. 
In 10/19 (53%) children Cmin values were found to be below target level (<1.0 mg/L) 
(10). In 3 of these patients, a lopinavir/ritonavir dose of 460/115 mg/m2 was 
sufficient to increase the Cmin plasma concentrations to levels above target after 
intake was changed to coincide with a larger and/or more fatty meal (evening 
meal). Because of this change in intake timing, a dose increase of 33% according 
to protocol did not take place. All these children were older than 3.5 years. The full 
pharmacokinetic curve or a trough level were repeated showing, that their lopinavir 
levels reached Cmin above the target >1.0 mg/L (1.5, 3.8 and 8.1 mg/L, respectively). 
In 7 patients, dose adjustment of lopinavir/ritonavir once-daily to 600/150 mg/m2 
was necessary. In 5 children who were 3.5 years and younger with an initial Cmin 
<1.0 mg/L and a 7-year-old girl a dosage increase to 600/150 mg/m2 lopinavir/
ritonavir and intake with the larger evening meal were necessary to obtain lopinavir 
Cmin levels above target (median 6.7 mg/L, range 1.1-12.49 mg/L). In the 7th patient 
with a dose increase, a 12-year old boy, intake with a larger meal was not necessary 
to achieve a lopinavir Cmin of 7.7 mg/L initially. But during follow-up TDM, his plasma 
lopinavir levels turned out to be very unstable and undetectable (<0.1 mg/L) on two 
occasions, probably because of non-adherence. This problem was only solved 
when time of intake was changed to dinner time. The effect of dose adjustments 
and food on Cmin is shown in Table 2. In fact, 5 of the 8 (63%) 1 to 3-year-olds in this 
cohort, needed a higher dose compared to only 2 out of 11 (19%) 4 to 12-year-olds 
(p=0.045). 
Antiretroviral and Immunologic responses
Eighteen of the 19 children had HIV-1-RNA <50 copies/ml at month 12. Three 
patients experienced a blip (52-136 copies/ml) during the study period. In two 
patients with a blip at month 2 and 3, the viral load returned to undetectable by 
discussing the findings with the parents and asking them to pay more attention to 
intake with food. The third patient had a detectable viral load of 80 copies/ml at 
month 12. The viral load increased to 2669 copies/ml one month later. A M36I 
mutation was detected. After intensification of adherence support, and without 
dose adjustment the HIV-1-RNA returned to undetectable levels. Once-daily dosing 
of abacavir and lamivudine from month 6 onwards did not lead to virological failure.
No changes in CD4 cell counts were detected over 12 months of treatment (Figure 1). 
At baseline, median CD4 cell count was 104% of normal corrected for age (absolute 
count 1340 * 106/l), and 97% (1120 *106/l) at month 12 (p=0.533).
Table 2  Lopinavir trough levels (Cmin), influence of intake with dinner instead of 
breakfast and/or dose increase 
Patient Age Lopinavir/ritonavir
 
(years)
 460/115 mg/m2 QD 460/115 mg/m2 QD 600/150 mg/m2 QD 600/150 mg/m2 QD
  with breakfast with dinner  with breakfast with dinner
   (day 14) (mg/L) (mg/L) (mg/L) (mg/L)
1 10.2 0.31 8.1  
2 4.4 0.41 1.5  
3 10.0 0.65 3.8  
4 12.8 0.14  7.7 
5 3.1 0.65  0.45 1.1
6 1.4 0.04  0.09 7.1
7 2.0 0.4  0.57 7.1
8 1.4 0.46   12.49
9 3.5 0.98   3.13
10 7.4 0.19   6.4
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Tolerability
There were no patients with discontinuations of treatment due to adverse events. 
Adverse events are shown in Table 3. Gastrointestinal side effects were most 
common. These were transient and all resolved by month 2. No abacavir 
hypersensitivity reaction occurred. Fasting lipid levels, glucose, insulin and 
c-peptide were available for 15 patients. There were no significant differences 
between baseline and month 12 values. 
Acceptability 
Seventeen parents/caretakers completed the acceptability questionnaires. Four 
children were able to answer the questions themselves. Sixteen of 17 parents and 
3 of 4 children preferred the once-daily dosing schedule over twice-daily. One 
parent and one child were indifferent. Reasons for preferring once-daily intake 
were: less stress before going to school and for younger children less stress of 
having to fight over eating and medication intake, possibility to sleep in, easier 
when on a trip or visit, and lower frequency of nausea. At baseline, 5 parents said 
they had to make many adjustments and 4 parents few adjustments to daily life to 
facilitate medication intake. At month 12, only 2 parents reported having to make 
Figure 1  CD4 cells as percentage of age-specific reference values, median 
(interquartile range) 
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Table 3 Adverse events 
adverse events Baseline: N=  Day 28 - Month 12: N=
gastrointestinal  7 0
nausea & vomiting grade 1,2: 4 0
abdominal pain grade 1,2: 3 0
diarrhea grade 1,2: 2 0 
abacavir hypersensitivity  0 0
laboratory measurements
raised amylase grade 1,2: 8 grade 3: 1
hyperbilirubinaemia grade 1,2: 3 grade 1: 2
 grade 3: 1 
anemia grade 1,2: 4   grade 1,2: 6 
low sodium grade 1: 1 grade 1: 2
raised urea grade 1,2: 4 grade 1,2: 4    
raised calcium grade 1: 1 grade 1: 2
raised alkaline phosphatase grade 1: 1 grade 1,2: 3
raised ALAT  0 grade 1: 1
raised ASAT   0 grade 1: 1
raised γ-GT grade 1: 6      grade 1: 1
low erythrocyte count grade 1: 9 grade 1: 1 
lipids & glucose, fasting baseline, median (IQR) month 12, median (IQR)
cholesterol, mmol/l 5.1 (4.3 - 5.85) 5.2 (4.4 - 6.1)*
triglycerides, mmol/l 1.24 (1.05 – 1.75) 1.59 (1.00 – 2.06)*
LDL-cholesterol, mmol/l 3.00 (2.32 – 3.73) 3.05 (2.39 – 3.98)*
HDL-cholesterol, mmol/l 1.52 (1.16 – 1.69) 1.64 (1.47 – 1.82)*
glucose, mmol/l 4.05 (3.83 – 4.75) 4.10 (4.00 – 4.63)*
insuline, pmol/l 25 (20 – 44)  35 (27 – 55)*
c-peptide, nmol/l 0.42 (0.25 – 0.57) 0.35 (0.28 – 0.57)*
IQR= interquartile range, * not statistically significantly different (p>0.05)
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many adjustments, ten parents few and five parents no adjustments. All parents 
understood that intake with food was very important and they easily managed to 
give the medication at meal times.
Parents and children found the total amount of lopinavir/ritonavir pills (3 or 4, 
exception: 7) or liquid (3.3 – 4.7 ml, exception: 6.7 ml) per day were acceptable 
although some children experienced difficulties in swallowing the large lopinavir/
ritonavir capsules. Most younger children got used to the very distinct taste of the 
lopinavir/ritonavir liquid. The total liquid burden decreased slightly because the use 
of abacavir resulted in lower volume of the syrup compared to zidovudine. 
Discussion
This study provides the first data on pharmacokinetics, effectiveness, tolerability 
and acceptability of a once-daily PI-based HAART regimen for HIV-infected 
children: lopinavir/ritonavir, abacavir and lamivudine. By providing these pediatric 
pharmacokinetic data for once-daily dosing in children, we show that this form of 
treatment, which improves convenience and therefore adherence in adults is also 
possible in children.
In this study lower than target Cmin plasma levels were significantly more common 
in the younger age group (<3.5 years). Five out of 8 children (63%) of 3.5 years and 
younger needed a dose increase to reach lopinavir plasma levels above target 
compared to only 2 out of 11 (19%) older children. The effect of changing time of 
intake and dose increase are remarkable since in adults no differences were 
observed in the pharmacokinetics of lopinavir/ritonavir after am or pm dosing with 
food (21) and dose increase did not lead to an increase of Cmin in the majority of 
patients (22). The suboptimal pharmacokinetic parameters of lopinavir/ritonavir in 
young children and the effect of dose modifications can be dually explained. Firstly, 
the fact that dose increase led to increased lopinavir plasma levels points in the 
direction of an elimination or distribution problem. Increasing the dose would not 
have helped if there was just an absorption problem. Secondly, increasing the dose 
only helped under the condition that the time of intake was moved to the evening 
meal, which shows that decreased absorption must have been part of the problem. 
It is known that pharmacokinetics in children changes depending on age influenced 
by continuously changing absorption and metabolism factors (23, 24). Although 
there were more young children in our study who needed a dose increase, the initial 
difference in Cmin between children younger and older than 3.5 years of age did not 
reach statistical significance. This could have been attributable to the small study 
population. The high interindividual variability in lopinavir plasma levels in HIV-1 
infected children was also noted by another study group (25). A similar proportion 
of children (3/7; 43%) had Cmin <1.0 mg/L. A relationship with age was not 
mentioned. In an earlier study on the 48-week follow-up of lopinavir/ritonavir twice 
daily in children, the pharmacokinetics of lopinavir did not appear to be dependent 
on age, race or gender, but this study did not include many young children (8). Data 
from our Rotterdam cohort recently showed that when lopinavir/ritonavir was dosed 
Figure 2  Median pharmacokinetic curves of children >3.5 years and  
≤3.5 years old, 25th and 75th percentiles 
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twice daily lopinavir plasma levels were suboptimal in children aged two years and 
below (26). 
The clinical efficacy results reported in light of the pharmacokinetic results 
observed in this study can only be applied to protease-inhibitor naive patients, 
because none of our patients had ever experienced virological failure. The target 
level for lopinavir Cmin and the virological response to lopinavir/ritonavir once daily 
may be different for PI-experienced children with low to intermediate PI resistance 
mutations. 
The studied regimen of lopinavir/ritonavir, abacavir and lamivudine provided 
continued viral suppression and immunological benefit in all patients enrolled. This 
could be influenced by patient selection bias that is associated to the nature of a 
simplification study (27). Data from a randomized clinical trial in antiretroviral-naive 
HIV-infected adults studying once-daily versus twice-daily lopinavir/ritonavir 
suggest that lopinavir/ritonavir taken once daily has antiretroviral and immunological 
activity similar to that of twice-daily lopinavir/ritonavir at the same total daily dose. 
Both regimens resulted in about 75% of all patients attaining a plasma HIV RNA 
level of <50 copies/ml at 48 weeks (5-7). No detectable lopinavir resistance was 
noted in any naive patient on either once-daily or twice-daily dosing schedules 
(5;7;28;29). In our study the only patient with virological rebound did not develop 
lopinavir resistance mutations either. Twice-daily lopinavir/ritonavir in children 
(N=100) led to excellent viral suppression in antiretroviral naive and PI-naive/NRTI-
pretreated children (84% and 88% <50 copies/ml, respectively). Viral suppression 
was acceptable for PI- and NRTI-experienced patients (58% <50 copies/ml) (8). 
It seems likely that in children lopinavir/ritonavir taken once daily also has the same 
antiretroviral and immunological activity as twice-daily lopinavir/ritonavir, but 
further studies in naive and PI-pretreated children are warranted. 
Once-daily administration of lopinavir/ritonavir was well tolerated. Clinically, only 
mild transient gastrointestinal side effects were seen, vomiting was the most 
frequent adverse event. In the study of Johnson et al. comparing once- versus 
twice-daily dosing in adult subjects, diarrhea was the most common adverse event 
and was significantly higher in the once-daily group versus the twice-daily group 
(16% versus 5%) (7). Few adverse events of at least moderate severity were noted 
when lopinavir/ritonavir was administered twice daily in children. Only pancreatitis, 
possibly related to study drugs, led to study discontinuation (8). In this study 
children apparently tolerated lopinavir/ritonavir better than adults in a once-daily 
dosing regimen. All adverse effects that caused discomfort for the patients were 
resolved by month 2, which is important in the light of adherence to a long-term 
treatment.
No abacavir hypersensitivity reaction occurred when zidovudine and lamivudine 
twice-daily were replaced by abacavir and lamivudine once daily. This could be 
attributable to the mainly African origin of our patients, which has shown to be a 
relative protection to develop abacavir hypersensitivity (30-33). Despite the initial 
risk of hypersensitivity abacavir and lamivudine are an attractive option for once-
daily dosed NRTIs in children (34). A palatable syrup is available for young children 
and a combination tablet for older children and teenagers. Pediatric pharmaco-
kinetic data is known for the once-daily dosing schedule and comparable to data 
on twice-daily dosing (11).
The pill burden for most children was lower than for adults taking this combination. 
This led to a very acceptable regimen of 5-6 pills once-daily (including NRTIs), 
even though the lopinavir/ritonavir soft gel capsules are quite large in size. Most 
younger children accepted the liquid. Most parents and children preferred the 
once-daily dosing schedule. There could be a selection bias because parents who 
did not think it would be advantage did not enroll their children in the trial. In the 
PENTA 13 trial of once-daily lamivudine and abacavir in HIV-1 infected children 96% 
of caregivers thought that switching from twice to once-daily medicines would 
make things easier for their child at baseline whereas only 71% confirmed that this 
happened by week 24 (12). The introduction of the abacavir/lamivudine combination 
tablet has already improved pill burden for the older children since the end of this 
study. The recently approved 200/50 mg tablet formulation of lopinavir/ritonavir 
would also be an advantage for children. Lopinavir/ritonavir tablets can be taken 
independent of meals in adults. For children being able to take lopinavir/ritonavir 
without food restrictions would mean more flexibility to incorporate taking HAART 
into daily life at a time of day preferred by parents and children, which would in its 
turn have a positive effect on adherence.
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We conclude that simplification of a twice-daily PI-based HAART regimen to once-
daily lopinavir/ritonavir, abacavir and lamivudine in HIV-1 infected children with 
HIV-1 RNA levels <50 copies/ml and with less than three mutations associated to 
lopinavir resistance provides continued viral suppression and immunological 
benefit. Once-daily administration of lopinavir/ritonavir was well tolerated. Replacing 
zidovudine/lamivudine twice daily with abacavir/lamivudine once daily did not lead 
to abacavir hypersensitivity reactions in our population. Intake with a reasonable 
amount of food (dinner) is important to obtain adequate plasma levels when 
lopinavir/ritonavir is dosed once daily in children. Most children of 3.5 years of age 
and younger needed a higher dose of 600/150 mg/m2 lopinavir/ritonavir to obtain 
adequate Cmin. Patients preferred once-daily intake over twice-daily intake and 
reported less interference with daily life. 
In the light of the large interindividual variability in plasma levels in this trial, we 
recommend therapeutic drug monitoring of lopinavir/ritonavir in the investigational 
once-daily regimen. Larger trials are needed to evaluate the need of a higher dose 
of 600/150 mg/m2 lopinavir/ritonavir in younger children and the efficacy of once-
daily dosing of lopinavir/ritonavir in antiretroviral naive children and children with 
mild PI-resistance.
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Ritonavir and drug-drug interactions
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Abstract
Background
Lopinavir/ritonavir-containing antiretroviral therapy can cause hyperlipidaemia in 
HIV-infected patients. However, most statins are contraindicated due to drug-drug 
interactions. Rosuvastatin undergoes minimal metabolism by CYP450, so no CYP450-
based interaction with lopinavir/ritonavir is expected. This pilot study explored the 
lipid-lowering effect of rosuvastatin and assessed the effect of lopinavir/ritonavir on 
the pharmacokinetics of rosuvastatin and vice versa.
Methods
HIV-infected patients on lopinavir/ritonavir (viral load<400 copies/mL) with total 
cholesterol (TC) >6.2 mmol/L were treated with rosuvastatin for 12 weeks, starting 
on 10 mg QD. If fasting target values (TC <5.0 mmol/L; HDL-c >1.0 mmol/L; LDL-c 
<2.6 mmol/L; TG <2.0 mmol/L) were not reached, rosuvastatin was escalated to 
20mg or 40mg at week 4 and 8. Plasma lopinavir/ritonavir trough levels (Cmin) were 
drawn at week 0, 4, 8, 12; rosuvastatin Cmin at week 4, 8, 12.
Results
22 patients completed the study. Mean reductions in TC and LDL-c from baseline 
to week 4 (on rosuvastatin 10 mg QD) were 27.6% and 31.8%. Lopinavir/ritonavir 
concentrations were not influenced by rosuvastatin (p=0.44 and 0.26, repeated-
measures analysis). Median (IQR) rosuvastatin Cmin for 10 mg, 20 mg and 40 mg 
QD were 0.97 (0.70–1.5), 2.5 (1.3–3.3) and 5.5 (3.3–8.8) ng/mL. Rosuvastatin was 
well tolerated; three patients experienced transient muscle pain.
Conclusions
Rosuvastatin appeared to be an effective statin in hyperlipidaemic HIV-infected 
patients. Lopinavir/ritonavir levels were not affected by rosuvastatin, whilst 
rosuvastatin levels unexpectedly appeared to be increased 1.6-fold as compared 
to data from healthy volunteers. So, probably another mechanism other than CYP450 
is involved in this interaction. Until safety and efficacy have been confirmed in 
larger studies, the combination of rosuvastatin and lopinavir/ritonavir should be 
used with caution.
Introduction
Lopinavir/ritonavir is one of the most widely-used HIV-protease inhibitors (PIs). 
One of the drawbacks when using lopinavir/ritonavir is the frequent development of 
hyperlipidaemia (1). A strategy to manage lopinavir/ritonavir-induced hyperlipidaemia 
may be treatment with lipid-lowering drugs such as 3-hydroxy-3-methylglutaryl 
coenzyme A reductase inhibitors (statins) and/or fibrates (2;3). The concomitant 
use of such drugs in conjunction with PIs unfortunately has been hampered by the 
occurrence of drug-drug interactions (4). Most statins are metabolized by 
cytochrome P450 (CYP450), while PIs, including lopinavir/ritonavir, are strong 
inhibitors of this enzyme. One exception is pravastatin for which CYP3A4 is not a 
significant enzyme in its metabolism. This agent, however, is metabolized by 
glucuronidation, and ritonavir is known to be an inducer of glucuronidating enzymes 
(5), resulting in lowered pravastatin levels (6;7).
Hence, there is a clear need for statins which have both potent lipid-lowering 
effects and are not subject to such drug-drug interactions with lopinavir/ritonavir 
and other PIs. The newly introduced statin rosuvastatin may fulfil these requirements. 
CYP450-based metabolism does not to play an important role in the clearance of 
rosuvastatin (8;9). Rosuvastatin is only minimally metabolized by CYP3A4 (10). 
Furthermore, rosuvastatin has been demonstrated to be an effective statin in HIV-
uninfected patients (11). However, the pharmacokinetics of rosuvastatin when used 
concomitantly with PIs has not yet been investigated.
The primary objective of this pilot study was to explore the effect of rosuvastatin on 
plasma lipids in HIV-infected patients with hyperlipidaemia who were on stable 
lopinavir/ritonavir containing antiretroviral therapy (ART). The bidirectional pharma-
cokinetics of rosuvastatin and lopinavir/ritonavir and the safety of the combination 
were also assessed.
Methods
This multiple-dose, open-label, three-period, pilot study was conducted from May 
2004 until July 2005 at the Radboud University Nijmegen Medical Centre, the 
74 75
P
ha
rm
ac
ok
in
et
ic
s 
an
d
 p
ha
rm
ac
od
yn
am
ic
s 
of
 c
om
b
in
ed
 u
se
 o
f 
lo
p
in
av
ir/
ri
to
na
vi
r 
an
d
 r
os
uv
as
ta
tin
 in
 H
IV
-i
nf
ec
te
d
 p
at
ie
nt
s
C
ha
p
te
r 
3
Academic Medical Center in Amsterdam, and the University Medical Centre Leiden, 
all in the Netherlands, and at the University of Bonn and the University of Cologne 
in Germany.
Study population
This pilot study was conducted in HIV-1-infected dyslipidaemic males and females, 
aged 18 to 65 years, who were on stable lopinavir/ritonavir 400/100 mg BID-
containing ART for at least 3 months and had signed informed consent. 
Hyperlipidaemia was defined as fasting total cholesterol >6.2 mmol/L (239 mg/dL). 
Plasma HIV-1 RNA had to be below 400 copies/mL on two consecutive occasions, 
at least one month apart. The main exclusion criteria were: history of sensitivity/
idiosyncrasy to rosuvastatin or chemically related compounds, hepatic disease, 
hypothyroidism, alcohol abuse, or a relevant history or current condition that might 
interfere with pharmacokinetics. Pregnant or breast-feeding females and Japanese 
or Chinese patients were excluded from participation. Japanese and Chinese 
patients were excluded because Asian patients are more likely to experience side 
effects of rosuvastatin such as rhabdomyolysis (12). Other exclusion criteria were: 
creatinine clearance <60 ml/min (calculated from serum creatinine), fasting plasma 
triglyceride level >8.0 mmol/L (700 mg/dL), a history of statin-related rhabdomyolysis 
or a family history of inheritable muscle disease and abnormal creatine kinase 
levels (>10 times upper limit of normal). The use of any statin or fibrate in the 6 
weeks prior to the first dose of rosuvastatin and/or previous use of rosuvastatin 
were not allowed. Patients using concomitant medication known to potentially 
interfere with the pharmacokinetics of rosuvastatin or lopinavir/ritonavir, such as 
efavirenz and nevirapine, were excluded as well. Subjects were advised not to 
change their dietary habits during the 12-week study period. At screening (within 3 
weeks prior to the first dose) patients’ eligibility for inclusion was established.
Study design
All subjects started with an oral dose of 10 mg rosuvastatin once-daily (QD) in 
addition to their regular dose of lopinavir/ritonavir (400/100 mg twice-daily [BID] as 
soft gelatine capsules) and other components of their current combination 
antiretroviral therapy (ART)-regimen. Patients continued with the combined use of 
lopinavir/ritonavir and rosuvastatin 10 mg QD until week 4 at which time fasting 
lipids were determined. The dose of rosuvastatin was escalated to 20 mg QD for 
the following 4 weeks if patients had not reached each of the four following targets 
derived from the Guidelines of the HIV Medical Association of the Infectious 
Disease Society of America (IDSA) and the Adult AIDS Clinical Trials Group (13): 
total cholesterol <5.0 mmol/L (192 mg/dL); LDL-cholesterol <2.6 mmol/L (100 
mg/dL); HDL-cholesterol >1.0 mmol/L (40 mg/dL); triglycerides <2.0 mmol/L (175 
mg/dL). If after an additional 4 weeks of 20 mg of rosuvastatin QD, the above-
mentioned targets were still not reached at week 8, rosuvastatin was escalated 
once more to 40 mg QD for the subsequent four weeks (up to week 12, which was 
the end of study). If patients had reached all targets at week 4 or week 8, they 
continued their current dose of rosuvastatin for the remainder of the study. Patients 
continued using the regular dose of lopinavir/ritonavir 400/100 mg BID during the 
whole study period of 12 weeks.
Relatively short periods, i.e. 4 weeks were chosen after which the dose of 
rosuvastatin could be escalated in case the abovementioned targets were not 
reached, because the maximum lipid-lowering effect of rosuvastatin has mostly 
been shown to be achieved after a 4 week dosing period (12), and also because 
we wanted to limit the overall duration of the trial.
The study was approved by the local ethics committees of each of the participating 
sites.
Biochemistry, safety assessments and pharmacokinetic sampling
Lopinavir/ritonavir trough levels, drawn just before the next dose of lopinavir/
ritonavir (within the time window of 9–15 hours after intake), were determined at 
week 0, 4, 8, and 12. Rosuvastatin trough levels, 24 hours after intake, were 
obtained at week 4, 8, and 12. Serum biochemistry, including total cholesterol, LDL-
cholesterol, HDL-cholesterol, triglycerides, hepatic and muscular enzymes, as well 
as hematology and urinalysis were performed at week 0, 4, 8, and 12 at the local 
sites. Adverse events were assessed at each of these time points.
Total cholesterol, HDL-cholesterol and triglycerides were measured using a 
cholesterolesterase/cholesteroloxidase/peroxidase colorimetric test, a homogeneous 
enzymatic (PEG-modified cholesterol-esterase and –oxidase) colorimetric test, 
and a enzymatic colorimetric test, respectively. In Nijmegen, Bonn, Cologne, and 
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Amsterdam LDL-cholesterol was calculated from the Friedewald formula (14). In 
Leiden LDL-cholesterol was directly measured with a cholinesterase/cholester-
inoxidase/peroxidase colorimetric test; In Cologne this assay was used if TG was 
>4.5 mmol/L. If in Bonn patients had TG levels above 4.5 mmol/L, LDL-cholesterol 
could not be calculated; In Nijmegen and Amsterdam none of the patients 
experienced high TG levels.
Bioanalysis of lopinavir/ritonavir and rosuvastatin concentrations in plasma
Plasma samples of lopinavir and ritonavir were analyzed at the Department of 
Clinical Pharmacy, Radboud University Nijmegen Medical Centre. The Department 
of Clinical Pharmacy has established an HPLC assay for lopinavir and ritonavir, 
derived from an HPLC method which has been published previously (15). For the 
determination of lopinavir and ritonavir in our trial, we used acetonitrile and 50 
mmol/L potassium phosphate adjusted to pH 5.60 as a mobile phase. The 
acetonitrile concentration was increased from 35% to 54% during a 21-minute 
period, thereafter it was returned to 35%. The accuracy for lopinavir was 104% at 
0.15 mg/L, 102% at 1.5 mg/L and 101% at 7.5 mg/L. For ritonavir, the accuracy was 
101%, 104% and 103%, respectively. The precision (within-day; coefficient of 
variation) for lopinavir was 3.34%, 1.37% and 1.42% at 0.15, 1.5 and 7.5 mg/L, 
respectively. For ritonavir, the precision was 3.22%, 1.70%, and 0.89%, respectively. 
The calibration curves were linear over the concentration range of 0.10 to 30 mg/L 
for lopinavir and 0.045 to 30 mg/L for ritonavir.
Rosuvastatin plasma samples were measured at Covance Laboratories, Inc.
Madison, Wisconsin, United States. The quantification of rosuvastatin in plasma 
was performed by automated solid-phase extraction using tandem mass 
spectrometric detection, as published previously (16). The lower limit of quantification 
of rosuvastatin was 0.1 ng/mL. This assay was linear over the range 0.1–30 ng/mL. 
The imprecision and inaccuracy were within the pre-specified acceptable limits of 
<±15% and <15%, respectively. 
Sample size and statistical analysis
No formal sample size calculation was performed as this was a descriptive pilot 
study of the pharmacodynamics, pharmacokinetics and safety of combined use of 
lopinavir/ritonavir and rosuvastatin.
The changes in total cholesterol, LDL-cholesterol, HDL-cholesterol, and triglycerides 
between baseline and week 4, and between baseline and week 12 were assessed 
using a Paired Samples T-test, because all these lipid parameters were normally 
distributed. For the comparison of lopinavir and ritonavir concentrations at week 0, 
4, 8, and 12 General Linear Model Repeated Measures analyses were performed 
using the logarithmic transformed trough concentrations.
Statistical evaluations were carried out using SPSS® for Windows, version 12.0.1 
[SPSS Inc, Chicago, IL, USA, 1989-2003].
Results
Baseline characteristics
Twenty-two HIV-1-infected patients without hepatitis co-infection were included in 
this trial. Six patients were included in Leiden, six in Bonn, five in Cologne, four in 
Nijmegen and one in Amsterdam. Baseline characteristics are shown in Table 1. 
Mean viral load and CD4 count did not change during the trial between baseline 
and week 12 (p=0.794 and p=0.783, respectively; Paired Samples T-test), so 
rosuvastatin did not appear to affect virological response.
Pharmacodynamics
At baseline, all patients started using 10 mg of rosuvastatin QD and were dose 
escalated if any of the targets for the lipid panel at week 4 or 8 were not met. 
At week 4, three patients continued using 10 mg of rosuvastatin QD, but nineteen 
patients were dose escalated to 20 mg of rosuvastatin QD. From week 8–12, only 
one patient was still using 10 mg of rosuvastatin QD, seven patients had been 
escalated to 20 mg QD while fourteen had been escalated to 40 mg QD. One male 
patient had developed an elevated level of creatinekinase at week 4 (493 U/L, 
which is about 4-fold higher than the upper limit of normal) and was therefore not 
dose escalated to 20 mg of rosuvastatin QD (as described in the adverse events 
section) in spite of the fact that he did not meet the predefined lipid targets.
Table 2 shows the effect of rosuvastatin on fasted total cholesterol, LDL-cholesterol, 
HDL-cholesterol and triglyceride levels at week 4, 8, and 12 compared to baseline. 
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Triglyceride levels of three patients were not included in the data analysis. In spite 
of the fact that their triglyceride levels at screening were above 8.0 mmol/L, which 
was an exclusion criterion, these patients met all other inclusion criteria and were 
nevertheless included to investigate the effect of rosuvastatin on total cholesterol, 
LDL-cholesterol and HDL-cholesterol. The local investigator who was responsible 
for their care was determined to start lipid-lowering therapy with a statin in them 
anyway, and therefore requested to waive the inclusion criterion for  triglycerides 
for these patients and allow them to be entered in the trial, which was granted.
The mean percent reduction (standard deviation [sd]) in total cholesterol, LDL-
cholesterol, and triglycerides resulting from 10 mg of rosuvastatin QD from week 0 
to 4 was 27.6% (7.6%), 31.8% (16.7%), and 20.7% (38.5%), respectively (p<0.001, 
p<0.001, and p=0.022 vs. baseline; Paired Samples T-test). The mean percent 
increase in HDL-cholesterol between week 0 and 4 was 3.1% and not statistically 
significant (sd: 12.5%; p=0.460). The overall mean reduction in lipid levels (sd), 
comparing week 12 to baseline, combining data from all dose groups, was 33.8% 
(9.7%), 38.9% (25.8%) and 37.0% (26.1%) for total cholesterol, LDL-cholesterol and 
triglycerides, respectively (p<0.001, p<0.001, and p=0.001). There was a mean 
increase in HDL-cholesterol of 16.9% which did not reach statistical significance 
(sd: 39.5%; p=0.080 vs. baseline).
Table 1 Baseline characteristics (week 0) 
Parameter
Gender 2 F, 20 M
Age (years); Median (IQR) 48 (40–56)
Weight (kg); Median (IQR) 78 (67–88)
Height (m); Median (IQR) 175 (172–178)
CDC class 12 A, 10 C
Mode of transmission 15 homosexual, 6 heterosexual, 1 unknown
Lopinavir/ritonavir as first HAART regimen 7 yes, 15 no
Backbone Number of patients
Zidovudine / lamivudine 10
Tenofovir / lamivudine 4
Didanosine / lamivudine 3
Abacavir / lamivudine 1
Abacavir / tenofovir 1
Stavudine / abacavir 1
Lamivudine / stavudine 1
Emtricitabine / tenofovir 1
CD4 (*106/L); Median (IQR) 399 (265–482)
CD8 (*106/L); Median (IQR) 935 (708–1263)
Viral load (copies/ml) 21 patients <50; 1 patient 206
Total cholesterol (mmol/L); Mean (sd) 7.1 (0.95)
LDL-cholesterol (mmol/L); Mean (sd) 4.2 (0.99)
Triglycerides (mmol/L); Mean (sd) 3.6 (1.8)
HDL-cholesterol (mmol/L); Mean (sd) 1.2 (0.43)
Apolipoprotein A1 (g/L); Median (IQR) 1.30 (1.20–1.50)
Apolipoprotein B (g/L); Median (IQR) 1.30 (1.15–1.50)
HsCRP (mg/L); Median (IQR) 3.0 (2.0–4.4)
Table 2  Mean total cholesterol, LDL-cholesterol, HDL-cholesterol, and  
triglycerides levels at weeks 0, 4, 8, and 12 
 Total cholesterol LDL-cholesterol HDL-cholesterol Triglycerides
 Mean (sd) Mean (sd) Mean (sd) Mean (sd)
 (mmol/L) (mmol/L) (mmol/L) (mmol/L)
 N=22 N=20 N=22 N=19
Week 0 7.1 (0.95) a 4.2 (0.99) c 1.2 (0.43) a 3.6 (1.8) a
Week 4 5.2 (0.81) b 2.8 (0.61) b 1.2 (0.41) b 2.6 (1.3) b
Week 8 4.9 (1.2) 2.7 (0.77)  1.2 (0.51) 2.2 (1.0)
Week 12 4.7 (0.79) 2.5 (0.61) d 1.4 (0.81) 2.3 (1.4)
a Two patients were excluded for data-analysis because of non-fasting; b One patient was 
excluded because of non-fasting; c Two patients were excluded because of non-fasting 
and one level could not be determined because of high triglyceride levels; d One level 
could not be determined because of high triglyceride levels
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Figure 1  Total cholesterol, LDL-cholesterol, HDL-cholesterol and triglyceride levels  
at weeks 0, 4, 8, and 12 compared to the targets of the lipid panel 
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At week 12, 32% (7/22) of the patients met all of the predefined lipid targets; when 
looking at each lipid parameter individually, 68% (15/22) of the patients reached the 
target for total cholesterol, 68% (13/19) for LDL-cholesterol, 68% (15/22) for HDL-
cholesterol and 53% (10/19) for triglycerides. Figure 1 shows the individual lipid 
levels compared to the target at weeks 0, 4, 8, and 12.
Pharmacokinetics
Lopinavir levels of twenty patients were included in our data analysis; lopinavir 
levels of two patients were excluded, because these samples were not drawn within 
the prespecified time window (9–15 hours after intake). Median (IQR) lopinavir Cmin 
were 5.2 (3.7–6.5), 5.4 (4.1–7.6), 5.6 (4.2–7.8) and 5.2 (3.6–6.3) mg/L at weeks 0, 4, 
8 and 12, respectively. A repeated-measures analysis showed no difference 
between logarithmic transformed lopinavir Cmin at weeks 0, 4, 8, and 12 (p=0.44).
For the analysis of the ritonavir trough levels, the same samples as for lopinavir 
data analysis were used. Median (IQR) ritonavir Cmin (9–15 hours after intake) were 
0.22 (0.17–0.28), 0.25 (0.14–0.36), 0.26 (0.14–0.33) and 0.20 (0.17–0.34) mg/L at 
weeks 0, 4, 8 and 12, respectively (repeated-measures analysis: p=0.26).
For rosuvastatin, trough levels were available for 12, 13, and 9 patients on 10 mg, 
20 mg, and 40 mg of rosuvastatin QD, respectively. Unfortunately, in some cases, 
the blood samples were drawn about 12 hours after intake instead of 24 hours after 
intake. This is the reason why median trough levels were not provided for all 
patients. For nine patients rosuvastatin plasma levels were available for rosuvastatin 
the doses of 10 mg, 20 mg, as well as 40 mg. Table 3 shows the median rosuvastatin 
trough levels for the different dosages compared to those obtained from historical 
HIV-uninfected controls without hyperlipidaemia (measured with the same method 
and at the same laboratories as the samples from our trial) (data on file AstraZeneca 
and (17-19)). Plasma trough levels of rosuvastatin appeared to be 1.6-fold higher 
compared to those in these historical healthy controls.
Adverse events and safety assessments
None of the included patients dropped out or temporarily stopped taking 
rosuvastatin during this 12–week trial. The reported adverse events were mild, as 
shown in Table 4. Three patients experienced transient muscle pain/cramps: one 
on 10 mg of rosuvastatin QD during week 3, one on 20 mg QD during week 8–12, 
and one on 40 mg QD during week 8–12, respectively. The patient who reported 
muscle pain on 20 mg of rosuvastatin QD during week 8–12 also had an elevated 
Table 3  Median rosuvastatin trough levels for 10, 20 and 40 mg compared  
to historical healthy controls 
Rosuvastatin dosage Rosuvastatin Cmin (ng/mL) Ratio Cmin rosuvastatin
 Our trial Historical healthy (Our trial / historical
 Median (IQR) controls a (17) controls)
  Mean (range)
10 mg (N=12) 1.0 (0.69–1.5) 0.63 (0.27–1.2) 1.6
20 mg (N=14) 2.5 (1.3–3.3) 1.6 (0.54–4.1) 1.6
40 mg (N=9) 4.5 (3.3–7.5) 2.9 (1.7–3.6) 1.6
a Data on file AstraZeneca
Table 4 Adverse events 
System organ class Adverse event Incidence
 Diarrhea  2
Gastrointestinal
 Obstipation  1
 Abdominal pain 1
 Oral redness  1 
Musculoskeletal  Joint and muscle pain 3
 Bronchitis  1
Respiratory Sinusitis  1
 Cough  1
 Headache  2
Systemic
 Floppines  1
 Cold  2
 Night sweat  1
Biochemisty Elevated creatinekinase 4
Overall   21
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creatinekinase level of 436 U/L at week 12; rosuvastatin was stopped after the trial. 
After stopping rosuvastatin, the symptoms disappeared and the creatinekinase 
level returned to normal. The other two patients had normal creatinekinase levels 
(range: 64–100 U/L) and continued to use rosuvastatin.
In addition, three patients had clinically asymptomatic elevations of creatinekinase 
above 250 U/L, ranging from 363 to 676 U/L. One of these patients already had an 
elevated creatininekinase level at baseline. For one of these patients the creatine-
kinase level at week 4 was 493 U/L and the dosage of rosuvastatin at week 4 was 
therefore not increased to 20 mg QD. However, at week 8 his creatinekinase level 
had returned to normal and the dosage of rosuvastatin was then increased to 20 
mg QD because criteria for the lipid panel were still not met. At week 12, the 
creatinekinase level remained in the normal range.
Median liver enzymes were as follows, comparing baseline to week 12: median 
(IQR) ALAT (N=20; in two patients ALAT was not determined) and ASAT (N=22) 
were 25.5 (16.0-37.8) and 28.0 (20.0-35.3) at week 0 and 26.5 (22.0-47.5) and 27.5 
(21.0-35.0) at week 12, respectively.
Discussion
The main finding of the present pilot study is that rosuvastatin appears to be an 
effective statin in hyperlipidaemic HIV-1-infected patients treated with a lopinavir/
ritonavir-containing ART regimen. Secondly, plasma trough levels of lopinavir/
ritonavir, as expected, were indeed not influenced by the concomitant use of 
rosuvastatin. In contrast, rosuvastatin trough levels were found to be 1.6-fold higher 
as compared to those previously found in HIV-uninfected subjects without 
hyperlipidaemia. 
In our prospective pilot study, following 4 weeks of treatment with 10 mg of 
rosuvastatin QD, mean reductions in total cholesterol, LDL-cholesterol and 
triglycerides were 27.6%, 31.8%, and 20.7% respectively. In a recently published 
study, performed in hyperlipidaemic HIV-1-infected patients on various ART 
regimens using 10 mg of rosuvastatin QD, similar reductions in the aforementioned 
lipid levels were observed following 24 weeks of treatment (20). 
In HIV-negative patients with hyperlipidaemia, rosuvastatin in a dose range of 10 to 
40 mg, reduced LDL-cholesterol by 43% to 63% (reviewed by Cheng (21)). For 10 
mg of rosuvastatin, we found in our trial, with a relatively small sample size, a 
somewhat lower effect on LDL-cholesterol. We cannot compare the results at 
weeks 8 and 12 of our study with other studies in HIV-negative patients because 
our trial was designed to titrate the patient to our predefined goals and only the 
poor responders were eligible for dose escalation of rosuvastatin.
The somewhat lower effect of rosuvastatin we found in our trial despite the 
increased plasma levels, could be explained by the fact that when rosuvastatin 
plasma levels are increased, the intake of rosuvastatin in the hepatocytes is 
decreased. Rosuvastatin conducts its effect in the hepatocytes. So, a decreased 
concentration of rosuvastatin in the hepatocytes could cause a decreased lipid-
lowering effect.
Intrapatient lopinavir trough levels were not affected by the concomitant use of 
rosuvastatin. Previous studies reported similar lopinavir trough concentrations 
(22;23). The same was true for ritonavir trough levels which were also similar to 
data from historical controls (24;25). These observations are in accordance with in 
vitro observations indicating an absence of inhibitory or inducing effects of 
rosuvastatin on cytochrome P450 enzymes (10;26).
Only a few trials investigated rosuvastatin pharmacokinetics in patients with 
hyperlipidaemia. In contrast, pharmacokinetic studies have been performed 
extensively in healthy volunteers, but trough levels have only been reported from a 
minority of these studies (17-19). We used data for comparison from a study in 
healthy subjects which were on file at AstraZeneca, the manufacturer of rosuvastatin. 
In our trial, rosuvastatin trough levels were 1.6-fold higher as compared to the levels 
found in that study in healthy, HIV-uninfected subjects without hyperlipidaemia for 
dosages of 10 mg, 20 mg and 40 mg of rosuvastatin QD. These higher rosuvastatin 
levels could not have been caused by a CYP450-based interaction since 90% of 
rosuvastatin is excreted unchanged in faeces (12) and CYP-based metabolism was 
anticipated not to play an important role in the clearance of rosuvastatin. With 
respect to the latter, rosuvastatin in vitro was shown not to be metabolized by 
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human hepatic microsomes nor by heterologously expressed human CYP450 
enzymes, and was very slowly metabolized in cultured human hepatocytes (10). 
Only a single metabolite, N-desmethyl rosuvastatin, was formed in the hepatocytes. 
CYP2C9 and CYP2C19 were the primary and CYP3A4 the minor metabolic enzymes 
involved (10). Moreover, studies in healthy volunteers showed no relevant drug-
drug interactions involving CYP2C9 (27), CYP2C19 (27), nor CYP3A4 (28-30), 
indicating the minor role of these pathways in rosuvastatin metabolism. Based on 
these previously reported observations and our data, we find it unlikely that the 
higher rosuvastatin levels can be explained by CYP450 enzyme inhibition by the 
lopinavir/ritonavir combination.
An alternative explanation for our observation might be that lopinavir/ritonavir 
affects a membrane transporter of rosuvastatin. In a study by Simonson et al. a 
significant increase in rosuvastatin exposure was observed in heart transplant 
recipients using cyclosporine (31). The mechanism for this was believed to be a 
cyclosporine-mediated inhibition of the human liver transporter organic anion 
transporting polypeptide C (also known as OATP-1B1). OATP-C (1B1) is a 
transporter protein, selectively expressed in the basolateral membrane of the liver 
(32), and is likely to be involved in the hepatic uptake of rosuvastatin (33-35). 
To our knowledge, no studies have been performed investigating the effect of the 
combination of lopinavir and ritonavir on OATP. However, ritonavir, saquinavir and 
indinavir are known to inhibit OATP1B1 (34;35).
A recently performed pharmacokinetic drug-drug interaction study with lopinavir/
ritonavir in 15 healthy volunteers also showed an increase in rosuvastatin exposure: 
a 2.1-fold increase in AUC and a 4.7-fold increase in Cmax were found (36). 
The effect of lopinavir/ritonavir on rosuvastatin AUC and Cmax, which Hoody 
observed, is in agreement with the results of our trial. However, we cannot explain 
why Hoody et al. did not find an effect on rosuvastatin trough levels while finding 
an increased AUC and Cmax.
Whether the increased rosuvastatin exposure, observed in our trial and by Hoody 
et al. (36), is clinically relevant, is questionable while the orders of magnitude are 
less than what has been reported in previous interaction studies between several 
different PIs and statins other than rosuvastatin. The combination of lopinavir/
ritonavir with atorvastatin (20 mg QD) for instance resulted in an increase in 
atorvastatin AUC by 590% (37); the combination of saquinavir/ritonavir (400/400 
mg BID) resulted in an increased simvastatin (40 mg QD) AUC of as high as 3059% 
(6). When nelfinavir (1250 mg BID) was co-administered with simvastatin (20 mg 
QD) an increased AUC of 505% was observed (38).
With respect to safety and tolerability, all patients remained on all drugs during the 
12-week study period. None of the patients reported moderate or serious adverse 
events. However, three patients experienced transient muscle pain/cramps, all of 
them on different doses of rosuvastatin. This favourable tolerability profile of 
rosuvastatin including the absence of any cases of rhabdomyolysis was observed 
both in our study and the one reported by Calza et al. (20). One needs to realize 
however that rhabdomyolysis is a relatively rare complication of statin use, and thus 
larger studies are needed to confirm the safety of using rosuvastatin in HIV-infected 
patients on antiretroviral therapy.
Our study has a number of limitations. Because of the relatively small sample size, 
no centralized plasma lipid measurements and the strict lipid target criteria which 
were used, the results regarding both safety and pharmacodynamic effects on 
lipids should be interpreted with caution. In addition, although patients were 
instructed not to change their diet during the study, formal data on diet were not 
collected during the trial and changes in dietary pattern may have influenced the 
results. Another limitation from our study is that it did not include a randomized 
control group. Rosuvastatin trough levels were compared to those reported in 
healthy uninfected historical controls, and lopinavir/ritonavir plasma levels for each 
patient were compared to baseline before adding rosuvastatin to their existing 
lopinavir/ritonavir-based ART regimen. Future drug-drug interaction studies 
between rosuvastatin and lopinavir/ritonavir or other PIs may consider including a 
randomized control group of HIV-infected patients using rosuvastatin in the 
absence of lopinavir/ritonavir and other ART regimens. Finally, in this exploratory 
pilot study we have chosen to only determine rosuvastatin trough levels in order not 
to burden patients with recording 24-hour pharmacokinetic curves at weeks 4, 8, and 
12. Nonetheless, determination of rosuvastatin AUCs would provide more information 
concerning any interaction between rosuvastatin and lopinavir/ritonavir, and for this 
reason we do suggest that in future trials pharmacokinetic curves are obtained. 
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In summary, in our pilot study rosuvastatin appeared to be an effective statin in 
hyperlipidaemic HIV-1-infected patients treated with lopinavir/ritonavir. Although 
plasma lopinavir/ritonavir levels were not demonstrated to be affected by the 
concomitant use of rosuvastatin, rosuvastatin levels were 1.6-fold higher compared 
to those in HIV-uninfected healthy volunteers without hyperlipidaemia. Our findings 
support further research, especially a randomized placebo-controlled trial, in larger 
numbers of patients to more fully elucidate the pharmacokinetics, the efficacy, as 
well as the safety of the combined use of rosuvastatin and lopinavir/ritonavir in HIV-
infected patients. Until such time, the combination of rosuvastatin and lopinavir/
ritonavir should continue to be used with caution.
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Abstract
Background
Limited data are available about the effect of lopinavir and low dose ritonavir on 
glucuronidation. Lamotrigine undergoes glucuronidation. We studied the effect of 
lopinavir/ritonavir on the pharmacokinetics of lamotrigine and vice versa.
Methods
Twenty-four healthy subjects received 50 mg lamotrigine QD on Days 1-2 and 100 
mg BID on Days 3-23. Lopinavir/ritonavir 400/100 mg BID was added on Day 11. 
Depending on the decrease in lamotrigine Cmin between Days 10 and 20, the study 
was either stopped (<20% decrease) or a dose increase was applied from Day 23 
to 31, as follows: increase to 150 mg lamotrigine BID if there was a 20 to 33% 
decrease, increase to 200 mg BID if there was a 34 to 66% decrease, and increase 
to 300 mg BID if there was a greater than 66% decrease. On Days 10, 20 and 31, 
12-hour-pharmacokinetic curves were drawn.
Results
The mean decrease in lamotrigine Cmin between Days 10 and 20 was 55.4% (N=18). 
A dose increment to 200 mg lamotrigine BID was used in all subjects. 
The AUCs of lamotrigine on Day 20 (with lopinavir/ritonavir) and Day 10 (without 
lopinavir/ritonavir) were bio-inequivalent with a point estimate of 0.50 (90% CI: 0.47-
0.54). After dose adjustment of lamotrigine to 200 mg BID, the AUC of Day 31 
(N=15) was bioequivalent to Day 10 with a point estimate of 0.91 (90% CI: 0.82-
1.02). The median (IQR) AUC-ratios of lamotrigine-2N-glucuronide/lamotrigine on 
Day 10 and Day 20 were 0.57 (0.39-0.75) and 1.12 (0.87-1.31). Pharmacokinetic 
parameters for lopinavir/ritonavir were similar to historical controls. 
Conclusion
Lopinavir/ritonavir decreases the AUC of lamotrigine, probably by induction of 
glucuronidation. A dose increment to 200% of the initial lamotrigine dosage is 
needed to achieve similar concentrations to those with lamotrigine alone. 
Lamotrigine does not appear to affect the pharmacokinetics of lopinavir/ritonavir.
Introduction
Highly active antiretroviral therapy (HAART) is used in the treatment of HIV/ AIDS. 
HAART consists of at least 3 antiretroviral drugs often including a protease inhibitor 
(PI) and two nucleoside reverse transcriptase inhibitors (NRTIs). Lopinavir/ritonavir 
(Kaletra®) is an efficacious antiretroviral agent (1), and is often selected as a first 
choice when a protease inhibitor is needed. Lopinavir is predominantly metabolized 
via cytochrome P450-3A4. The metabolism of lopinavir is strongly inhibited by 
ritonavir, which causes higher plasma levels and a better efficacy of lopinavir (2-4).
Therapeutic treatment of comorbidity may complicate the treatment of HIV-
infection, because of the occurrence of drug-drug interactions, especially with PIs. 
Seizure disorders may complicate HIV disease, either as a direct result of HIV or as 
a manifestation of a secondary opportunistic infection such as cerebral toxoplas-
mosis (5;6). Retrospective studies estimate that 11% to 17% of HIV-infected patients 
will have seizures sometime during their course. Current treatment guidelines 
recommend the use of anticonvulsant drugs in patients with seizures with an 
irreversible cause (7;8). 
In addition, symptomatic neuropathies occur in approximately 10% to 15% of HIV-
1-infected patients overall and pathological evidence of peripheral nerve involvement 
is present in virtually all end-stage AIDS patients. Distal sensory polyneuropathy 
(DSP) is the most common among HIV-1-associated neuropathies (9). Approximately 
one-third of the patients with HIV/AIDS have DSP, characterized by pain, numbness 
and burning primarily in the soles and dorsum of the feet. Evidence to date 
indicates that the two prevalent mechanisms are immunological dysfunction 
secondary to HIV and the neurotoxic effects of antiretroviral drugs, particularly 
dideoxynucleosides (didanosine, stavudine, zalcitabine). Antiretroviral toxic 
neuropathy is clinically similar to DSP caused by HIV-infection and difficult to 
distinguish. DSP and toxic neuropathy may coexist in a patient (10;11).
Lamotrigine is an anticonvulsant drug and exerts its antiepileptic effect by blocking 
voltage-dependent sodium channels, thus by stabilizing presynaptic neuronal 
membranes. It can be used for the treatment of epilepsy of HIV-infected patients as 
mono- or add-on therapy. Furthermore, lamotrigine is used for the treatment of 
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neuropathic pain. Lamotrigine is one of the few agents with documented efficacy 
against HIV-associated neuropathic pain, both in patients receiving neurotoxic 
antiretroviral therapy and for DSP (10).
Concurrent use of lamotrigine in HIV-infected patients using HAART, however, may 
result in a drug-drug interaction. Lamotrigine undergoes hepatic biotransformation 
by UDP-glucuronyltransferases, with the 2N-glucuronide as the principal metabolite 
(12). It appears that high dose ritonavir decreases the exposure of certain drugs, 
such as ethinyloestradiol (13), pravastatin (14) and levothyroxine (case report) (15). 
The proposed mechanism for this interaction is induction of glucuronidation by 
ritonavir, but plasma levels of the glucuronide-metabolites of the drugs were not 
determined to support this hypothesis. For low dose ritonavir (with or without 
lopinavir) there are neither clear data available about the influence on glucuronidation. 
Conflicting data are available about the effect of ritonavir on UDP-glucuronosyl-
transferases (UGT) in vitro. One study showed an inhibitory effect on UGT1A1 (16), 
while another study showed an inducing effect of ritonavir (17).
Based on the above, there is a clear need for performing a clinical trial in healthy 
volunteers to determine the effect of lopinavir/ritonavir on lamotrigine and 
lamotrigine-2N-glucuronide. Because there are limited data available on the effect 
of low dose ritonavir on other drugs that undergo glucuronidation, the outcome of 
this trial could also predict the effect of lopinavir/ritonavir on other drugs that 
undergo the same type of glucuronidation.
Methods
Study design
This open-label, sequential, 3-period, single-centre, phase-IV, multiple-dose trial 
was conducted in November and December 2004 in the Radboud University 
Nijmegen Medical Centre, Nijmegen, the Netherlands. The study was designed to 
examine the effect of lopinavir/ritonavir on the pharmacokinetics of lamotrigine and 
lamotrigine-2N-glucuronide determined by intra subject comparison and to 
determine the effect of lamotrigine on the pharmacokinetics of lopinavir/ritonavir 
when compared to historical controls. Furthermore, the necessary dose adjustment 
of lamotrigine was determined if an effect of lopinavir/ritonavir on the pharma-
cokinetics of lamotrigine would be found. The secondary objective of this trial was 
to evaluate the safety of combined use of lamotrigine and lopinavir/ritonavir. 
To examine the objectives of this trial, lamotrigine was given alone for the first 10 
days of the trial. Then lopinavir/ritonavir was added to determine the effect of the 
combination of the drugs on their pharmacokinetics. If the trough levels of 
lamotrigine (measured immediately during the study) were decreased in combination 
with lopinavir/ritonavir, the lamotrigine dose was adjusted and the trial was 
continued until Study Day 31. The trial was approved by the Review Board of the 
Radboud University Nijmegen Medical Centre.
Study population
This trial was conducted in healthy males and females between 18 and 65 years of 
age at the day of first dosing. Subjects were included, who did not smoke more 
than 10 cigarettes, 2 cigars, or 2 pipes per day for at least 3 months prior to the first 
dosing, had a Quetelet Index (Body Mass Index) of 18 to 30 kg/m2, and were able 
and willing to sign the Informed Consent Form prior to screening evaluations. 
Subjects had to be in a good age-appropriate health condition as established by 
medical history, physical examination, electrocardiography, and biochemistry, 
hematology and urinalysis testing within 3 weeks prior to the first dose. The main 
exclusion criteria were a history of sensitivity/idiosyncrasy to lopinavir, ritonavir or 
lamotrigine or chemically related compounds or excipients, a positive HIV test, a 
positive hepatitis B or C test or therapy with any drug (for two weeks preceding 
dosing), except for acetaminophen, hormonal contraceptives and loperamid 
(which could be used if diarrhea occurred). Other exclusion criteria were: 
participation in a drug trial or donation of blood within 60 days prior to the first 
dose. Pregnant females and female subjects of childbearing potential who were not 
willing to take precautions in order to prevent a pregnancy were also excluded.
Study drug and dosing
The subjects received 50 mg lamotrigine once daily on Study Days 1 and 2. From 
Day 3 until Day 23 (morning) the subjects received 100 mg lamotrigine twice daily. 
This lamotrigine dose is commonly used in clinical practice in patients with 
epilepsy. The chosen dose escalation of lamotrigine was different from the drug 
label (18), but based on previous trials in which the same dose escalation (19) or a 
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dose escalation over a shorter period were used (20-22). From Day 11 until Day 23 
(morning) lopinavir/ritonavir 400/100 mg twice daily (3 capsules of 133.3/33.3 mg 
of lopinavir/ritonavir to be taken with food) was added to lamotrigine. Depending 
on the mean decrease in lamotrigine trough level (Cmin) between Days 10 and 20, 
the study was either stopped (<20% decrease) or a dose increase of lamotrigine 
was applied from Day 23 (evening) until Day 31: to 150 mg lamotrigine BID if 
20-33% decrease; to 200 mg BID if 34-66%; and to 300 mg BID if >66%. The 
dosage of lopinavir/ritonavir remained 400/100 mg BID during the entire study. 
The dosage of lopinavir/ritonavir was similar to the licensed BID dosage regimen.
Safety assessments and pharmacokinetic sampling
Blood samples for pharmacokinetics were collected throughout a 12-hour period 
(0, 1, 2, 3, 4, 5, 6, 8, 10, and 12 hours) after dosing on Days 10 and 20 for lamotrigine 
and on Day 20 for lopinavir/ritonavir to characterize drug absorption and elimination. 
Trough levels, just before intake of the drugs, were collected on Days 1, 3, 6, 8, 13, 
16, 18 and a randomly taken plasma level was taken on Day 23. Trough levels on 
Days 8 and 18 were collected to determine if steady state concentrations on Days 
10 and 20 were reached. If the dosage of lamotrigine was adjusted, blood samples 
were also taken just before dosing in the morning on Days 26 and 29 and at 0, 1, 
2, 3, 4, 5, 6, 8, 10, and 12 hours after dosing (10 samples) on Study Day 31 
(lamotrigine and lopinavir/ritonavir).
Serum biochemistry, hematology and urinalysis were checked on Days 1, 3, 6, 8, 
10, 13, 16, 18, 20 and 23. If the dosage of lamotrigine was adjusted, this was 
repeated on Days 26, 29 and 31. Adverse events were assessed during the same 
visits. A pregnancy test for women and a screening for drugs of abuse were 
conducted on Days 1, 10, 20 and 31.
Compliance 
Study personnel supervised all medication intakes at the clinical trial unit. The exact 
times of dosing were recorded. Drug intakes by the subjects at home were 
monitored by the use MEMS caps (Aardex Ltd., Zug, Switserland), which record the 
opening of the medication bottle. Furthermore, subjects were asked to write down 
the exact times of medication intake in a booklet.
Bioanalysis of lopinavir/ritonavir, lamotrigine and lamotrigine-2N-glucuronide 
concentrations in plasma
Plasma samples of lopinavir, ritonavir, lamotrigine and lamotrigine-2N-glucuronide 
were analyzed at the Department of Clinical Pharmacy, Radboud University 
Nijmegen Medical Centre. The Department of Clinical Pharmacy has established 
an HPLC assay for lopinavir and ritonavir, derived from a reversed-phase HPLC 
method which has been published previously (23). The method involved liquid-
liquid extraction from plasma, followed by HPLC with an OmniSpher 3 C18 column 
(100x4.6mm; Varian B.V., Middelburg, the Netherlands) and ultraviolet detection at 
λ=215 nm. For the determination of lopinavir and ritonavir in our trial, we used 
acetonitrile and 50 mmol/L potassium phosphate adjusted to pH 5.60 as a mobile 
phase. The acetonitrile concentration was increased from 35% to 54% during a 
21-minute period, thereafter it was returned to 35%. The accuracy for lopinavir was 
104% at 0.15 mg/L, 102% at 1.5 mg/L, and 101% at 7.5 mg/L. For ritonavir, the 
accuracy was 101%, 104% and 103%, respectively. The precision (within-day; 
coefficient of variation) for lopinavir was 3.34%, 1.37%, and 1.42% at 0.15, 1.5 and 
7.5 mg/L, respectively. For ritonavir, the precision was 3.22%, 1.70%, and 0.89%, 
respectively. The calibration curves were linear over the concentration range of 0.10 
to 30 mg/L for lopinavir and 0.045 to 30 mg/L for ritonavir.
Plasma levels of lamotrigine were analyzed using a validated reversed-phase HPLC 
method. This method consists of a precipitation step followed by HPLC. In brief, 
100 ml plasma was mixed in a vortex blender and centrifuged with 200 ml internal 
standard (butalbital in acetonitrile). Phosphate buffer 50 mM was added to the 
supernatant in the sample vials and mixed in a vortex blender. These samples were 
run with calibration curves and quality controls on an Omnispher 5 C18 column 
protected by a Chromoguard RP column (Varian B.V., Middelburg, the Netherlands) 
with acetonitril/50mM phosphate buffer pH 4.5. The acetonitrile concentration was 
increased to 45% in 25 minutes and returned to 20% in 2 minutes. Lamotrigine and 
the internal standard were detected at λ=210 nm. The accuracy of this method was 
97%, 99%, and 98% at 3.51, 14.04, and 28.08 mg/L, respectively. The precision 
(within-day; coefficient of variation) was 0.85%, 0.75%, and 0.68% at the same 
concentrations, respectively. The calibrated range of the method was 0.72-36.0 
mg/L lamotrigine.
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Plasma levels of lamotrigine-2N-glucuronide were analyzed using a validated 
reversed-phase HPLC method. This method consists of a precipitation step 
followed by HPLC. Briefly, 100 µl plasma was mixed with a vortex blender and 
centrifuged with 100 µl 0.55 M perchloric acid. These samples were run with 
calibration curves and quality controls on a 15 cm Polaris 3u C18-A column (Varian 
B.V., Middelburg, the Netherlands) with acetonitrile/60mM phosphate buffer pH 6.5 
(flow 0.7 mL/min). The acetonitrile concentration was 7% during 0-9 minutes after 
start, 25% during 9.1-20 minutes of the run and 7% during 20.1-30 minutes 
(re-equilibration). Lamotrigine-2N-glucuronide was detected at λ = 266 nm during 
0-11 minutes after start of the assay. For lamotrigine-2N-glucuronide, the accuracy 
was 99.4%, 100.5%, and 99.4% at 0.218, 1.09, and 7.25 mg/L, respectively. The 
precision (within-day; coefficient of variation) was 4.69%, 2.79%, and 1.04% at 
0.218, 1.09, and 7.25 mg/L, respectively. The calibration curve was linear over the 
concentration range of 0.123 to 12.27 mg/L.
Trough levels of lamotrigine on Days 10 and 20 were measured immediately on 
Study Days 21 and 22 to determine whether dose adjustment of lamotrigine and 
continuation of the trial until Study Day 31 was necessary.
Pharmacokinetic analysis
Pharmacokinetic parameters for lamotrigine, lamotrigine-2N-glucuronide, lopinavir 
and ritonavir were calculated by noncompartmental methods by use of WinNonlin 
software package (version 4.1; Pharsight Corporation, Mountain View, Calif.) and 
the log/linear trapezoidal rule. On the basis of the individual plasma concentration-
time data, the following pharmacokinetic parameters were determined: the area 
under the plasma concentration-time curve (AUC) from 0 to 12 hours after intake 
(AUC0-12; in milligram.hour per liter), the maximum concentration of the drug in 
plasma (Cmax; in milligrams per liter), the time to reach Cmax (Tmax; in hours), the 
trough concentration in plasma (Cmin (12 hours after intake); in milligrams per liter), 
the apparent elimination half-life (t1/2; in hours), the apparent oral clearance (Cl/F; 
in liters per hour), and the volume of distribution (V/F; in liters).
Sample size and statistical analysis
The study was powered to detect a 20% difference in the lamotrigine plasma 
trough concentration. The required number of participants was calculated as 16. 
With an estimated drop out rate of 33% a total of 24 subjects had to be included in 
this trial to ensure completed data from 16 subjects.
For the determination of a clinically relevant interaction we used the bioequivalence 
approach (24). Geometric means were calculated for the AUC0-12, Cmin, Cmax, t1/2, 
Cl/F, and V/F. Geometric Mean Ratios (GMR) with 90% Confidence Intervals (CI) 
were calculated after log-transformation of within-patient ratios. GMRs with 90% CI 
falling entirely within the range of 0.80 of 1.25 were considered to indicate 
bioequivalence. 
We calculated AUC-ratios of lamotrigine-2N-glucuronide and lamotrigine on Day 10 
(lamotrigine alone) and Day 20 (lamotrigine in combination with lopinavir/ritonavir) 
to determine the effect of lopinavir/ritonavir on the metabolism (glucuronidation) of 
lamotrigine.
Statistical evaluations were carried out using SPSS® for Windows, version 12.0.1 
[SPSS Inc, Chicago, IL, USA, 1989-2003]. 
Results
Baseline characteristics
Twenty-four healthy subjects, 12 males and 12 females, with a mean age of 36.4 
(range: 19.3-63.6) years, were included in this trial. Mean (range) weight, height 
and body mass index were 71 (53-88) kg, 1.75 (1.57-2.00) m and 23 (18- 29) kg/m2, 
respectively. Twenty-two subjects were Caucasians, 2 others had a mixed racial 
background.
Compliance
The compliance of the subjects was good as indicated by the subject’s statements 
about the intake of the previous doses, the amount of tablets and capsules in the 
returned vials, the booklets and the MEMS caps (data not shown). Only one subject 
missed one dose of lamotrigine on Day 7, all other subjects took all doses of 
lamotrigine and lopinavir/ritonavir.
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Pharmacokinetics
Eighteen subjects completed Day 20 of the trial. All 18 subjects were included for 
statistical evaluation of pharmacokinetics. The reasons for drop out are discussed 
below. In all 18 subjects the Cmin of lamotrigine was decreased after adding 
lopinavir/ritonavir. The mean (sd) decrease in lamotrigine Cmin comparing Day 20 
(lamotrigine in combination with lopinavir/ritonavir) to Day 10 (lamotrigine alone) 
was 55.4 (7.5) %. Because the mean decrease in lamotrigine trough levels between 
Days 10 and 20 was 55.4%, the dosage of lamotrigine in all participants was 
increased to 200 mg twice daily from Day 23 in the evening until Day 31 of the trial.
The median (IQR) AUC0-12, Cmax, Cmin, T1/2 and CL/F of lamotrigine on Day 10 were 
38.2 (30.6-54.9) h.mg/L, 3.8 (3.2-5.6) mg/L, 2.3 (1.9-4.1) mg/L, 20.1 (15.9-27.2) hrs 
and 2.6 (1.8-3.3) L/hrs, respectively which is similar to data from other studies with 
the same dosage (18;19). Table 1 shows the pharmacokinetic parameters of 
lamotrigine on Days 10, 20 and 31 and the geometric mean ratios comparing Day 
20 (combination of lamotrigine and lopinavir/ritonavir) to Day 10 (lamotrigine alone) 
and Day 31 (lopinavir/ritonavir and adjusted dose of lamotrigine) to Day 10. 
The AUC0-12, Cmax, Cmin, T1/2 and CL/F of Days 10 and 20 were considered bio-
inequivalent. The geometric mean ratio for the AUC0-12 (Day 20/Day 10) was 0.50 
(90% Confidence Interval (CI): 0.47-0.54), indicating that there is an interaction 
between lamotrigine and lopinavir/ritonavir. By adding lopinavir/ritonavir to 
lamotrigine the half-life of lamotrigine is significantly shortened and the clearance 
of lamotrigine is significantly increased. 
Fifteen healthy subjects completed Day 31 of the trial. Increasing the dose of 
lamotrigine to 200% of the initial dose resulted in bioequivalence of the AUC0-12 and 
Table 1  Pharmacokinetic parameters of lamotrigine on Days 10 (lamotrigine 
alone), 20 (combination of lamotrigine and lopinavir/ritonavir), and 31 
(lopinavir/ritonavir and adjusted dose of lamotrigine) 
Para Day 10  Day 20 Day 31 Geometric Mean Geometric Mean
meter Median (IQR) Median (IQR) Median (IQR) Ratio Day 20/10 Ratio Day 31/10
     (CI 90%) (CI 90%)
 N=18 N=18 N=15 N=18 N=15
AUC0-12 38.2 (30.6-54.9) 20.7 (16.8-25.4) 39.8 (30.5-48.7) 0.50 (0.47-0.54) 0.91 (0.82-1.02)
(h.mg/L)     
Cmin 2.3 (1.9-4.1) 1.2 (0.84-1.6) 2.1 (1.6-2.8) 0.44 (0.40-0.47) 0.79 (0.69-0.90)
(mg/L)     
Cmax 3.8 (3.2-5.6) 2.2 (1.9-2.7) 4.6 (3.8-5.2) 0.54 (0.49-0.58) 1.03 (0.90-1.17)
(mg/L)     
T1/2 20.1 (15.9-27.2) 11.0 (8.9-13.8) 10.4 (8.0-14.8) 0.54 (0.48-0.61) 0.53 (0.43-0.65)
(hrs)     
Cl/F
(L/hrs) 2.6 (1.8-3.3) 4.8 (4.0-6.0) 5.0 (4.1-6.6) 1.98 (1.87-2.11) 2.19 (1.96-2.45)
V/F
(L) 76.2 (63.4-91.8) 80.0 (66.0-92.9) 77.6 (71.8-96.3) 1.07 (0.94-1.22) 1.16 (0.95-1.40) 
Figure 1  Pharmacokinetic curves of lamotrigine on Days 10, 20 and 31  
(N=15; geometric means [sd]) 
LTG=lamotrigine
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Cmax of Days 10 and 31. The median Cmin of Day 31 is increased compared to Day 
20, but not bioequivalent to Day 10. The median clearance and half-life of Day 31 
are similar to Day 20. The volume of distribution (V/F) of lamotrigine was not 
changed during the trial, as shown in Table 1. This was what would be expected 
given the changes in clearance and half-life. Figure 1 shows the 12-hour pharma-
cokinetic curves of lamotrigine on Days 10, 20 and 31 of the 15 subjects, who 
completed the entire trial.
The median (IQR) AUCs of lamotrigine-2N-glucuronide were 21.1 (19.2-23.4) h.mg/L 
and 22.2 (20.3-24.7) h.mg/L on Day 10 and Day 20, respectively. The median (IQR) 
AUC-ratios of lamotrigine-2N-glucuronide/lamotrigine on Day 10 and Day 20 were 
0.57 (0.39-0.75) and 1.12 (0.87-1.31), respectively. A paired t-test showed a 
significant difference in AUC-ratios of Day 10 and Day 20 (p<0.001).
The pharmacokinetic parameters of lopinavir and ritonavir on Day 20 are shown in 
Table 2. The pharmacokinetic parameters of lopinavir and ritonavir were similar to 
the results of other trials, suggesting that lamotrigine did not affect the pharma-
cokinetics of lopinavir/ritonavir.
Because lamotrigine did not affect the pharmacokinetics of lopinavir and ritonavir 
on Day 20, we expected that an increased dosage of lamotrigine would not change 
the pharmacokinetics of lopinavir/ritonavir on Day 31. Therefore, we only measured 
the trough levels of lopinavir and ritonavir on Day 31. The mean (sd) trough levels 
(N=15) of lopinavir and ritonavir were 6.1 (2.3) mg/L and 0.26 (0.16) mg/L, 
respectively. These levels were similar to the trough levels on Day 20 and to 
historical controls (shown in Table 2).
Finally, we compared the trough concentrations of lamotrigine on Days 8 and 10, 
Days 18 and 20, and Days 29 and 31 to prove that steady state concentrations were 
reached on Days 10, 20, and 31. Mean (95% CI) lamotrigine trough levels were 3.4 
(2.5-4.2) and 3.0 (2.2-3.8) mg/L on Days 8 and 10, respectively; 1.7 (1.3-2.1) and 
1.3 (1.0-1.6) mg/L on Days 18 and 20; 2.7 (2.3-3.2), and 2.3 (1.9-2.6) mg/L on Days 
29 and 31, respectively. Unexpectedly, the mean logarithmic differences between 
Days 8 and 10, Days 18 and 20, and Days 29 and 31 were statistically significant: 
p=0.016, p<0.001 and p=0.038 (Paired-samples T-test), respectively. Therefore, 
we could not demonstrate that steady state concentrations were reached on Days 
10, 20 and 31, when the 12-hour pharmacokinetic curves were drawn.
Adverse events and safety assessments
Table 3 shows the most frequently occurred adverse events (e.g. more than 3 
persons experienced the adverse event) during the different periods of the trial 
(overall, Days 1-10, Days 11-23 (morning), Days 23 (evening) -31). Most of the 
experienced adverse events during the trial were mild, but 7 subjects dropped out 
Table 2  Pharmacokinetic parameters of lopinavir and ritonavir on Study Day 20 
compared to population data 
Parameter Lopinavir  Ritonavir
 Our trial Population data Our trial Population data
 Mean (sd) Mean (sd) (2;27) Mean (sd) Mean (4)
AUC0-12 (h.mg/L) 98.8 (23.5) 82.2 (44.5) 5.8 (1.9) 4.6
Cmin (mg/L) 6.0 (1.9) 5.5 (4.0) 0.24 (0.12) 0.3
Cmax (mg/L) 11.3 (2.8) 9.6 (4.4) 1.2 (0.6) 0.7
T1/2 (hrs) 9.8 (4.9) 5-6 5.1 (1.9) 3-5
Table 3  Number of subjects experiencing adverse events during the different
 periods of the trial 
Adverse event Overall: Days 1-31 Days 1-10 Days 11-23 Days 23-31
 N=24 N=24 N=22 N=16
Diarrhea 16 (67%) 1 (4%) 14 (64%) 3 (19%)
Abdominal pain 6 (25%) 3 (13%) 3 (14%) -
Rash 6 (25%) 1 (4%) 4 (18%) 1 (6%)
Itching 5 (21%) 3 (13%) 2 (9%) -
Flatulence 4 (17%) 2 (8%) - 2 (13%)
Headache 4 (17%) - 1 (5%) 3 (19%)
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because of rash or elevations of ALAT and ASAT. Diarrhea occurred more often 
when lopinavir/ritonavir was added to lamotrigine. Rash occurred mostly from Day 
11 to 23. 
As mentioned above, 15 subjects completed Day 31, so 9 subjects dropped out 
during the trial. One subject was excluded on Day 2, because metabolites of 
cannabis were detected in his urine. The use of cannabis was prohibited during the 
trial. Another subject decided to withdraw from the trial on Day 23 because of 
personal reasons, not related to trial medication. 
The other 7 subjects experienced adverse events that were severe enough to stop 
taking the study medication. One of these 7 subjects dropped out on Day 19 
because of elevations of ASAT and ALAT. The intake of lopinavir/ritonavir and 
lamotrigine was immediately stopped. Eighteen days after drop out the liver 
enzyme levels were normalized. The other 6 subjects (5 females and 1 male) 
experienced rash. Immediately after occurrence of rash the intake of trial medication 
was stopped to prevent worsening of the symptoms; if needed the rash was treated 
with cetirizine (5 subjects) or prednisolone (1 subject). Three subjects had a mild 
rash (erythema, pruritus) and 2 had a moderate rash (diffuse, maculo papular, dry 
rash), defined according to the Adult Toxicity Table of the Division of Microbiology 
and Infectious Diseases, National Institute of Allergy and Infectious Diseases. In all 
participants, the rash disappeared after a few days. None of the drop-outs 
experienced permanent damage due to the use of trial medication.
Differences between males/females and effect of contraceptives
Trough levels of lamotrigine on Day 10 were not different between males and 
females, between patients with or without rash, or between females with contra-
ceptives use or no contraceptives use (p=0.960, 0.491 and 0.184, respectively). 
The AUC of lamotrigine on Day 10 was similar in women with or without contra-
ceptive-use (p=0.155). Neither was the AUC of lamotrigine different between men 
and women on Days 10, 20 and 31 (p=0.638, 0.777 and 0.705, respectively). 
Chi square analysis of contraceptives use and rash in women, showed no difference 
(Fisher’s Exact Test, p=0.222).
Discussion
This trial shows that the AUC0-12, Cmax, Cmin, T1/2 and CL/F of lamotrigine are changed 
in combination with lopinavir/ritonavir, indicating that there is an interaction between 
lamotrigine and lopinavir/ritonavir. The half-life of lamotrigine is shortened, the 
exposure of lamotrigine is decreased and the clearance of lamotrigine is increased. 
Increasing the dosage of lamotrigine to 200% of the initial dosage results in 
bioequivalence of the AUC0-12 and Cmax of Days 10 (lamotrigine alone) and 31 
(lopinavir/ritonavir and increased dose of lamotrigine). The median Cmin of Day 31 
is increased compared to Day 20, but not bioequivalent to Day 10. The median 
clearance and half-life of Day 31 are similar to Day 20. The pharmacokinetic 
parameters of lopinavir and ritonavir were similar to results of other trials, indicating 
that lamotrigine did not affect the pharmacokinetics of lopinavir/ritonavir.
It is not clear whether there is a correlation between plasma levels and effect of 
lamotrigine. In most studies, there is a considerable overlap between plasma 
concentrations of lamotrigine between responders and non responders or between 
patients with or without side effects (25;26). Therefore, it is not clear if the interaction 
we found between lamotrigine and lopinavir/ritonavir is clinically relevant. However, 
we think that a decrease of about 50% in the AUC0-12 of lamotrigine must be 
considered a clinically relevant change in exposure to the drug. Our study showed 
that a dose increase to 200% of the initial dose of lamotrigine overcomes the 
interaction with lopinavir/ritonavir. The AUC0-12, Cmax and Cmin of lamotrigine 100 mg 
BID on Day 10 are similar to data from other studies with the same dosage of 
lamotrigine (18;19).
It is probable that the mechanism behind this interaction is increased formation of 
lamotrigine-2N-glucuronide, since glucuronidation is the main metabolic pathway 
for lamotrigine. This is also supported by the shortened half-life of lamotrigine after 
adding lopinavir/ritonavir. It is unlikely that the mechanism behind this interaction is 
a change in the bioavailability of lamotrigine given the magnitude of the effect on 
lamotrigine exposure.
To confirm our hypothesis of the cause of the interaction, plasma levels of 
lamotrigine-2N-glucuronide were determined on Day 10 and Day 20. Our data 
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showed that the median (IQR) AUC-ratios of lamotrigine-2N-glucuronide/lamotrigine 
on Day 10 and Day 20 were 0.57 (0.39-0.75) and 1.12 (0.87-1.31), respectively. A 
paired t-test showed a significant difference in AUC-ratios of Day 10 and Day 20 
(p<0.001). Thus, in combination with lopinavir/ritonavir, the formation of the main 
metabolite of lamotrigine, lamotrigine-2N-glucuronide, is doubled, which confirms 
our hypothesis about the effect of lopinavir/ritonavir on glucuronidation. 
The induction of glucuronidation is probably caused by ritonavir because other 
studies also show that ritonavir (at a high dose of 400-600 mg BID) decreases the 
exposure of drugs that are metabolized by glucuronidation (13-15). However, as 
both lopinavir and low-dose ritonavir were given simultaneously, we cannot rule out 
that lopinavir also plays a role in the effect on glucuronidation. Further research is 
necessary to determine whether this interaction also appears when low-dose 
ritonavir is combined with other PIs. The net effect of lopinavir is difficult to study 
as bioavailability is extremely low if not combined with low-dose ritonavir, and 
therapeutic plasma concentrations cannot be reached with lopinavir alone.
With the results of our trial, we could not prove (but also not exclude) that steady 
state was reached on Days 10, 20 and 31. We have chosen our study design based 
on another trial in which steady state of lamotrigine was reached on Day 8 of the 
trial (19). Lamotrigine trough levels on the Days, on which pharmacokinetic curves 
were drawn (10, 20 and 31), were 0.4 mg/L lower than two days before (Days 8, 18, 
and 29, respectively), but the 95% confidence intervals of the trough levels of the 
compared Study Days are overlapping. The difference in trough levels might 
suggest auto-induction of lamotrigine but even if that would be true than this would 
occur in all periods of the trial, because all periods have concentration changes in 
lamotrigine. Because of this and the small differences in levels between Days 8 and 
10, Days 18 and 20, and Days 29 and 31, it is believed that this does not have any 
consequences for the interpretation of our results. The measured trough levels of 
lamotrigine are comparable to therapeutic levels (19;25), so the decrease in levels 
in the second period of the trial cannot be caused by auto-induction alone. For 
future trials we suggest periods to reach steady state longer than 10 days to 
ensure steady state is reached and can be demonstrated.
We have chosen to perform this trial in healthy subjects and not in HIV-infected 
patients because of two reasons: by performing a trial like this, there is always a 
risk for the development of subtherapeutic plasma levels of the drugs. Furthermore, 
it is important to perform interaction studies in a homogeneous population to 
obtain a clear answer to the research question. HIV-infected patients always use 
co-medication, which can influence the outcome of the trial.
Most of the adverse events during the trial were mild. Diarrhea, abdominal pain and 
rash were the most common adverse events. Diarrhea and abdominal pain are 
known to occur frequently as an adverse event for lopinavir/ritonavir (27). Rash 
occurred mostly from Days 10-23. We expect the rash to be an adverse event of 
lamotrigine, although in 2 subjects rash occurred at the end of the study, on Study 
Days 23 and 29. The incidence of rash as an adverse event of lamotrigine in other 
trials ranges between 3.9 and 16.5% (28-31); the package insert states an incidence 
of >1/10 (18). Seven subjects dropped out because of adverse events. None of the 
drop-outs experienced permanent damage due to the use of trial medication.
More females experienced rash (5 females compared to 1 male), but no difference 
in AUC or Cmin of lamotrigine could be determined between males and females. 
Neither was there a difference in lamotrigine Cmin in women with or without rash, nor 
was the Cmin affected by the use of contraceptives in women. Recently, it was 
discovered that contraceptives use can alter lamotrigine plasma levels and the 
product information was updated (18). It is difficult to draw conclusions about the 
effect of contraceptives and gender on the lamotrigine plasma levels and 
occurrence of rash, given the small sample size of this trial. Further research with 
lamotrigine in women on a PI and oral contraceptives is necessary to fully elucidate 
the effect of contraceptives and estrogen levels on lamotrigine pharmacokinetics 
and adverse events. We found a higher incidence in rash compared to other trials 
(28-31), which can be caused by the titration schedule we used for lamotrigine. It 
is known that rapid titration is a risk factor for rash and that a very slow titration rate 
has led to a successful rechallenge in 84% of the patients after initial drug-induced 
rash (31). Therefore, for future research with lamotrigine we would recommend a 
slower titration rate for lamotrigine and participation of only male subjects to 
exclude the effect of contraceptives and estrogens.
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It can be concluded that our data show a significant interaction between lopinavir/
ritonavir and lamotrigine. Lopinavir/ritonavir decreases the AUC of lamotrigine, 
probably by induction of glucuronidation. Dosage increment to 200% of the initial 
lamotrigine dosage is needed to achieve similar concentrations compared to 
lamotrigine alone. Lamotrigine does not appear to have an effect on the pharma-
cokinetics of lopinavir/ritonavir. When the combination of lopinavir/ritonavir and 
lamotrigine is used in patients, the dose of lamotrigine may have to be titrated up 
to as much as twice the dose to maintain effectiveness.
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Abstract
Background
HIV-infected patients have an increased risk for depression. Despite the high 
potential for drug-drug interactions, limited data are available on combined use of 
antidepressants and antiretrovirals. Theoretically, ritonavir-boosted protease inhibi-
tors may inhibit CYP2D6-mediated metabolism of paroxetine. We wanted to deter-
mine the effect of fosamprenavir/ritonavir on paroxetine pharmacokinetics and vice 
versa and to evaluate the safety of the combination.
Methods
Group A started with paroxetine 20 mg QD for 10 days; after a wash-out period of 
16 days, subjects received paroxetine 20 mg QD + fosamprenavir/ritonavir 700/100 
mg BID from Days 28-37. Group B received the regimens in reversed order. At Days 
10 and 37, pharmacokinetic curves were recorded.
Results
26 healthy subjects (18 females, 8 males) were included. Median (range) age and 
weight were 44.4 years (18.2-64.3) and 68.8 kg (51.0-89.4). Three subjects were 
excluded (2 because of adverse events; 1 for non-adherence). Addition of 
fosamprenavir/ritonavir to paroxetine resulted in a significant decrease in paroxetine 
exposure: geometric mean ratio (90% CI) of paroxetine with fosamprenavir/ritonavir 
versus paroxetine alone was 0.45 (0.41-0.49) for AUC0-24, 0.49 (0.45-0.53) for Cmax, 
and 0.75 (0.71-0.80) for t1/2. The free fraction of paroxetine showed a median (IQR) 
increase of 30% (18-42%) after adding fosamprenavir/ritonavir. The AUC0-12, Cmax, 
Cmin, and t1/2 of amprenavir and ritonavir were similar to historical controls. No 
serious adverse events occurred.
Conclusion
Fosamprenavir/ritonavir reduced total paroxetine exposure by 55%. This is partly 
explained by protein displacement of paroxetine. We think that this interaction is 
clinically relevant and titration to a higher dose of paroxetine may be necessary to 
accomplish the needed antidepressant effect.
Introduction
Psychotropic medications, including antidepressants, neuroleptics, and some anti-
convulsants are often prescribed for HIV-infected patients to manage drug- or 
disease related effects, mood stabilizing effects, or concurrent psychiatric 
conditions. HIV-infected patients may have an increased risk for the development 
of depression, due to social stigmatization, loss of friends or relatives to AIDS, 
isolation of social support, and other factors. The lifetime prevalence of depression 
in HIV-infected patients has been estimated at 22-45% (reviewed by (1)) which is 
higher than for the general, HIV-negative population (13-20%). Therefore, HIV-
infected patients frequently use antidepressants. A recently published study 
showed that antiretroviral adherence in depressed HIV-infected patients was higher 
in patients on antidepressant therapy than in HIV-infected depressed patients that 
are not on antidepressant treatment (2). Thus, treatment of depression in HIV-
infected patients is important to improve adherence of antiretroviral agents.
Protease inhibitors (PIs) and most antidepressant drugs are metabolized by 
cytochrome P450 (CYP450) enzymes and possess enzyme-inhibiting and/or 
-inducing properties. Therefore, there is a high potential for clinically significant 
interactions between antidepressant drugs and protease inhibitors. These 
interactions often have clinical implications, because antidepressant drugs and 
antiretroviral agents have narrow therapeutic indices.
Selective serotonin reuptake inhibitors (SSRIs) are often considered the first choice 
when antidepressant drugs are needed. They are better tolerated than tricyclic 
antidepressants. Paroxetine is frequently prescribed in HIV-infected patients with a 
depression (3). 
One of the PIs used in the treatment of HIV/AIDS is fosamprenavir (Telzir®/Lexiva®), 
a prodrug of amprenavir. Fosamprenavir is given in combination with ritonavir to 
increase the plasma exposure of amprenavir. Fosamprenavir is a substrate for 
CYP3A4 and a mixed inhibitor/inducer of CYP3A4 (4). Ritonavir is a potent inhibitor 
of CYP450 and inhibits CYP3A4, CYP2D6, CYP2C9, CYP2C19 and others, when 
given in a high dosage of about 600 mg BID. Given in a low dose of 100 mg BID, 
ritonavir inhibits CYP3A4. Ritonavir is substrate for CYP3A4 and minor for CYP2D6 
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(5). Paroxetine is metabolized by CYP2D6 (6). At the same time paroxetine is a 
potent inhibitor of CYP2D6. Therefore, the combination of paroxetine and 
fosamprenavir/ritonavir can result in a potential drug interaction. The Summary of 
Product Characteristics of Norvir® (ritonavir) (5) states that concomitant use of 
CYP2D6 substrates (such as paroxetine) and ritonavir is not allowed unless the risk 
and benefit of this combination are evaluated. In clinical practice this means that 
ritonavir and paroxetine often are not combined. However, the effect of low dose 
ritonavir (100 mg BID, given as a boosting agent) on paroxetine has not been 
established. Only a very few drug interactions between antiretroviral drugs and 
antidepressants have been described in the literature (7). 
Based on the above, the primary objective of this trial was to determine the effect 
of fosamprenavir/ritonavir on paroxetine pharmacokinetics. Furthermore, we 
wanted to determine the effect of paroxetine on the pharmacokinetics of 
fosamprenavir/ritonavir, the safety of the combination of fosamprenavir/ritonavir 
and paroxetine, and the effect of fosamprenavir/ritonavir on paroxetine pharma-
codynamics.
Methods
Study design and dosing of study drugs
This was an open-label, multiple-dose, two-arms, two-sequences, two periods, 
pharmacokinetic drug-drug interaction study in 26 healthy subjects. In group A, 13 
subjects received 10 oral doses of 20 mg of paroxetine once daily (1 capsule of 20 
mg of Seroxat® taken at approximately 8:00 AM with a meal) during the first period 
of 10 days. After a wash-out period of 16 days (Study Days 11-27), all subjects in 
group A received 10 oral doses of 20 mg of paroxetine once daily, 20 oral doses of 
700 mg of fosamprenavir twice daily (1 tablet of 700 mg of Telzir®/Lexiva® taken at 
approximately 8:00 AM and PM with a meal) and 20 oral doses of ritonavir twice 
daily (1 capsule of ritonavir 100 mg (Norvir®) taken at approximately 8:00 AM and 
PM with a meal) during the second phase of 10 days (Study Days 28-37). In Group 
B, 13 other subjects received the regimens in reversed order. 
A cross-over design with a wash-out period of 16 days was chosen to exclude a 
period and carry-over effect on the pharmacokinetics of amprenavir/ritonavir and 
paroxetine.
Study population
This trial was conducted in healthy males and females between 18 and 65 years of 
age at the day of first dosing. Subjects did not smoke more than 10 cigarettes, 2 
cigars, or 2 pipes per day for at least 3 months prior to the first dosing, had a 
Quetelet Index (Body Mass Index) of 18 to 30 kg/m2, and were able and willing to 
sign the Informed Consent Form prior to screening evaluations. Subjects had to be 
in a good age-appropriate health condition as established by medical history, 
physical examination, electrocardiography, biochemistry, hematology and urinalysis 
testing within 3 weeks prior to the first dose. The main exclusion criteria were a 
history of psychiatric illness, poor and ultrarapid metabolizers for CYP2D6 as 
determined by genotyping, history of sensitivity/idiosyncrasy to fosamprenavir, 
ritonavir, paroxetine or chemically related compounds or excipients, a positive HIV 
test, a positive hepatitis B or C test or therapy with any drug for two weeks 
preceding dosing (except for acetaminophen, hormonal contraceptives and 
loperamide). Other exclusion criteria were: history of or current abuse of drugs, 
alcohol or solvents, participation in a drug trial or donation of blood within 60 days 
prior to the first dose. Pregnant or breast-feeding females and female subjects of 
childbearing potential, who were not willing to take precautions in order to prevent 
a pregnancy, were also excluded.
CYP2D6 genotyping
DNA samples were analyzed at the Laboratory of Anthropogenetics, Radboud 
University Nijmegen Medical Centre. The genotyping of CYP2D6*3, *4 and *6 was 
performed according to a pyrosequencing technology (8). CYP2D6*5 and 
CYP2D6*xn alleles were determined with XL-PCRs (9;10). Depending on the 
presence of the different alleles, poor (homozygote for alleles CYP2D6*3, *4, *5 
and *6) and ultrarapid (at least one CYP2D6*xn allele and none of the other alleles) 
metabolizers were excluded.
Safety assessments and pharmacokinetic sampling
Blood samples for pharmacokinetics were collected throughout a 12-hour period 
(0, 1, 2, 3, 4, 5, 6, 8, 10, and 12 hours) after dosing on Days 10 and 37 for 
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amprenavir/ritonavir and throughout a 24-hour period (0, 1, 2, 3, 4, 5, 6, 8, 10, 12 
and 24 hours) after dosing for paroxetine. Trough levels, just before intake of the 
drugs, were collected on Days 1, 4, 8, 28, 31, and 35.
Serum biochemistry, hematology and urinalysis were checked on Days 1, 4, 8, 10, 
28, 31, 35 and 37. Adverse events and physical condition of the subjects were 
assessed during the same visits. A pregnancy test for women and screening for 
drugs of abuse were conducted on Days 1, 10, 28 and 37.
Pharmacodynamics
Serotonin is transported into blood platelets and central neurons by a similar active 
uptake transporter mechanism. It has been described that changes in serotonin 
transport activities in platelets, induced by serotonin reuptake inhibitors, may be 
indicative of their effectiveness (serotonin reuptake inhibition) at the synaptosomal 
membrane in the brain (reviewed by (11)). Therefore, serotonin concentrations in 
platelets were measured at the Laboratory of Pediatrics and Neurology at the 
Radboud University Nijmegen Medical Centre to determine the peripheral pharma-
codynamic effect of paroxetine. For the determination of serotonin concentrations, 
venous whole blood was collected pre-dose on Days 1, 10, 28 and 37 of the trial. 
While the blood was clotting, platelets released serotonin which was measured in 
serum.
Compliance 
Study personnel supervised all medication intakes during the visits to the clinical 
trial unit on Days 1, 4, 8, 10, 28, 31, 35 and 37. The exact times of dosing were 
recorded. Drug intakes by the subjects at home were monitored by the use of 
MEMS caps (manufacturer Aardex Ltd., Zug, Switserland), which record the 
opening of the medication bottle. Furthermore, subjects were asked to write down 
the exact times of medication intake in a booklet.
Bioanalysis of amprenavir/ritonavir and paroxetine (total and unbound) 
concentrations in plasma
Plasma samples of amprenavir, ritonavir, and paroxetine (total concentrations) were 
analyzed at the Department of Clinical Pharmacy, Radboud University Nijmegen 
Medical Centre. The Department of Clinical Pharmacy has established an HPLC 
assay for amprenavir and ritonavir, derived from a reversed-phase HPLC method 
which has been published previously (12). The method involved liquid-liquid 
extraction from plasma, followed by HPLC with an OmniSpher 3 C18 column 
(100x4.6mm) and ultraviolet detection at λ = 215 nm. For the determination of 
amprenavir and ritonavir in our trial, we used acetonitrile and 50 mM phosphate 
buffer pH 5.60 as a mobile phase. The acetonitrile concentration was increased 
from 35% to 54% during a 21-minute period, thereafter it was returned to 35%. 
The accuracy for amprenavir was 102% at 0.15 mg/L, 105% at 1.5 mg/L, and 103% 
at 7.5 mg/L. For ritonavir, the accuracy was 101%, 104% and 103%, respectively. 
The precision (within-day; coefficient of variation; N=15) for amprenavir was 
3.98%, 4.05%, and 2.55% at 0.15, 1.5 and 7.5 mg/L, respectively. For ritonavir, the 
precision (within-day; coefficient of variation; N=15) was 3.22%, 1.70%, and 0.89%, 
respectively. The precision (between-day; coefficient of variation; N=3) for 
amprenavir was 5.04%, 2.67%, and 1.18% at 0.15, 1.5 and 7.5 mg/L, respectively; 
for ritonavir 3.64%, 1.17%, and 1.10%, respectively. The calibration curves were 
linear over the concentration range of 0.10 to 30 mg/L for amprenavir and 0.045 to 
30 mg/L for ritonavir.
Total (bound plus unbound) plasma levels of paroxetine were analyzed using a 
validated reversed-phase HPLC method. This method consists of a liquid-liquid 
extraction step followed by HPLC. Briefly, 0.5 mL plasma was mixed by a vortex 
blender and centrifuged with 50 µl internal standard (dibucaine in methanol/water), 
0.5 mL 0.2M NH4OH and 5 mL tert-buthylmethylether. The organic layer was 
removed and dried. Thereafter, 0.25 mM potassium hydrogen phosphate in 
acetonitrile (60/40) was added and mixed by a vortex blender. These samples were 
run with calibration curves and quality controls on a SymmetryShield RP18 3.5 µm 
(150x4.6mm, from Waters) column with in-line filter (Sure-guard) and acetonitrile/
25mM potassium hydrogen phosphate as mobile phase. The acetonitrile 
concentration was 34% for 6 minutes, then increased to 60% for 2.5 minutes and 
returned to 34% for the final 4.5 minutes. The total run time was 13 minutes. 
Paroxetine and the internal standard were detected with fluorescence (extinction at 
λ = 296 nm; emission at λ = 350 nm). The accuracy for paroxetine was between 
95.9 to 104.1% over a concentration range of 0.0025 to 0.25 mg/L. The overall 
precision (coefficient of variation) was 4.2% or less over a concentration range of 
0.0025 to 0.25 mg/L. The calibration curve was linear over the concentration range 
of 0.0025 to 0.25 mg/L.
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Unbound paroxetine plasma concentrations were measured at ABL (Analytical 
Biochemical Laboratories), Assen, the Netherlands, to determine the effect of 
fosamprenavir/ritonavir on the free fraction of paroxetine. The percentage of 
unbound paroxetine in human plasma samples was determined via equilibrium 
dialysis using the Dianorm® equilibrium dialyser system. With this equilibrium 
dialyser, free paroxetine were separated from the bound fraction using dialysis 
membranes with a molecular weight cut-off of 5000. Human plasma samples were 
dialysed against a buffer solution pH 7.4, containing potassium biphosphate (1.9 
g/L), disodium phosphate (8.1 g/L), sodium chloride (4.1 g/L) and Dextran 
(molecular weight 64000-76000, 30 g/L), for 4 hours. After dialysis, the buffer 
compartment was diluted with blank human heparin plasma (1:1) and the plasma 
fraction was diluted with dialysis buffer solution (1:1). Both the free/unbound and 
the total maximum concentration of paroxetine were analyzed using a validated 
LC-MS/MS method. The samples were run on a Synergi RP80A 4µm Fusion 
(75x4.6mm, from Phenomemex) column and ammonium formate/formic acid 
buffer/methanol as mobile phase, which was applied as a gradient. Finally, the 
percentage of free paroxetine was calculated. We have chosen to determine 
maximum concentrations of the unbound paroxetine, because it was not possible 
to measure trough levels, which would be lower than the lower limit of quantification 
of paroxetine. The accuracy of the quality control samples for the free concentration 
of paroxetine was 107.5% at 0.150 ng/mL, 106.6% at 1.50 ng/mL, and 104.3% at 
40.0 ng/mL. The overall precision (coefficient of variation) was 3.2%, 5.3%, and 
4.3% at 0.150, 1.50 and 40.0 ng/mL, respectively. The calibration curve was linear 
over the concentration range of 0.0500 to 50.0 ng/mL paroxetine in human plasma.
Pharmacokinetic analysis
Pharmacokinetic parameters for paroxetine, amprenavir, and ritonavir were 
calculated by noncompartmental methods by use of WinNonlin software package 
(version 4.1; Pharsight Corporation, Mountain View, Calif.) and the log/linear 
trapezoidal rule. Based on the individual plasma concentration-time data, the 
following pharmacokinetic parameters were determined: the area under the plasma 
concentration-time curve (AUC) from 0 to 24 hours after intake for paroxetine 
(AUC0-24; in milligram.hour per liter) and from 0 to 12 hours after intake for 
amprenavir and ritonavir (AUC0-12; in milligram.hour per liter), the maximum 
concentration of the drugs in plasma (Cmax; in milligrams per liter), the trough 
concentration in plasma (Cmin (12 hours after intake for amprenavir/ritonavir; 
24 hours after intake for paroxetine); in milligrams per liter), the apparent elimination 
half-life (t1/2; in hours), and the apparent oral clearance (Cl/F; in liters per hour).
Sample size and statistical analysis
The power analysis for proving equivalence in a cross-over design according to the 
method by Hauschke et al. (13) was used for calculating the sample size for this 
trial. The sample size was determined to attain a power of 80% at an α= 0.05 level 
in the case of an equivalence range (0.8-1.25), an intra-individual coefficient of 
variation of 20% and an inter-individual coefficient of variation of 65% (13;14). 
The calculated sample size was 20 (10 per group) subjects. We estimated a drop 
out rate of 25% based on previous pharmacokinetic interaction studies in healthy 
volunteers carried out by our department. Therefore, a total of 26 subjects were 
included in this trial to ensure completed data from 20 subjects.
For the determination of a clinically relevant interaction we used the bioequivalence 
approach (15). Geometric means were calculated for the AUC0-12 (amprenavir/
ritonavir), AUC0-24 (paroxetine), Cmin, Cmax, t1/2, and Cl/F. Geometric Mean Ratios 
(GMR) with 90% Confidence Intervals (CI) were calculated after log-transformation 
of within-subject ratios for AUC0-24, Cmax, and t1/2 for paroxetine. A GMR with 90% CI 
falling entirely within 0.80-1.25 was considered as bioequivalence. 
Statistical evaluations were carried out using SPSS® for Windows, version 12.0.1 
[SPSS Inc, Chicago, IL, USA, 1989-2003]. 
Results
Baseline characteristics
Twenty-six healthy subjects, 8 males and 18 females, with a median age of 44.4 
years (range: 18.2-64.3), were included in this trial. Median (range) weight, height 
and body mass index were 68.8 kg (51.0-89.4), 1.71 m (1.58-1.83) and 24.0 kg/m2 
(17.5-29.7), respectively. Twenty-four subjects were Caucasians, one was Oriental 
and one had a Mediterranean background.
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Study completion
In 25 of the 26 included subjects the compliance was good as indicated by the 
subject’s statements about the intake of the previous doses, the amount of tablets 
and capsules in the returned vials, the booklets and the MEMS caps (data not 
shown). One subject missed one dose of paroxetine on Day 3 because of nausea; 
five subjects took paroxetine BID instead of QD for one or two days in the beginning 
of the trial period when paroxetine was combined with fosamprenavir/ritonavir 
which had to be taken twice daily; all other subjects took all doses of paroxetine 
and fosamprenavir/ritonavir at the right time points.
One female subject was excluded for pharmacokinetic data-analysis because of 
significant non-adherence (deviating plasma paroxetine levels and MEMS data 
indicating that medication bottles were not opened properly), discovered after the 
end of the study. Two subjects (one male, one female) discontinuated the use of 
trial-medication because of adverse events (as described below).
Pharmacokinetics
Pharmacokinetic parameters were calculated for 23 evaluable subjects. The geometric 
mean (95% CI) AUC0-24, Cmax, Cmin, t1/2 and CL/F of paroxetine (total of unbound and 
protein bound paroxetine, given alone without fosamprenavir/ritonavir) were 0.59 
h.mg/L (0.51-0.85), 0.034 mg/L (0.030-0.047), 0.019 mg/L (0.017-0.030), 21 hrs 
(18-27), and 33.1 L/hrs (29.1-46.9), respectively, which are similar to data from 
other studies with the same dosage (14;16;17). Table 1 shows the geometric mean 
ratios of the AUC0-24, Cmax, and t1/2 comparing paroxetine given alone and in 
combination with fosamprenavir/ritonavir. The AUC0-24, Cmax, and t1/2 of paroxetine 
alone compared to paroxetine with fosamprenavir/ritonavir were considered bio-
inequivalent. The geometric mean ratio for the AUC0-24 of paroxetine was 0.45 (90% 
CI: 0.41-0.49), indicating that the AUC0-24 of paroxetine (total of bound and unbound 
concentration) was significantly decreased by fosamprenavir/ritonavir. Figure 1 
shows the pharmacokinetic 24-hour curves of paroxetine, given alone and given in 
combination with fosamprenavir/ritonavir.
The free fraction (unbound paroxetine divided by total of unbound and bound 
paroxetine concentration) was increased in all subjects after adding fosamprenavir/
ritonavir to paroxetine. The median (IQR) increase was 30 % (18-42), indicating that 
relatively more unbound paroxetine was present in combination with fosamprenavir/
ritonavir and that protein displacement had occurred.
Table 1  Comparison of pharmacokinetic parameters of the combination of 
paroxetine and fosamprenavir/ritonavir (fAPV/r) and paroxetine alone 
(N=23) 
Parameter Period 1 Period 2 Geometric mean ratio 
 Paroxetine 20 mg QD Paroxetine 20 mg QD +  (Period 2 / Period 1) 
  fAPV/r 700/100 mg BID (CI 90%)
 Geometric mean (95% CI) Geometric mean (95% CI)
 
AUC0-24 (h.mg/L) 0.59 (0.51 - 0.85) 0.27 (0.24 - 0.36) 0.45 (0.41 - 0.49)
Cmax (mg/L) 0.034 (0.030 - 0.047) 0.017 (0.015 - 0.022) 0.49 (0.45 - 0.53)
T1/2 (hrs) 21.1 (18.4 - 27.1) 15.9 (13.4 - 20.9) 0.75 (0.71 - 0.80)
Figure 1  Pharmacokinetic curves (geometric mean and sd) of paroxetine alone 
and in combination with fosamprenavir/ritonavir (fAPV/r) (N=23) 
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The free/unbound maximum concentration (Cmax) of paroxetine decreased in 
combination with fosamprenavir/ritonavir compared to given alone by 39.8 % 
(median; IQR: 26.9-45.5%).
The pharmacokinetic parameters of amprenavir and ritonavir are shown in Table 2. 
The pharmacokinetic parameters of amprenavir and ritonavir were similar to the 
results of other trials (4;5;18-20), suggesting that paroxetine did not affect the 
pharmacokinetics of amprenavir/ritonavir. Figure 2 shows the median curve of 
amprenavir compared to historical controls (18).
Paroxetine levels were compared between the two groups to exclude a period 
effect or a carry-over effect on the pharmacokinetic parameters. Comparing 
paroxetine concentration ratios between group A and B showed no difference 
(Independent-samples T-test, p=0.238).
Pharmacodynamics
Paired serotonin concentrations in platelets could be determined for only 17 
subjects, because at least one whole blood sample of the other subjects was 
hemolytic. Median decrease in serotonin concentration in platelets after a 10-day 
use of paroxetine alone was 87% compared to baseline. Median decrease of 
serotonin concentrations after a 10-day use of paroxetine in combination with 
fosamprenavir/ritonavir was 81% compared to baseline serotonin concentrations. 
There was no significant difference in change in serotonin concentration using 
paroxetine alone versus paroxetine in combination with fosamprenavir/ritonavir 
(Wilcoxon Signed Ranks Test: p=0.554). 
Adverse events and safety assessments
Table 3 shows the most frequently occurring adverse events (defined as any 
adverse event experienced by ≥ two persons per group) during the different periods 
of the trial (paroxetine alone and paroxetine in combination with fosamprenavir/
ritonavir). No serious adverse events were reported. Two subjects withdrew 
because of adverse events: one female subject experienced grade III diarrhea, 
another male subject had grade II nausea; both subjects were using paroxetine and 
fosamprenavir/ritonavir when they withdrew. Eight subjects (two males, six females) 
experienced rash at the end of the period in which they received paroxetine 
combined with fosamprenavir/ritonavir; one of these subjects had grade III rash. 
Four of the subjects experiencing rash received cetirizine. The subject with severe 
Table 2  Pharmacokinetic parameters of amprenavir and ritonavir (N=23)  
compared to population data 
Parameter Amprenavir  Ritonavir
 Our trial Population data Our trial Population data
 Geometric  Geometric Geometric Geometric
 mean (95% CI) mean (95% CI) mean (95% CI) mean (95% CI)
  (4;18;20)  (5;18)
AUC0-12 (h.mg/L) 44.1 (40.5 - 50.2) 39.6 (34.5 - 45.3) 5.1 (4.5 - 6.2) 5.8 (4.8 - 7.0)
Cmin (mg/L) 2.7 (2.4 - 3.2) 2.1 (1.8 - 2.5) 0.18 (0.16 - 0.23) 0.15 (0.11 - 0.22)
Cmax (mg/L) 5.8 (5.4 - 6.6) 6.1 (5.4 - 6.9) 0.92 (0.81 - 1.3) 1.2 (0.98 - 1.5)
T1/2 (hrs) 11.5 (10.1 - 15.2) 15 - 23 4.1 (3.6 - 5.0) 3 - 5
Figure 2  Median pharmacokinetic curve of amprenavir (N=23) compared to  
historical controls 
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rash also received clemastine and hydrocortisone (once, subcutaneously). The 
other adverse events were mild. None of the subjects experienced permanent 
damage due to the use of trial medication.
As shown in Table 3, seven subjects experienced diarrhea when paroxetine was 
combined with fosamprenavir-ritonavir. These subjects had a significantly smaller 
difference in paroxetine AUC en Cmax (total concentrations) between the period with 
paroxetine alone and the period in which the combination of paroxetine and fosam-
prenavir-ritonavir was used than subjects who did not experience diarrhea 
(P = 0.040 and P = 0.048, respectively; Independent-Samples T-test). So, fosam-
prenavir-ritonavir-associated diarrhea did not cause a reduced absorption of 
paroxetine, because if it had, we would have expected to find a greater difference 
in AUC and Cmax between the two trial periods in patients experiencing diarrhea.
Discussion
This trial shows that paroxetine plasma concentrations (AUC0-24 and Cmax) appear to 
be decreased by about 55% in combination with fosamprenavir/ritonavir 700/100 
mg BID. The effect on half-life of paroxetine was less pronounced (25% 
decrease).
No effect of paroxetine on amprenavir or ritonavir pharmacokinetics was found. 
The pharmacokinetic parameters of amprenavir and ritonavir were similar to the 
results of other trials in which fosamprenavir/ritonavir was administered without 
paroxetine (4;5;18-20).
The decrease of 55% in paroxetine plasma exposure when combined with fosam-
prenavir/ritonavir was unexpected. Based on the fact that ritonavir and paroxetine 
are both inhibitors of CYP2D6 (5;6), we expected that either ritonavir would inhibit 
the metabolism of paroxetine which would have caused higher paroxetine levels, or 
that paroxetine would inhibit ritonavir metabolism and that the associated increase 
in ritonavir levels would have caused a greater booster effect and increased 
amprenavir levels. 
We could think of four possible explanations for the decrease in paroxetine plasma 
levels by fosamprenavir/ritonavir: 1. Displacement of protein binding of paroxetine 
by fosamprenavir and/or ritonavir; 2. CYP3A acts as a secondary metabolic 
pathway for paroxetine, and is induced by fosamprenavir; 3. Induction of CYP2D6-
mediated metabolism of paroxetine by fosamprenavir and/or ritonavir; 4. Decreased 
absorption of paroxetine by fosamprenavir and/or ritonavir.
The first and most likely mechanism of the interaction (displacement of protein 
binding) is possible because paroxetine (95% (6)), amprenavir (90% (4)) and 
ritonavir (98-99% (5)) are all highly bound to the same plasma proteins (alpha-1 
acid glycoprotein and albumin). The Prescriber’s Information of Prezista® (darunavir), 
a novel protease inhibitor, describes the same effect on total paroxetine 
concentrations when paroxetine is combined with darunavir/ritonavir (21). In our 
trial we found a median increase of 30% in paroxetine free fraction which is 
indicative of protein displacement. An interaction caused by protein displacement 
is usually not clinically relevant because after establishment of a new equilibrium 
the free and effective concentration of a drug is not changed. However, in this trial 
Table 3  Number of subjects (≥ 2 subjects/group) experiencing adverse events 
during the different periods of the trial  
System organ class Adverse event Paroxetine Paroxetine with 
  alone fosamprenavir/ritonavir
  (N=25) (N=26)
Gastrointestinal
 Diarrhea 2 7
 Nausea 4 13
Musculoskeletal and Stiff jaws 3 - 
connective tissue 
 Headache 3 4
Nervous system
 Flat emotions 4 -
 Tiredness 8 8
 Dizziness - 4
Skin and subcutaneous Rash - 8
Overall  37 62
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the free and effective maximum concentration of paroxetine decreased by 40%, so 
the interaction can only be partly explained by protein displacement. In our trial we 
did not find a significant difference in change in serotonin concentration in platelets 
using paroxetine alone versus paroxetine in combination with fosamprenavir/
ritonavir (Wilcoxon Signed Ranks Test: p=0.554). A possible explanation for a lack 
of a pharmacodynamic effect could be that the effect on reuptake of serotonin is 
already saturated with a low paroxetine concentration. Furthermore, whole blood 
serotonin levels are indicative of serotonin reuptake in plasma and most likely also 
reflect the activity taking place in the central neurons, but depletion of platelet 
serotonin is not a reliable index of antidepressant efficacy. Previously, no correlation 
was found between changes in platelet levels and the Hamilton Depression Rating 
Scale scores (11).
The second explanation for the decrease in paroxetine levels (induction of 
metabolism) is based on data that (fos)amprenavir can induce CYP3A4 (4). 
One study suggests that CYP3A4 is the secondary metabolic pathway of paroxetine. 
A trial combining phenytoin (a CYP3A4 inducer) with paroxetine showed decreased 
paroxetine levels (data on file GlaxoSmithKline). These data are, however, in 
contrast with those of other trials that showed no interactions between paroxetine 
and two well known CYP3A4 substrates: alprazolam (22) and terfenadine (23). 
Another factor which makes this explanation less likely is that ritonavir is a very 
strong inhibitor of CYP3A4 (5) and would increase paroxetine levels (in contrast to 
the observed decrease) if paroxetine was metabolized through CYP3A4. In a 
recently performed study, our group showed that lopinavir/ritonavir decreases the 
AUC of lamotrigine, probably by induction of glucuronidation. A dose increment to 
200% of the initial lamotrigine dose is needed to achieve concentrations similar to 
those with lamotrigine alone (24). It is not known whether other boosted PIs also 
induce glucuronidation and whether glucuronidation plays a role in paroxetine 
metabolism, so we cannot confirm or rule out this explanation.
The third explanation for the decreased paroxetine plasma levels (induction of 
CYP2D6-mediated paroxetine metabolism) is less likely as so far no data have 
been reported about induction of CYP2D6 by fosamprenavir or ritonavir. Furthermore, 
it is known that CYP2D6 is not easily induced. Rifampin, which is a strong inducer 
of several enzymes, only decreases plasma levels of CYP2D6 substrates by 
approximately 25% (25;26). Our trial showed a decrease in paroxetine AUC0-24 of 
55%. Moreover, in a previously conducted study, our group found a modest 
inhibitory effect of ritonavir 100 mg BID on the activity of CYP2D6 (27).
Decreased absorption of paroxetine is our fourth and final explanation for the effect 
on the paroxetine plasma levels. So far, no effect of fosamprenavir/ritonavir on 
absorption of other drugs has been described. We thought a decreased absorption 
could have been caused by the fact that diarrhea occurred more frequently when 
fosamprenavir/ritonavir was combined with paroxetine than when paroxetine was 
dosed alone. However, the subjects with diarrhea had a significantly lower 
difference in AUC and Cmax between the two trial periods (with or without fosam-
prenavir/ritonavir) than patients without diarrhea. 
In summary, we showed that this interaction could partly be explained by a 
decrease in protein binding of paroxetine. The other mechanism(s) behind this 
interaction remain unclear.
We found that the half-life of paroxetine was decreased by 25% in combination with 
fosamprenavir/ritonavir. It is described that a decrease in protein binding results in 
a shorter half-life. However, this is mostly described for drugs with a relatively small 
apparent volume of distribution (<0.25 L/kg) (28) and the apparent volume of 
distribution of paroxetine is larger (about 8.7 L/kg) (29); paroxetine is extensively 
distributed into tissues (6;29). Furthermore, the elimination half-life of paroxetine 
is approximately 1 day according to the literature. The elimination half-life is 
calculated during steady state with a dosing interval of 24 hours and the last two 
blood samples taken at 12 and 24 hours after intake, so there is a large uncertainty 
under these conditions. Therefore, one should be very cautious with the interpretation 
of changes in elimination half-life.
No serious adverse events were reported during the trial and none of the included 
subjects experienced permanent damage due to the use of trial medication. 
Two subjects withdrew because of adverse events, but the other adverse events 
were mild. Surprisingly, rash occurred in eight subjects, when paroxetine was 
combined with fosamprenavir/ritonavir. We expect the rash to be an adverse event 
of fosamprenavir, as it is described as “common” (≥1/100 and ≤1/10) in the 
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summary of product characteristics of fosamprenavir (4), but we cannot explain 
the higher incidence in our trial than mentioned in the summary of product 
characteristics. The combination of fosamprenavir/ritonavir with paroxetine seems 
safe but larger studies are needed to confirm our observation, as the sample size 
of our trial was too small to draw definite conclusions about safety.
In this trial we found a change in total and free (unbound) paroxetine plasma 
concentrations, which was not what we predicted based on theoretical grounds. 
In recent HIV drug interaction literature, some other unexpected findings have been 
reported, for example the interaction of atazanavir with tenofovir (30;31) and the 
substantial reduction of amprenavir and lopinavir exposure when combining 
fosamprenavir with lopinavir/ritonavir (32). Therefore, we recommend to always 
actually perform a clinical trial if there is a clinically relevant research question 
about a possible drug interaction.
As stated in the introduction section, only a few interactions between antiretroviral 
drugs and antidepressants have been investigated so far (7). As mentioned above, 
a study in 13 healthy male volunteers found a modest inhibitory effect of ritonavir 
(100 mg BID) on the activity of CYP2D6 in extensive metabolizers (27). 
Coadministration with ritonavir resulted in a statistically significant 26% increase in 
the geometric mean AUC of desipramine (a tricyclic antidepressant). It was 
suggested that the standard dose of desipramine should be titrated carefully and 
patients should be monitored closely for adverse events. Furthermore, 
coadministration of fluoxetine (an SSRI and inhibitor of CYP2D6) 30 mg BID and 
ritonavir as a single dose in 16 healthy subjects resulted in a 19% increase in 
ritonavir AUC. Fluoxetine concentrations were not measured. However, post 
marketing experience has revealed reports of cardiac and neurologic events when 
ritonavir and fluoxetine have been combined (5;33) and several cases of the 
serotonin syndrome have been reported in HIV-infected patients receiving antiviral 
therapy and fluoxetine (34). Moreover, escitalopram (an SSRI and substrate for 
CYP3A4, CYP2C19 and CYP2D6) and ritonavir were studied in 21 healthy subjects. 
No pharmacokinetic interaction was observed between escitalopram and ritonavir. 
The fourth study we found was an in vitro study with bupropion (antidepressant, but 
also used as smoking cessation aid) and ritonavir which showed that ritonavir has 
a low IC50 value for inhibition of bupropion hydroxylation through CYP2B6, indicating 
the possibility of a clinically important CYP2B6 inhibition in vivo (35). Unfortunately, 
a study combining bupropion with ritonavir in vivo has not been performed yet. 
Finally, short-term low-dose administration of ritonavir (four doses of 200 mg) 
showed a decreased oral clearance of trazodone (a CYP3A substrate) and 
increases in AUC and adverse reactions (36). We think that our trial contributes to 
the limited data on interactions between antidepressants and antiretroviral 
agents.
In conclusion, our data show an interaction between paroxetine and fosamprenavir/
ritonavir. Fosamprenavir/ritonavir decreases the AUC0-24 of paroxetine (total 
concentration) by 55%. The Cmax of the unbound concentrations was decreased by 
40%. We think that this interaction is clinically relevant and titration to a higher dose 
of paroxetine may be necessary to accomplish the needed antidepressant effect. 
More research is necessary to fully elucidate the mechanism behind this interaction. 
It appears that paroxetine does not have an effect on the pharmacokinetics of 
amprenavir/ritonavir.
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mutations predict the response 
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Abstract
Objectives
To determine the predictive value of the genotypic inhibitory quotient (GIQ) for 
lopinavir, and to set cut-off values.
Methods
Baseline genotypic susceptibility was determined in protease inhibitor (PI)- 
experienced patients starting lopinavir/ritonavir therapy. The GIQ was calculated as 
the lopinavir plasma trough level divided by the number of mutations. Three sets of 
mutations were explored, the PI-associated mutations (PAMs), the lopinavir-
associated mutations (LAMs), and the Lopinavir Mutations Score (LMS). Cumulative 
numbers of mutations, using previously performed genotypic tests, were also 
studied. Virological response was defined as a viral load <500 copies/mL after 12 
months. 
Results
95 included patients had a median lopinavir trough level of 5.2 mg/L (IQR: 3.7-6.3). 
The median number of PAMs, LAMs, and LMS was 4 (IQR: 2-7), 3 (IQR: 1-6) and 3 
(IQR: 1-6), respectively. The median GIQ based on PAMs (GIQPAM) was 1.2 (IQR: 
0.7-2.3), the GIQLAM was 1.9 (IQR: 0.8-3.7), and GIQLMS was 1.8 (IQR: 0.8-3.8). 
All three GIQs and all three mutation sets were significantly associated with 
virological outcome (p-values ≤ 0.003). The GIQ did not show a larger predictive 
value than the number of mutations. Cut-off values were set at 0.9, 1.1 and 1.5 for 
GIQPAM, GIQLAM, and GIQLMS, respectively. Calculation of the GIQ with cumulative 
mutation sets including previous genotypic tests showed significant better 
association with response.
Conclusions
The predictive value of the lopinavir GIQ was no different from that of the number 
of mutations alone. Cut-off values for lopinavir GIQ were set.
Introduction
The emergence of resistance and broad cross-resistance of the human immuno-
deficiency virus (HIV) to protease inhibitors (PIs) is a significant barrier to successful 
long-term suppression of viral replication (1-3). The development of resistance to 
PIs is considered as a gradual increase in the inhibitory concentration needed to 
suppress viral replication, to a level higher than that of wild-type virus. The 
effectivity of PIs could therefore be dependent on the drug plasma levels in relation 
to the level of resistance of the virus (4;5). The genotypic inhibitory quotient (GIQ), 
expressed as the ratio of the plasma trough level to the number of relevant protease 
mutations of the virus, might be a helpful tool in setting individual target drug 
plasma levels for a virological response to treatment (6-9). However, consensus 
about the appropriate way to calculate the GIQ has not been reached, since 
several mutation sets have been used in previous studies (9-11). 
Lopinavir, administered in a co-formulation with ritonavir, is one of the most potent PIs, 
and is therefore widely used (12-14). Lopinavir demonstrates a high resistance barrier, 
meaning that a relative large amount of mutations is required for the development 
of resistance (8;15;16). Previous studies have shown that the GIQ is associated with 
a favourable response to lopinavir therapy after 12 and 24 weeks (6;8).
The objective of the present study was to determine whether the GIQ for lopinavir 
is associated with long-term response, and furthermore whether the predictive 
value of the GIQ for response is larger than that of the lopinavir plasma levels and 
the number of mutations alone. A second study objective was to assess the optimal 
way to calculate the GIQ, by comparing three sets of mutations for calculation of 
the GIQ: PI-associated mutations (noted as PAMs), lopinavir-associated mutations 
(noted as LAMs), and the Lopinavir Mutation Score (LMS). This comparison has not 
been described before within one study. Finally, cut-off values for the number of 
mutations and the GIQs were determined.
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Methods
Study design
Patients were retrospectively selected from the Netherlands national HIV 
observational cohort (ATHENA), maintained by the HIV Monitoring Foundation (17). 
HIV-1 infected individuals were selected if they were given a lopinavir-containing 
regimen and had previous virological failure during a PI-containing regimen. 
Patients who used lopinavir for less than six months were excluded. A therapy 
interruption with a maximum duration of three weeks was allowed, but not in the 
month before the endpoint of 12 months. Patients were included if resistance 
testing was performed at a maximum of six months before start of lopinavir therapy, 
and if lopinavir plasma levels were available during therapy. 
Study parameters
Plasma levels were measured previously using High Performance Liquid 
Chromatography (18;19). Randomly taken plasma levels were extrapolated to 
trough levels using population data of lopinavir plasma levels, and in case of 
multiple measurements the average trough level was calculated. HIV genotyping 
was performed previously by DNA sequence analysis. The protease gene and the 
amino terminal 300 amino acids of the reverse transcriptase gene were sequenced 
using an Applied Biosystems automated sequencer (Applied Biosystems, Foster 
City, CA, USA). Three sets of resistance-associated mutations were used. First, the 
PI-associated mutations (PAMs), defined by the International AIDS Society of the 
USA (IAS) as mutations at positions 10, 20, 24, 30, 32, 33, 36, 46, 47, 48, 50, 53, 
54, 63, 71, 73, 77, 82, 84, 88, and 90 (20); secondly, the lopinavir-associated 
mutations (LAMs) defined by the IAS at positions 10, 20, 24, 32, 33, 46, 47, 50, 53, 
54, 63, 71, 73, 82, 84 and 90 (20); finally, the mutations of the Lopinavir Mutation 
Score (LMS), which consists of mutations at positions 10, 20, 24, 46, 53, 54, 63, 71, 
82, 84 and 90 (21). The GIQs were calculated by dividing the mean lopinavir 
plasma trough level by the number of mutations; depending on which set of 
mutations was used, this was noted as GIQPAM, GIQLAM and GIQLMS. Since a lopinavir 
trough level value cannot be divided by zero, the GIQ of patients with virus with no 
relevant mutations was calculated by dividing the trough level value by one. 
Furthermore, since the use of a single genotypic test might underestimate the level 
of antiretroviral drug resistance, mutations from previously performed genotypic 
tests were also added to the number of mutations, resulting in a cumulative score 
that represents a longitudinal resistance pattern (22). This cumulative number of 
PAMs, LAMs and LMS and their corresponding cumulative GIQs were compared to 
the baseline (single-test) number of mutations and their corresponding GIQs. 
Response was defined as a viral load of ≤ 500 copies/mL after 12 months (± 3 
months) of therapy. Counting the number of active drugs besides lopinavir 
assessed the effect of the other drugs in the regimen on the virological response. 
For that purpose, the baseline genotypic results for all patients were interpreted by 
the Stanford algorithm (http://hivdb6.stanford.edu/asi/deployed/HIVdb.html). 
Drugs were classified as ‘active’ if the virus showed no or low-level resistance, and 
as ‘not active’ if the virus showed intermediate or high-level resistance. 
Statistical analysis
The analysis was performed on an intention-to-treat basis; the last viral load 
measurement of the patients that did not complete 12 months of therapy was 
carried forward. The results were analyzed by univariate logistic regression 
analysis, using SPSS 12.0 (SPSS Inc., Chicago, Illinois, USA). A natural log-
transformation was applied on variables that did not show a normal distribution. 
ROC-curves (receiver operating characteristic curves) were made to compare 
predictors of response, and to set cut-off values. Areas under the curve (AUCs), 
reflecting the predictive value, were compared using Mann-Whitney statistics (23). 
Cut-off values for the GIQ were set by determining the value with the highest 
sensitivity and specificity in the ROC-curve, with equal appraisal of sensitivity and 
specificity for all variables.
Results
Baseline characteristics of patients
The baseline characteristics of the 95 included patients are shown in Table 1. 
The duration of previous PI-use and the number of PIs taken were significantly 
different between the responder-group and the non-responder-group (p=0.003 
(PI-use in months) and p=0.001 (number of PIs)). The number of active drugs 
besides lopinavir in the study regimen also differed significantly between the two 
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groups (p=0.011). Consequently, the study variables were corrected for this 
backbone effect to prevent confounding. Finally, the number of patients that did not 
continue therapy up to 12 months was different between the two groups (p=0.044) 
(Table 1). The patients that had dropped out had been using lopinavir therapy for 
a median of seven months (interquartile range (IQR): 6.3-11.0 months).
Predictors of response
Of the 95 included patients, 72 (76%) showed a virological response. The median 
lopinavir plasma trough level was 5.1 mg/L in the group of responders and 4.9 
mg/L in the group of non-responders, which was not significantly different 
(corrected p=0.068) (Table 2). In 57% of the patients more than one trough level 
had been measured, the median number of measurements was two (range: 1-12). 
The responders had a median of three PAMs, compared to seven PAMs in the 
group of non-responders (corrected p=0.014) (Table 2). The median number of 
LAMs was two in the responder-group and six in the non-responder-group 
(corrected p=0.003). The LMS showed a median of two and five mutations in the 
groups of responders and non-responders, respectively (corrected p=0.003) 
(Table 2). The median value of the GIQPAM was 1.7 in the responder-group, while it 
was 0.7 in the non-responder-group (corrected p=0.003) (Table 2). The median 
Table 1  Baseline characteristics of the study population 
 Total Responders Non-responders p-value
Nº of patients (%) 95 (100%) 72 (76%) 23 (24%) 
Male sex (%) 74 (78%) 56 (78%) 18 (78%) 0.961 1)
Age, mean 43 43 46 0.074 2)
HIV RNA (log10  4.4 4.3 4.4 0.342
 2)
copies/ml),  (3.7-5.0) (3.6-5.0) (3.8-5.3)
median (IQR) 
CD4 + (cells/mm3),  240 250 195 0.08 2)
median (IQR) (168-400) (188-420) (122-355) 
Previous PI-use  44 41 64 0.003 2)
(months), median  (24-70) (21-59) (40-108)
(IQR) 
Nº PIs previously  2 2 3 0.001 2)
used, median  (1-3) (1-3) (2-4)
(IQR) 
RT mutations,  5 (2-7) 5 (2-7) 6 (3-8) 0.162 3)
median (IQR)    
NNRTI within 34 (36%)  25 (35%) 9 (39%) 0.701 1)
study regimen (%)     
Nº of dropouts 10 (11%) 5 (7%) 5 (22%) 0.044 1)
Nº of active drugs 1 1 1  <0.001 1)
besides LPV,  (1-2) (1-2) (0-2)
median (IQR)
1) Chi Square Test; 2) Mann Whitney U-test; 3) Students T-test
IQR: Interquartile Range; RT: Reverse Transcriptase; NNRTI: Non-nucleoside Reverse 
Transcriptase Inhibitors; LPV: lopinavir
Table 2  Study parameter results 
 Total Responders Non-responders p-value 1) p-value 2)
     corrected
PAMs  4 3 7 0.003 0.014
(median) (IQR) (2-7) (2-5) (6-8)  
LAMs 3 2 6 0.001 0.003
(median) (IQR) (1-6) (1-4) (5-7)  
LMS  3 2 5 <0.001 0.003
(median) (IQR) (1-6) (1-4) (4-7)  
Cmin  5.2 5.1 4.9 0.418 0.068
(median) (IQR) (3.7-6.3) (3.8-6.3) (3.0-6.3) 
GIQPAM  1.2 1.7 0.7 0.003 0.003
(median) (IQR) (0.7-2.3) (0.8-2.6) (0.4-0.9)  
GIQLAM 1.9 2.5 0.8 0.003 0.002
(median) (IQR) (0.8-3.7) (1.0-4.4) (0.5-1.1) 
GIQLMS  1.8 2.9 0.9 0.002 0.002
(median) (IQR) (0.8-3.8) (1.3-4.8) (0.6-1.5) 
1) Logistic regression analysis, univariate; 2) Logistic regression analysis with correction  
for other active drugs in the regimen
IQR: Interquartile Range; PAMs: Protease inhibitor-associated Mutations; LAMs:  
Lopinavir-associated Mutations; LMS: Lopinavir Mutation Score; Cmin: lopinavir plasma 
trough levels; GIQPAM: GIQ based on PAMs; GIQLAM: GIQ based on LAMs; GIQLMS:  
GIQ based on the LMS
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GIQLAM was 2.5 for responders and 0.8 for non-responders (corrected p=0.002). 
The GIQLMS showed a median of 2.9 for responders and 0.9 for non-responders 
(corrected p=0.002) (Table 2). Figure 1 shows the boxplots of the mutation sets 
and the GIQs based upon these mutation sets, in which the responders are 
compared to the non-responders.
Previous genotypic results were available for 36 of the 95 patients. Nineteen 
patients had one previous genotypic test, eight patients had two previous genotypic 
tests and nine patients had three or more previous tests, with a maximum of eight 
tests. In 12 of the 36 patients with previous genotypic test results, PAMs were found 
that were not detected in the baseline genotypic test just before start of lopinavir 
therapy. Logistic regression models were performed for all the parameters and their 
cumulative variants. For the mutation sets as well as the GIQs, the cumulative 
variants stayed in the model, while the baseline (single-test) mutation sets and 
GIQs were excluded. The cumulative mutation sets and the cumulative GIQs thus 
showed a stronger (inverse) association with virological response. 
Comparison of predictors of response and cut-off values
To compare the predictive values of the numbers of mutations and the GIQs for 
response, ROC-curves were made and their AUCs were calculated. The results are 
shown in Table 3. The small differences in the AUC of the numbers of mutations 
and the GIQs were not significant (all p-values >0.2 by Mann-Whitney). For the 
GIQPAM, a cut-off value was set to 0.9, for the GIQLAM to 1.1, and for the GIQLMS to 
1.5. The cut-off values for the GIQs based on the cumulative PAMs, LAMs and LMS 
were set on 0.9, 1.1, and 1.3, respectively. The corresponding sensitivity and 
specificity scores are shown in Table 3. 
Figure 1  Box plots of the mutation sets LAMs, PAMs and LMS, and the GIQs  
based on these mutation sets, comparing non-responders to responders 
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Table 3  Areas under the ROC-curve of the study parameters reflecting  
their predictive value, and cut-off values for the study parameters  
with their sensitivity and specificity scores, set by ROC-curves 
 AUC Cut-off value Sensitivity Specificity
PAMs 0.739 ≤ 5 0.83 0.76
LAMs 0.743 ≤ 4 0.78 0.78
LMS 0.754 ≤ 3 0.83 0.74
GIQPAM 0.736 0.9 0.75 0.74
GIQLAM 0.754 1.1 0.75 0.78
GIQLMS 0.755 1.5 0.72 0.83
GIQcumPAM 0.774 0.9 0.74 0.78
GIQcumLAM 0.793 1.1 0.74 0.83
GIQcumLMS 0.793 1.3 0.74 0.83
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Discussion
Recently, the GIQ has been introduced as a predictive marker of response to HIV 
treatment with PIs (6-8). However, consensus about the way of calculation of the 
GIQ has not yet been reached. To calculate the GIQ, different sets of mutations are 
being used, either associated with the PI under investigation (7-9) or with PIs in 
general (6;10). Furthermore, different algorithms have been used, defined by the 
IAS-USA (6;10), the ANRS (the French National Agency for AIDS Research) (8) or 
by the study-groups themselves (7;9). In order to improve agreement about the way 
of calculation of the GIQ for lopinavir, the present study directly compared different 
groups of mutations on the same dataset.
In this retrospective study, lopinavir plasma trough levels were measured repeatedly 
in a slight majority of the patients (57%), which is expected to be more representative 
of the exposure to the drug than a single measurement (24). In contrast to other 
study groups (5;6;8), our results showed that the plasma trough levels of lopinavir 
were not associated with the virological response (corrected p-value=0.068). 
This can be explained by the fact that the distribution of the average trough levels 
was relatively narrow, with few extreme low values, compared to other studies in 
which single measurements were used (6). 
To assess the level of resistance for the calculation of the GIQ, mutations were 
counted as if they all have the same impact on the susceptibility of the virus to 
lopinavir. Although there are no known mutations that can lead to high-level 
lopinavir resistance on their own, and adding-up mutations has proved to be 
inversely associated with virological response, there may be differences in the 
impact of each of the mutations used in this study (6;8;25;26). Despite this potential 
shortcoming, the number of mutations has shown to be a significant predictor of 
response, concordant to publications by other study groups (6;8;26). Three sets of 
mutations were explored in this study, but the differences in predictive value 
between these mutation sets did not reach statistical significance. The GIQ can 
thus be calculated with either set of mutations.
The GIQ, calculated with either set of mutations, was significantly associated with 
virological response. The differences in predictive value between the three GIQs 
were not statistically significant, analogous to the predictive value of the mutations 
alone. Furthermore, the GIQ did not demonstrate a greater predictive value than the 
number of mutations. This is probably because the GIQ mainly represented the 
number of mutations, since the average trough levels were not associated with 
virological response. We assume that when the GIQ will be used to target plasma 
levels, the average trough levels will be better associated with the virological 
response. Gonzalez et al. found that the GIQ was a better predictor than the 
number of mutations, but in their study population, the trough levels were 
significantly associated with response and thus contributing to the predictive value 
of the GIQ (6). 
A subanalysis was performed in a smaller study-group with a more strict definition 
of response: a viral load of ≤ 50 copies/mL after 12 months of therapy instead of 
≤ 500 copies/mL. In this analysis, the p-values of all study parameters had slightly 
increased, resulting in p-values of 0.051 to 0.079 for the GIQs. A possible 
explanation for this result is that a viral load of ≤ 50 copies/mL might be aimed to 
high for this extensively pretreated population, and is therefore not representative 
for response. 
Another subanalysis was performed in which patients were excluded who had no 
relevant PI-mutations, to evaluate if replacing the value of zero mutations by one 
was permitted. The results were similar indeed, although in contrast to the analysis 
described above, the inclusion of previous genotypic test-results and thereby using 
a cumulative number of mutations was not more predictive of response than usage 
of a single baseline genotypic test. Furthermore, an on-treatment analysis showed 
similar results compared to the intention-to-treat analysis.
Gonzalez et al. and Breilh et al. have used cut-off values of 0.7 and 1.0, respectively 
(6;8). The study performed by Breilh et al. used mutation sets defined by the ANRS 
to calculate the GIQ, and is therefore not comparable to the present study. 
Gonzalez et al. used the PI-mutations defined by the IAS, but did not describe in 
what way the cut-off value was determined (6). In the present study, ROC-curves 
have been used to determine the most discriminative value with the highest 
sensitivity and specificity for all three sets of mutations and the GIQs based on 
those three sets. Furthermore, when we used cumulative mutation sets instead of 
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single measurements, the corresponding GIQ showed a significantly stronger 
association with response than the GIQ based on the number of mutations of a 
single baseline test. Cut-off values were set for these cumulative GIQs as well and 
are shown in Table 3.
Using the GIQ principle, an individual target for the lopinavir trough level (in mg/L) 
can easily be calculated, by multiplying the (cumulative) number of mutations by 
the cut-off value for the GIQ, e.g. 1.1 for GIQLAM. Increasing the drug dosage to 
reach this target level could overcome resistance and thereby increase the 
effectivity of lopinavir therapy (4;27). Of course, dosage increase is possible until 
adverse events become unacceptable. It is expected that when the trough level is 
adapted according to the number of mutations of a patient’s virus, the trough levels 
will show a better relationship with response, and the predictive value of the GIQ 
will increase. It has been reported by others that the GIQ has got a greater 
predictive value than the number of mutations or the trough levels alone (6). Thus, 
prospective trials are needed to validate the clinical value of the GIQ.
It can be concluded that the number of mutations and the GIQ for lopinavir are 
associated with response, in contrast to lopinavir trough levels. The GIQ, calculated 
with either set of mutations, did not demonstrate to be a better predictor of 
response than the number of mutations alone. However, the GIQ can be used to 
set target plasma levels for patients with a relatively resistant virus. This target 
lopinavir trough level can be achieved by adjusting drug dosage. For this purpose, 
cut-off values were set for GIQs based on both cumulative and single-test mutations 
sets. By use of the GIQ in this way, an effective therapy might be achieved in 
patients, even when the number of mutations indicates substantial resistance to 
lopinavir. 
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Chapter 7
Clinical prospective use of the 
genotypic inhibitory quotient (GIQ) 
in PI-experienced 
HIV-infected patients starting 
fosamprenavir/ritonavir
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Abstract
This case series describes the prospective use of the genotypic inhibitory quotient 
(GIQ) for fosamprenavir/ritonavir in 6 protease inhibitor-experienced HIV-infected 
patients. When the GIQ (ratio of number of mutations to trough level of amprenavir 
[ng/mL]) was below 750, dose modifications were recommended. Correlation of 
GIQ with virological response, problems concerning dose increment of fosam-
prenavir/ritonavir, and the interaction with lopinavir/ritonavir are discussed.
Introduction
The concept of the inhibitory quotient has recently been introduced in the treatment 
of HIV-infected patients (1-5). This concept is based on the assumption that 
development of resistance is a relative phenomenon, and that increased drug 
concentrations of antiretroviral agents can overcome resistance of the virus.
The genotypic inhibitory quotient (GIQ) is the ratio of the plasma trough 
concentration of an antiretroviral agent to the number of protease mutations 
measured before initiating an antiretroviral regimen. Marcelin et al. showed that the 
GIQ for amprenavir was a predictor of virological response (3). In the calculation of 
the GIQ, only those mutations were included that were significantly related to 
suboptimal virological response. An optimal virological response was seen in 
patients with a GIQ above 750 (3).
So far, only retrospective trials have been conducted to determine the correlation 
between the GIQ for several protease inhibitors and the virological response. 
The presented data describe the prospective use of the GIQ in patient care in 
6 HIV-infected patients. 
Materials and methods
From September 2003 until April 2006, dose modifications of fosamprenavir/
ritonavir were advised based on the calculated GIQ. The authors selected patients 
who started fosamprenavir/ritonavir 700/100 mg BID after genotypic resistance 
testing. Patients had to have failed on a protease inhibitor containing regimen, 
without previous amprenavir use. Besides fosamprenavir/ritonavir, at least two 
other drugs were chosen based on the genotypic resistance test. Drugs for which 
low level or no resistance according to the Stanford algorithm (Stanford University 
HIV Drug Resistance Database) was found were considered to be active, while 
drugs with intermediate or high level resistance were considered to be non-active.
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For calculating the GIQ the cumulative number of the following mutations were 
used: L10F/I/V, K20M/R, E35D, R41K, I54V, L63P, V82A/F/T/S, and I84V, as 
previously determined to be correlated to virological response (3). The authors 
have chosen to use the cumulative number of mutations available from all genotypic 
resistance tests performed because this correlated best with virological response 
in a previous study on the GIQ for lopinavir (6).
Table 1  Patient characteristics at start of fosamprenavir/ritonavir-containing regimen 
 Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6
Gender M M M M M M
Age at start (yrs) 50 43 60  43 54 47
Weight (kg) 73.5 68.0 56.0 71.3 75.8  70.5
Height (cm) 176 183 176 179 180 169
Race Caucasian Caucasian Caucasian Antillean Caucasian Caucasian
First positive HIV-test September 1993 May 1995 January 1996 June 1993 December 1990 July 1990
Way of transmission  Homosexual Homosexual Unknown Heterosexual Homosexual Homosexual
Previous PIs SQV, RTV, LPV/r, ATV SQV, NFV, RTV, LPV/r SQV, RTV, LPV/r NFV IDV, RTV RTV, IDV, SQV, LPV/r, 
      TPV/r
CDC-class B A B B B C
Date of last resistance testing June 2003 April 2003 January 2003 April 2004 July 2004 June 2004
Mutations last resistance test 10I/F, 54V, 63P, 82A 10I, 20M, 35D, 54V, 63P, 82A  10I, 20R, 41K, 63P 63P 35D, 41K, 54V, 63P, 82A 10I, 35D, 54V, 63P, 82T
Total number of resistance tests 3 3 3 3 1 3
Cumulative number of mutations at start fAPV/r 4 (10I/F, 54V, 63P, 82A) 6 (10I, 20M, 35D, 54V, 63P,  7 (10I, 20R, 35D, 41K, 2 (41K, 63P) 5 (35D, 41K, 54V, 63P, 5 (10I, 35D, 54V, 63P,
  82A) 54V, 63P, 82A)  82A) 82T/S)
Start date fAPV/r September 2003 September 2003 September 2003 July 2004 September 2004 September 2004
Start dosage fAPV/r 700/100 mg BID 700/100 mg BID 700/133 mg BID 700/200 mg BID 700/100 mg BID 700/100 mg BID
Viral load before start (copies/mL) 127,000 (August 2003) >200,000 (September 2003) >200,000 (July 2003) >100,000 (April 2004) 50,000 (September 2004) 182,164 (September 2004)
CD4 before start (*106/L) 110 (August 2003) 150 (September 2003) 70 (August 2003) 160 (April 2004) 290 (September 2004) 110 (September 2004)
Backbone at start LPV/r 400/100 mg  3TC 150 mg BID, LPV/r 533/133 mg BID,  NVP 200 mg BID, TDF 245 mg QD, EFV 600 mg QD,
 BID, ddI 400 mg QD,  ddI 400 mg QD 3TC 150 mg BID, T20 90 µg BID ddI 250 mg QD T20 90 µg BID,
 3TC 150 mg BID,   TDF 245 mg QD,   3TC 300 mg QD
 T20 90 µg BID  T20 90 µg BID       
Number of effective drugs in backbone 1 (T20) 0 1 (T20) 2 (NVP, T20) 2 (TDF, ddI) 2 (EFV, T20)
ATV: atazanavir; BID: twice daily; ddI: didanosine; EFV: efavirenz; fAPV/r: fosamprenavir/ritonavir; IDV: indinavir; 
LPV/r: lopinavir/ritonavir; NFV: nelfinavir; NVP: nevirapine; PI: protease inhibitor; QD: once daily; RTV: ritonavir; 
SQV: saquinavir; TDF: tenofovir; TPV/r: tipranavir/ritonavir; T20: enfuvirtide; 3TC: lamivudine
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Amprenavir plasma levels were analyzed at the Department of Clinical Pharmacy, 
Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands 
according to a reversed-phase HPLC method which was published previously (7). 
The measured amprenavir concentrations were extrapolated to trough levels. 
If patients had a GIQ below 750, dose modifications were advised. Virological 
response was defined as a viral load below 50 copies/mL.
Results
Six patients were included in our follow-up. Patient characteristics at start of fosam-
prenavir/ritonavir-containing regimens are shown in Table 1. Calculated GIQs and 
virological response data are shown in Figure 1.
At start of fosamprenavir, patient 1 used 3 capsules (=400/100 mg BID) of 
lopinavir/ritonavir in combination with fosamprenavir 700 mg BID. After one month, 
an extra capsule of lopinavir/ritonavir (133/33 mg) was added, because fosam-
prenavir decreased lopinavir concentrations. After five months, the ritonavir dosage 
was further increased to 233 mg BID because of a low GIQ, and eleven months 
after start the fosamprenavir dosage was increased to 1400 mg BID, but the GIQ 
target values were still not achieved (GIQ=300). However, viral load decreased and 
became undetectable after three months with only one active drug in the backbone 
(shown in Table 1). Lopinavir trough concentrations were around 4 to 5 mg/L, which 
is somewhat lower than historical controls who received 400/100 mg of lopinavir/
ritonavir (8;9). After the follow up, the authors calculated GIQs for lopinavir based 
on the study of Hoefnagel et al. (6). These GIQs were lower than the cut-off values 
determined in that article (6). Fosamprenavir/ritonavir was stopped eight months 
after start, because of the low GIQ values. However, it was soon restarted because 
of an increasing viral load. Subsequently, the viral load became undetectable again 
until the last measurement in March 2006.
For patient 2, the dosage of fosamprenavir was increased after four months to 
alternating 700/1400 mg (total daily dose of 2100 mg), because the GIQ was below 
the cut-off value. Nine months after start, fosamprenavir was further increased to 
1400 mg BID. However, the GIQ values remained below 750 despite of dose 
Figure 1  Individual GIQ and viral load data
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increment (except for one value of 833; as shown Figure 1), probably because of 
the high number of 6 fosamprenavir-associated mutations. Viral load decreased 
but remained detectable (1,000 copies/mL).
For patient 3, the calculated GIQs were 400, 213 and 275, from one to five months 
after start, using fosamprenavir/ritonavir 700/133 mg during the first two calculations 
of the GIQ and 700/233 mg BID during the final calculation, respectively. GIQ 
values were calculated using data of the last resistance test (4 mutations). Dose 
increment was advised but not applied. Lopinavir concentrations using lopinavir/
ritonavir 533/133 mg BID were similar to those in historical controls who received 
400/100 mg of lopinavir/ritonavir BID (8;9). After starting fosamprenavir the viral 
load became undetectable. After nine months, fosamprenavir use was stopped 
because of inadequate GIQ values and the patient continued to use lopinavir/
ritonavir, lamivudine, tenofovir and enfuvirtide; the viral load remained undetectable. 
The total number of 7 fosamprenavir specific mutations is expected to be too high 
for fosamprenavir to be effective, even in a high dosage. 
The above discussed patients showed increased total cholesterol and triglyceride 
levels after start of fosamprenavir/ritonavir which are well known adverse events of 
lopinavir/ritonavir (10) and fosamprenavir (11). Total cholesterol and triglycerides 
levels were successfully decreased by administration of pravastatin with or without 
gemfibrozil.
Patient 4 had adequate GIQ values (>1100) from the start of fosamprenavir/
ritonavir, however in January 2006 (18 months after start) the calculated GIQ was 
440. From six months after start the viral load was undetectable, but in January 
2006 it was 10,000 copies/mL.
For patient 5, the calculated GIQ was continuously too low, varying between 188 
and 460. Unfortunately, the patient disagreed on dose increment. However, the viral 
load decreased 2 log10 copies/mL within 2 months and varied between being 
undetectable to 300 copies/mL afterwards.
Although patient 6 had GIQs of around 1000 and two active drugs in the backbone 
of his antiretroviral regimen, viral load increased to >100,000 copies/mL after five 
months. Therefore, fosamprenavir/ritonavir was stopped 17 months after start and 
a new protease inhibitor (darunavir) was started.
Discussion and conclusion
In conclusion, an association between the GIQ and the virological response was 
seen in patients 2, 4, and 5, although patient 2 did not use a backbone of two 
active drugs which might have confounded the association between the GIQ for 
fosamprenavir and virological response. The relationship could not be determined 
for patient 3 because the viral load was undetectable with and without using fosam-
prenavir. For patient 1 and 6 no relation between GIQ and response was found. 
After the follow up, it was discovered that patient 6 had failed virologically on many 
previously used antiretroviral regimens, so the authors assume that more viral 
mutations are present than were determined in the three resistance tests. 
The authors believe that the correct GIQ would be lower than what was calculated 
which explains the lack of correlation between the GIQ and virological response. 
In the study of Marcelin et al. (3) a virological response was observed in patients 
who had up to 5 mutations. Two of our patients (number 2 and 3) had more than 
5 mutations which might explain why fosamprenavir was not effective. Additionally, 
the backbone of these patients did not contain two active drugs either.
Furthermore, the authors experienced that the combination of lopinavir/ritonavir 
and fosamprenavir causes subtherapeutic plasma concentrations of lopinavir, as 
well as amprenavir. Lopinavir plasma concentrations were increased by adding an 
extra capsule of lopinavir/ritonavir (133/33 mg BID), but amprenavir concentrations 
remained subtherapeutic although the dosage of fosamprenavir/ritonavir was 
increased. At the time the authors started using the GIQ in patient care, this 
interaction had not been described yet. Now, the interaction of lopinavir/ritonavir 
and fosamprenavir is well known and this combination is contra-indicated (12). 
Finally, it was noticed that adding an extra capsule of 100 mg ritonavir BID to the 
standard dosage of fosamprenavir/ritonavir (700/100 mg BID) did not result in an 
appropriate increase in amprenavir concentrations to achieve a GIQ above 750. 
Thus, doubling of the fosamprenavir dosage to 1400 mg BID combined with 
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ritonavir 100 mg BID is necessary for an adequate rise in GIQ. However, dose 
increment may potentially increase adverse events. Nevertheless, our patients 
endured all dosages of fosamprenavir/ritonavir well.
To our knowledge, these are the first data on prospective implementation of 
the GIQ in patient care. More prospective studies are warranted to determine the 
cut-off value for the GIQ, the correlation of the GIQ with virological response and 
the implementation of the GIQ in clinical practice.
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Introduction
The overall objective of this thesis was to optimise Clinical pharmacology of 
ritonavir-boosted antiretroviral regimens in HIV-treatment. Since the introduction of 
protease inhibitors and highly active antiretroviral therapy (HAART) in 1996, 
life-expectancy of HIV-infected patients has been prolonged, so other issues in 
HIV-treatment have become more important. Then, adverse events, treatment of 
co-morbidity and patient compliance became issues of more interest. For example, 
protease inhibitors can cause hyperlipidaemia (Chapter 3) and the incidence of 
epilepsy and neuropathic pain (Chapter 4) and depression (Chapter 5) in 
HIV-infected patients is high. If adverse events occur, the antiretroviral drug, which 
is causing the adverse events, can be replaced by another antiretroviral drug or the 
symptoms of the adverse events can be treated. Furthermore, optimising dosing 
regimens and changing from twice-daily to once-daily dosing (Chapters 1 and 2) 
are objectives of clinical trials more often to make adherence easier. Finally, while 
pharmacokinetics and plasma drug levels are not standing on their own in HIV-
treatment, the combination with virological data defined in the relatively new 
concept of genotypic inhibitory quotient (GIQ) is an issue of interest (Chapters 6 
and 7). These aspects of ritonavir-boosted antiretroviral regimens are discussed in 
the chapters of this thesis.
Overviewing this thesis, several items for discussion can be assessed. Therefore, 
this general discussion will focus on the following objectives: unexpected drug-
drug interactions, pharmacokinetic interactions with ritonavir-boosted antiretroviral 
regimens, research in patients versus healthy volunteers, research in children, 
importance of GIQ, and ritonavir as a booster. This general discussion is concluded 
with future perspectives.
1. Unexpected drug-drug interactions
Because treatment of co-morbidity and adverse events have become more 
important issues in HIV-treatment, nowadays HIV-infected patients use chronic co-
medication for these indications more often. Therefore, it is necessary to perform 
pharmacokinetic interaction studies combining antiretroviral drugs with drugs used 
for the treatment of co-morbidity and adverse events. Drug-drug interactions can 
be predicted by speculations based on theoretical grounds, in vitro data, or results 
from previous trials. However, it is not always easy to predict the outcome because 
drug-drug interactions with antiretroviral agents can be complex. 
In literature, drug-drug interactions of antiretroviral agents are described which 
were not predicted on forehand. An example of unexpected results from interaction 
studies is the combination of tenofovir and didanosine in which didanosine 
exposure was increased by 44% to 60% following fasted or fed administration (1). 
Furthermore, a significant decrease of 25% in the area under the concentration-
time curve (AUC) of atazanavir was found when it was co-administrated with 
tenofovir (2;3). The mechanism of this interaction remains to be elucidated because 
tenofovir is eliminated unchanged via the kidneys, so an interaction at the 
biotransformation level is unlikely. Although the exact mechanism underlying this 
interaction was not elucidated, it was hypothesized that induction of P-glycoprotein 
by tenofovir could play a role in the decrease in exposure of atazanavir (2). 
A physiochemical interaction between atazanavir and tenofovir, when they are 
simultaneously present in the gut, was another postulated hypothesis (2). A third 
example of a complex and unexpected interaction is the substantial reduction of 
amprenavir and lopinavir exposure when combining fosamprenavir with lopinavir/
ritonavir (4). Induction of CYP3A by amprenavir, displacement from protein binding 
and induction of P-glycoprotein are suggested to account for this interaction.
A factor which also affects the outcome of drug-drug interactions and could be the 
cause of unexpected results is pharmacogenetics. Although it was not part of this 
thesis, we recommend future research determining the effect of pharmacogenetics 
on pharmacokinetic interactions of ritonavir-boosted antiretroviral regimens. 
An example of the effect of polymorphism on a drug-drug interaction is the  geno-
type-related interaction between voriconazole (primarily metabolized by CYP2C19 
and to a lesser extent by CYP3A4 and CYP2C9) and ritonavir (8). CYP2C19 is a 
polymorphically expressed enzyme with 2.2% of the Caucasian population being 
poor metabolizers. This study showed that coadministration of ritonavir, a potent 
CYP3A4 inhibitor, leads to a higher and prolonged exposure of voriconazole that 
might increase the risk of development of adverse drug reactions, particularly in 
CYP2C19 poor metabolizers. In extensive metabolizers the interaction was less 
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profound, probably because in these subjects voriconazole could also be partly 
metabolized by CYP2C19 when metabolism through CYP3A4 was inhibited by 
ritonavir.
In this thesis two trials are described in which unexpected drug-drug interactions 
were found. When combining fosamprenavir (a prodrug of amprenavir, which is 
converted to amprenavir in the gut epithelium) and ritonavir (700/100 mg BID) with 
the antidepressant paroxetine (20 mg QD), paroxetine exposure appeared to be 
decreased by about 55% (Chapter 5). Based on the fact that ritonavir and 
paroxetine are both inhibitors of CYP2D6 (5;6), it was expected that either ritonavir 
would inhibit the metabolism of paroxetine which would have caused higher 
paroxetine levels, or that paroxetine would inhibit ritonavir metabolism and that the 
associated increase in ritonavir levels would have caused a greater booster effect 
leading to increased amprenavir levels. 
In addition, the interaction of rosuvastatin, an HMG-CoA reductase inhibitor, and 
lopinavir/ritonavir was not expected because rosuvastatin is not in a great extent 
metabolized by cytochrome P450 or prone to glucuronidation. However, a 1.6-fold 
increase in trough levels compared to data of healthy volunteers was determined 
(Chapter 3) which was confirmed by a recently performed trial in healthy subjects 
in which a 2.1-fold increase in rosuvastatin AUC was found (7).
Overviewing our data and unexpected results from other pharmacokinetic 
interaction studies, it is recommended to always actually perform a clinical trial if 
there is a clinically relevant research question about a possible drug-drug 
combination because the outcome of an interaction cannot always be predicted.
2. Pharmacokinetic interactions with ritonavir: high vs. low dose
After licensing, ritonavir was used solely administered in a dose of 600 mg BID. So, 
most drug-drug interactions studies were performed with high dose ritonavir 
(600 mg BID or 400 mg BID). However, nowadays ritonavir is almost solely used as 
a booster of other protease inhibitors in a low dose of 100-200 mg QD or BID, 
although it is not licensed for low dose administration (5;9), only in combination 
with lopinavir in Kaletra® (10). It is difficult to predict which drug-drug interactions 
occur with a low dose of ritonavir because it is not known whether the effect on 
cytochrome P450 enzymes and glucuronidation of ritonavir dosed as 100 mg BID 
is similar to the effect of dosage of 400-600 mg BID. Therefore, more research is 
necessary to fully elucidate the effect of low dose ritonavir on the pharmacokinetics 
of co-administered drugs.
In clinical practice ritonavir is used in combination with several protease inhibitors, 
such as lopinavir, atazanavir, fosamprenavir, indinavir, tipranavir and darunavir. 
When designing a trial on determining an interaction with ritonavir, it has to be 
considered whether to investigate the effect of ritonavir alone or in combination with 
the boosted protease inhibitor. Aarnoutse et al. have chosen to determine the effect 
of ritonavir alone on CYP2D6 by combining ritonavir 100 mg BID with desipramine and 
found an increase of 26% in the geometric mean of the AUC of desipramine (11). 
Another pharmacokinetic study combined single oral doses of desipramine with a 
high dose of ritonavir (500 mg BID) and found a mean AUC-ratio for desipramine 
(AUC during ritonavir divided by AUC without ritonavir) of 2.45 (12). A third study 
showed no effect of low dose ritonavir (100 mg BID) combined with lopinavir 
(400 mg BID) on the activity of CYP2D6 (13). The results of these trials show that 
drug-drug interactions with high or low dose ritonavir can differ and that the 
boosted protease inhibitor (in this case lopinavir) can also affect the outcome of the 
interaction study. If an effect of ritonavir alone is determined, it is not known what 
the result of the interaction would be when ritonavir would be combined with a 
boosted protease inhibitor. To determine the effect of the boosted protease inhibitor 
on ritonavir and on the co-administered drug, an additional interaction study has to 
be performed.
Another example of the influence of the boosted protease inhibitor on the outcome 
of the interaction, is the additional effect of lopinavir on glucuronidation. When 
combining lamotrigine with lopinavir/ritonavir, a decrease of 55% in geometric 
mean AUC of the lamotrigine was found (Chapter 4 (14)). The induction of 
glucuronidation was expected to be an effect of ritonavir, but as both lopinavir and 
low-dose ritonavir were given simultaneously the effect of lopinavir on glucuronidation 
could not be ruled out. To determine whether other protease inhibitor-combinations 
also would affect lamotrigine pharmacokinetics, our study group has performed 
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another drug-drug interaction trial with lamotrigine in healthy male subjects. These 
subjects received a single dose of lamotrigine on days 1, 13 and 27 and took 
atazanavir 400 mg QD from days 8-17 and atazanavir/ritonavir 300/100 mg QD 
from days 18-30. It was concluded that atazanavir alone did not significantly 
influence glucuronidation of a single dose of lamotrigine, however, atazanavir/
ritonavir moderately (32%) decreased exposure to lamotrigine (15). The effect of 
atazanavir/ritonavir was smaller than the effect of lopinavir/ritonavir on 
glucuronidation of lamotrigine, so an additional effect of lopinavir alone is 
suggested.
As described above, boosted protease inhibitors can influence pharmacokinetic 
properties of co-administered agents, but they also affect the pharmacokinetics of 
ritonavir itself. Available data suggest that the exposure to ritonavir is lower in the 
combination with lopinavir or amprenavir (explained by induction of CYP3A4) and 
that indinavir (inhibition of CYP3A4) slightly increases the exposure to low-dose 
ritonavir (16;17). To illustrate the varied effect of other protease inhibitors on 
ritonavir exposure, Table 1 shows the pharmacokinetic parameters of ritonavir in all 
currently available ritonavir-boosted antiretroviral regimens.
In summary, drug-drug interactions with ritonavir-boosted antiretroviral regimens 
are highly complex, because not all is known about the effect of low dose ritonavir 
(100-200 mg QD or BID) on cytochrome P450 and glucuronidation in combination 
with different protease inhibitors. Furthermore, there can be a pharmacokinetic 
effect of the boosted protease inhibitor on ritonavir and the co-administered drug. 
The outcome of these interactions cannot be predicted theoretically, so the effect 
of all boosted protease inhibitor-regimens on cytochrome P450 enzymes and 
glucuronidation should be investigated in clinical trials.
3. Research in healthy volunteers versus (HIV-infected) patients
When a drug-drug interaction trial is designed, the decision has to be made 
whether to perform the trial in patients or in healthy subjects. Clinical experience 
indicates that the outcome of drug-drug interaction studies is similar in HIV-infected 
patients compared to healthy volunteers. So, when designing a trial, the pros and 
cons of including healthy volunteers have to be considered. It cannot always be 
predicted whether a drug-drug interaction will occur, as described above. 
Table 1  Pharmacokinetic parameters of ritonavir as booster in several antiretroviral regimens 
Drug regimen Dosage AUC0-12 (h.mg/L) Cmin (mg/L) Cmax (mg/L) Tmax (h) T1/2 (hrs)
ATV/RTV 300/100mg QD (15) 6.00 (48.8) a * 0.03 i 1.23 (39.5) a 4.0 (1.0-5.0) c 3.39 (25.2) a
DRV/RTV  400/100mg BID ** (50) 11.670 ± 3.039 b 0.437 ± 0.184 b 1.906 ± 0.506 b 4.0 (1.0-5.0) c -
FAPV/RTV  700/100mg BID (5;51) 5.8 (4.8-7.0) d 0.15 (0.11-0.22) d 1.2 (0.98-1.5) d 2.50 (1.00-5.00) c 3-5 e
IDV/RTV  400/100mg BID (52) 9.25 (4.37-21.47) f 0.23 (0.09-0.67) f 1.55 (0.67-3.64) f 1.50 (0.50-5.00) f 3.26 (2.51-5.50) f
 600/100mg BID (52) 11.47 (5.75-27.02) f 0.42 (0.16-1.72) f 1.66 (0.78-5.04) f 4.08 (1.00-6.00) f 3.35 (1.80-6.52) f
 800/100mg BID (53) 14.3 (10.0-20.3) g 0.36 (0.31-0.66) g 1.9 (1.6-3.6) g 2.5 (1.0-2.5) g 3.0 (2.8-3.8) g
LPV/RTV  400/100mg BID (54) 4.6 h 0.3 h 0.7 h - 3-5 e
SQV/RTV  1000/100mg BID (55) 6.53 (4.14-10.45) g 0.23 (0.12-0.50) g 0.95 (0.70-1.31) g - 3.9 (2.5-4.8) g
TPV/RTV 500/200mg BID (56) 8.542 ± 3.952 b 0.084 ± 0.085 b 1.874 ± 0.861 b - -
ATV: atazanavir; DRV: darunavir; FAP: fosamprenavir; IDV: indinavir; LPV: lopinavir; NFV: nelfinavir; 
RTV: ritonavir; SQV: saquinavir; TPV: tipranavir.  A: geometric mean (% CV); B: mean ± standard deviation;
C: median (range); D: geometric mean (95% confidence interval); E: range; F: geometric mean (range);  
G: median (IQR); H: mean; I: geometric mean.  * AUC0-24; **: Licensed dose is DRV/RTV 600/100mg BID
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Therefore, by performing a drug-drug interaction study in HIV-infected patients, 
there is always a risk for the development of subtherapeutic plasma levels of either 
the antiretroviral drug or the co-administered drug. When subtherapeutic plasma 
levels of antiretroviral drugs occur, there is a possibility of development of 
resistance to these agents. Then the specific antiretroviral regimen cannot be used 
anymore for future treatment of the patients. We performed our interaction studies 
to investigate the combined use of lopinavir/ritonavir and lamotrigine and of 
fosamprenavir/ritonavir and paroxetine in healthy subjects and found a decrease in 
lamotrigine and paroxetine plasma levels, respectively. These effects would not 
have been desirable in epileptic or depressed patients.
Furthermore, it is important to perform interaction studies in a homogeneous 
population to get a clear answer on the research question. HIV-infected patients 
mostly use co-medication which can influence the outcome of the trial.
A great disadvantage of research in healthy subjects is the unnecessary exposure 
of a healthy population to (antiretroviral) drugs which can cause multiple adverse 
events. Recently, our study group has performed a study in healthy subjects 
combining rifampin (600 mg QD) and new lopinavir/ritonavir tablets (600/150 mg 
or 800/200 mg BID). This study had to be terminated prematurely, because all 11 
subjects showed increases in ASAT/ALAT levels (N=2 grade II and N=9 grade IV 
abnormalities) and all but one subject suffered from nausea and/or vomiting when 
lopinavir/ritonavir was added to rifampin (18). Another example of a trial in healthy 
volunteers which has resulted in serious adverse events and even hospital 
admittance for all 6 male subjects, was a Phase I trial with a new drug, TGN1412, 
conducted in the United Kingdom in March 2006 (19). Lessons about trial-design 
should be learned from the problems observed in these trials (20).
To assure trials are performed in an ethical manner, an international code of ethics 
for clinical research, the Declaration of Helsinki, has been established (21). 
When research in healthy volunteers is performed, a risk-benefit analysis should be 
done and the risks should be minimized. It has to be remembered that healthy 
volunteers do not have a chance to benefit from research participation, so the risks 
to which they are exposed can be justified only by the value of the knowledge to be 
gained in their research participation (22;23). If trials are conducted in healthy 
subjects, it is necessary to burden the healthy subjects as less as possible by 
undertaking short trial periods, using licensed drug dosages and by including 
many study visits to check clinical symptoms and abnormal biochemical and 
hematological laboratory values of the volunteers.
Another consideration for the determination of a trial-design is whether to include 
women. In our trial combining lopinavir/ritonavir with lamotrigine (14), a higher 
incidence of rash was found compared to other trials (24-28), which can be partly 
explained by the titration schedule we used for lamotrigine. However, more females 
experienced rash (5 females compared to 1 male), but no difference in AUCs or 
trough levels of lamotrigine could be determined between males and females. In 
other trials an effect of contraceptives on pharmacokinetics of lamotrigine is 
described (29;30). To exclude effects of female hormones or contraceptives and to 
prevent the occurrence of rash, the next interaction study conducted by our study 
group, combining atazanavir (with or without ritonavir) and lamotrigine, was 
performed in male subjects only and only single doses of lamotrigine were given. 
In the latter study one male (1 out of 21 included healthy male volunteers) was 
excluded because of the occurrence of rash (15).
Although inclusion of women in trials might cause uncertainties because of 
hormonal effects, it is necessary to perform pharmacokinetic trials also in women 
because data in women are often lacking. If women are included, investigators 
should be aware of possible hormonal effects on drug plasma levels.
In conclusion, when designing a new trial, the pros and cons of performing a study 
in healthy volunteers versus patients have to be considered and it has to be 
decided to include women or not. Furthermore, results, also the negative ones, of 
all conducted trials should be published so lessons can be learned for future 
research.
4. Research in children
The pharmacokinetics of drugs in children are different from those in adults. It is 
known that the pharmacokinetics in children change depending on age. Several 
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age-related factors, including gastric emptying time, intestinal transit time and 
gastrointestinal motility, influence the absorption of drugs in pediatric patients. 
Total body water, tissue binding, hepatic enzyme activity, glomerular filtration and 
tubular secretory capacity are also changing during childhood (31-33). All these 
factors except for the effect on renal function may affect the bioavailability and 
excretion of ritonavir-booster antiretroviral agents.
Because pharmacokinetics of drugs change depending on age, differences in 
exposure to antiretroviral agents can occur in children during their growth. Our 
findings in Chapter 1 (34) indicate that 460/115 mg/m2 lopinavir/ritonavir once 
daily leads to mean pharmacokinetic parameters comparable to data of 800/200 
mg lopinavir/ritonavir once daily in adults, although the variability observed in the 
trough levels is much higher in children. Younger children, below 3.5 years of age, 
more often experienced subtherapeutic trough levels. Nelfinavir also shows a high 
interindividual variability in children. Administration of nelfinavir resulted in lower 
AUCs and lower trough levels in small and young children when compared to other 
children (35;36).
Unfortunately, drugs are not always licensed for the use in children, so often there 
are no trials performed to determine the optimal pediatric dosage. If drugs are 
licensed for use in children, mostly only a dose recommendation for children older 
than 6 months or over 2 years of age is given in package inserts. The dosages are 
frequently not specified for certain age-groups, for example younger than 1 year of 
age, 3-12 and 12-18 years of age, but only for children in general. Dosing is mostly 
advised on body surface area but as stated above, this is not always sufficient to 
reach the predetermined target plasma levels. In younger children usually a higher 
dosage per body surface area is necessary. For this reason, our study group, in 
cooperation with the CHAPAS study group, has conducted a prospective trial 
investigating the pharmacokinetics of nevirapine, stavudine and lamivudine in HIV-
infected children who were dosed according to body weight. The children were 
divided into different groups (3-6kg, 6-10kg, 10-15kg, 15-20kg, 20-25kg, and 25-
30kg). Because of this trial-design the appropriate pediatric dose according to 
body weight could be determined (37). 
To assure optimal exposure in children, especially in younger children, therapeutic 
drug monitoring (TDM) is recommended. If trough levels tend to be too low, dosa-
ges can be increased to optimise their antiretroviral regimen.
In summary, it is recommended, also by the European Medicines Agency (EMEA) 
and the Food and Drug Association (FDA), not only to approve new drugs for the 
use in adults but also to perform pharmacokinetic studies in children to prevent 
off-label use. When performing pharmacokinetic trials in children, it is necessary to 
divide the children in several age groups to determine the optimal dosages for all 
ages. To assure adequate dosing in children, TDM should be used to determine 
whether target drug levels are obtained.
5. Genotypic Inhibition Quotient: combining knowledge
The development of resistance, especially for protease inhibitors is a stepwise 
process of accumulation of mutations that causes a gradual increase in the 
inhibitory concentration which can be overcome by increased drug plasma levels. 
The results of TDM and resistance testing are combined in the inhibitory quotient 
(IQ), as the quotient of the plasma drug level and the drug susceptibility of the HIV 
virus to the drug. Thus, when the susceptibility is diminished, the IQ can provide 
information about the effectiveness of the treatment with an antiretroviral agent. 
In patients with resistance to protease inhibitors, the combined use of resistance 
testing and TDM provides a mechanism for individualising the clinical pharmaco-
dynamics of protease inhibitors.
The inhibitory quotient can be calculated as a phenotypic inhibitory quotient, virtual 
inhibitory quotient, normalized inhibitory quotient and genotypic inhibitory quotient 
(GIQ, studied in this thesis, Chapters 6 (38) and 7); pros and cons of these 
inhibitory quotients are described in the reviews of Hoefnagel (39) and Morse (40). 
The GIQ is calculated by dividing the plasma trough level by the number of 
mutations. More research is necessary to optimise this concept. Studies should be 
attempted to differentially weigh the significance of the different mutations. So far, 
all mutations were rated equally. Also mutations from previous resistance tests 
should be included in the calculation of the GIQ, which might improve the 
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association with virological response. An advantage of the concept of the GIQ is 
that it is not a static parameter, but that it can be modified by dosage adjustment. 
Therefore, it can be helpful in choosing patient’s optimal regimen. However, 
increasing the drug dosage is only possible until adverse events as a result of 
higher plasma levels become unacceptable. Prospective studies are needed to 
determine cut-off values and to implement the use of the GIQ in clinical practice.
As the inhibitory quotient combines pharmacokinetics and virology, knowledge 
from several disciplines in clinical pharmacology and pharmacotherapy are 
combined. Because the treatment of HIV is complex, as described in the 
introduction, multidisciplinary work combining knowledge of several specialists is 
necessary for optimal patient care. Physicians, pharmacists, virologists, and 
nurses should work together to optimise and individualise pharmacotherapy with 
ritonavir-boosted HIV-regimens. The IQ is a tool with possibilities in the future of 
HIV-treatment because of the combination of knowledge from several medical 
disciplines.
6. Ritonavir as booster
Ritonavir is at the approved dose of 600 mg BID the least tolerated protease 
inhibitor, with nausea, diarrhea, taste alterations, and paresthesia as commonly 
reported adverse events (5;9). Liver function abnormalities in persons with hepatitis 
co-infection also appear more common at 600 mg BID-dosage than at lower 
dosages. Lower dosages appear to be much better tolerated than the approved 
dose, and a dose-response effect may be observed with lipid disturbances and 
adverse events. Therefore, the lowest dosage necessary to achieve the booster 
effect is used, which is mostly 100 mg BID. Lower dosages of ritonavir increase 
exposure of the second protease inhibitor to a lesser extent (41). Ritonavir was 
chosen as a pharmacokinetic enhancer because of its potent inhibitory effect on 
CYP3A4 (42). Co-administration of low-dose ritonavir, as a booster, has been 
successfully adopted as a strategy to improve the pharmacokinetic profile of 
protease inhibitors. This has become standard of care in the therapeutic 
management of HIV-infection.
The advantages of boosting include raising protease inhibitors’ trough 
concentrations, diminishing interpatient variability, prolonging drug half-life to allow 
twice-daily and possibly once-daily dosing, and diminishing food requirements 
and tablet volume. In addition, increases in drug exposure may potentially enable 
inhibition of the virus in the presence of reduced sensitivity (42).
A disadvantage of using ritonavir as a booster is the occurrence of adverse events 
and the possibility for several drug-drug interactions, as described previously. 
Therefore, attempts were made to develop other boosting agents for protease 
inhibitors. Ketoconazole is a known inhibitor of CYP3A4 and could therefore act as 
a boosting agent for protease inhibitors. Co-administration of ketoconazole 
resulted in a decreased clearance and higher exposure of saquinavir/ritonavir and 
lopinavir/ritonavir (43;44). However, when ketoconazole was combined with 
saquinavir, a lower exposure and reduced plasma trough levels were seen 
compared to saquinavir/ritonavir regimens (45;46). In addition, the boosting 
capacity of itraconazole on saquinavir was determined in HIV-infected patients. 
Saquinavir soft gel capsules (SGC) 800 mg or 1200 mg BID boosted with 
itraconazole once daily resulted in adequate pharmacokinetics, being not 
significantly different from saquinavir SGC 1400mg BID (47).
In other medical disciplines boosting agents are developed, as well. For example, 
cyclosporin is investigated as a booster for orally administered paclitaxel to 
increase its bioavailability. Cyclosporin is a potent inhibitor of both P-glycoprotein 
and CYP3A4, which are the major pathways in decreasing bioavailability of 
paclitaxel. Several studies have shown that cyclosporin is successful in increasing 
paclitaxel exposure after oral administration (48;49).
In conclusion, boosters are commonly used to increase exposure of poorly 
absorbed drugs. In HIV-treatment, co-administration of ritonavir has become 
standard of care, although it has some disadvantages such as drug-drug 
interactions and adverse events. A future goal for research would be to develop an 
ideal booster for protease inhibitors. In my opinion, the ideal booster should cause 
no adverse events and lack a pharmacodynamic effect, so resistance of the HIV-
virus cannot occur. Furthermore, the booster should be a specific inhibitor of 
CYP3A4 and not affect other metabolizing enzymes. Finally, the booster should be 
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easily to administer with a low pill burden, optimally in a once-daily dosing regimen 
in a combination tablet with the active drug.
Conclusions and future perspectives
In conclusion, more research is necessary to disentangle the complexity of 
possible drug-drug interactions of ritonavir-boosted antiretroviral regimens. When 
designing future trials, all pros and cons of performing trials in healthy subjects 
versus patients have to be considered, as well as the inclusion of women. It is also 
recommended to do more pharmacokinetic research in children to determine the 
optimal pediatric dosing regimens of antiretroviral drugs. Furthermore, an important 
future role is assigned to the GIQ-concept because of its multidisciplinary aspects 
of combining virology and pharmacokinetics. Finally, an effort should be made to 
develop the ideal boosting agent with specific inhibition on cytochrome P450 3A4 
enzymes and lack of adverse events.
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Introduction
This thesis presents studies that were undertaken to optimise the Clinical pharma-
cology of ritonavir-boosted antiretroviral regimens in HIV-treatment. This thesis can 
be divided in three parts which each assess important issues concerning ritonavir-
boosted regimens. In Part I, once-daily dosing for simplification of the antiretroviral 
therapy is described. Part II discusses pharmacokinetic interaction studies and 
Part III focuses on the newly introduced concept of the genotypic inhibitory quotient 
which combines data on resistance and drug concentration.
Part I: Ritonavir and once-daily dosing
In Chapter 1, the pharmacokinetics of a once-daily regimen of lopinavir/ritonavir in 
HIV-infected children were explored. HIV-1-infected children, on stable antiretroviral 
therapy with a viral load <50 copies/mL for at least 6 months, received lopinavir/
ritonavir 460/115 mg/m2 once daily in combination with zidovudine and lamivudine. 
In all children, a 24-hour pharmacokinetic curve was drawn after observed intake 
during steady state. The target trough level for lopinavir was 1.0 mg/L, based on in 
vitro IC50 data. Our findings indicated that 460/115 mg/m
2 lopinavir/ritonavir 
once daily leads to mean pharmacokinetic parameters similar to data of 800/200 
mg lopinavir/ritonavir once daily in adults, although the variability observed in the 
trough levels is much higher in children. Five of the 7 (71%) children younger than 
3.5 years had subtherapeutic trough levels compared to 5/12 (42%) in the group of 
children older than 3.5 years. Further research, especially in young children, is 
necessary to determine whether a higher dosage of lopinavir/ritonavir once daily 
must be given to reach the target trough level.
Chapter 2 focuses on the virological effect and safety of once-daily dosing of 
lopinavir/ritonavir in HIV-infected children. It describes the 12-month follow up of 
the children receiving lopinavir/ritonavir 460/115 mg/m2 once daily, as described in 
Chapter 1. It was concluded that simplification of a twice-daily protease inhibitor-
based HAART regimen to once-daily lopinavir/ritonavir in HIV-1 infected children 
provides continued viral suppression and immunological benefit. However, most 
children younger than 3.5 years old needed a higher dose of 600/150 mg/m2 of 
lopinavir/ritonavir once daily to obtain adequate trough levels. Furthermore, the 
results showed that intake with a reasonable amount of food is important to obtain 
adequate plasma levels. Because of the large interindividual variability in plasma 
levels in this trial, therapeutic drug monitoring of lopinavir/ritonavir in the investigated 
once-daily regimen was recommended. Finally, the once-daily administration of 
lopinavir/ritonavir was well tolerated. 
Part II: Ritonavir and drug-drug interactions
Chapter 3 describes a pilot study exploring pharmacokinetics and pharmaco-
dynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected 
patients. This study was undertaken because lopinavir/ritonavir-containing anti-
retroviral therapy can cause hyperlipidaemia in HIV-infected patients. However, 
most statins are contraindicated due to drug-drug interactions. Rosuvastatin is not 
in a great extent metabolized by cytochrome P450, so no interaction with lopinavir/
ritonavir was expected. HIV-infected patients on lopinavir/ritonavir (viral load <400 
copies/mL) with a total cholesterol above 6.2 mmol/L were treated with rosuvastatin 
for 12 weeks, starting on 10 mg QD. If fasting target values (total cholesterol 
<5.0 mmol/L; HDL-cholesterol >1.0 mmol/L; LDL-cholesterol <2.6 mmol/L; 
triglycerides <2.0 mmol/L) were not reached, rosuvastatin was escalated to 20 mg 
or 40 mg at weeks 4 and 8. Plasma lopinavir/ritonavir and rosuvastatin trough levels 
were drawn at weeks 0, 4, 8, and 12. The results of this pilot study showed that 
rosuvastatin appeared to be an effective statin in hyperlipidaemic HIV-infected 
patients. Lopinavir/ritonavir levels were not affected by rosuvastatin, whilst rosuvas-
tatin levels unexpectedly appeared to be increased 1.6-fold as compared to data 
from healthy volunteers. Therefore, it was concluded that until safety and efficacy 
have been confirmed in larger studies, the combination of rosuvastatin and 
lopinavir/ritonavir should be used with caution.
In Chapter 4, the effect of lopinavir/ritonavir on the pharmacokinetics of lamotrigine 
and its major metabolite lamotrigine-2N-glucuronide was determined. Twenty-four 
healthy subjects were included and received lamotrigine (100 mg BID) in 
combination with lopinavir/ritonavir 400/100 mg BID. Depending on the decrease 
in lamotrigine trough levels, the study was either stopped or a dose increase of 
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lamotrigine was applied. This trial showed that lopinavir/ritonavir decreases the 
AUC of lamotrigine by 50%, probably by induction of glucuronidation. Dosage 
increment to 200% of the initial lamotrigine dosage was needed to achieve similar 
concentrations compared to lamotrigine alone. Lamotrigine itself does not appear 
to affect the pharmacokinetics of lopinavir/ritonavir.
In Chapter 5 the combined use of paroxetine and fosamprenavir/ritonavir was 
studied in healthy subjects who received paroxetine 20 mg QD alone or in 
combination with fosamprenavir/ritonavir 700/100 mg BID. Fosamprenavir/ritonavir 
was found to reduce total paroxetine exposure by 55%. This can partly be explained 
by protein displacement of paroxetine. To our opinion, this interaction is clinically 
relevant and titration to a higher dose of paroxetine may be necessary to accomplish 
the required antidepressant effect.
Part III: Ritonavir and resistance
Chapter 6 showed that the Genotypic Inhibitory Quotient (GIQ) and the (cumulative) 
number of mutations predict the response to lopinavir/ritonavir therapy. For 95 
protease inhibitor-experienced HIV-1 infected patients, the GIQ (plasma trough 
level / number of mutations) was calculated for lopinavir. Three different sets of 
mutations showed equal predictive value. However, usage of cumulative numbers 
of mutations for calculation of the GIQ showed significantly better association with 
the virological response. Furthermore, the predictive value of the GIQ was not 
different from that of the number of mutations alone.
Chapter 7 describes the clinical prospective use of the GIQ in protease inhibitor-
experienced HIV-infected patients starting on fosamprenavir/ritonavir. This case 
series describes the prospective clinical use of the GIQ for fosamprenavir/ritonavir 
in 6 PI-experienced HIV-infected patients. When the GIQ (ratio of number of 
mutations to trough level of amprenavir [ng/mL]) was below the cut-off value of 750, 
dose modifications were recommended. In this chapter, the correlation of GIQ with 
virological response, problems concerning dose increment of fosamprenavir/
ritonavir, and the interaction with lopinavir/ritonavir are discussed.
General discussion
In the general discussion the following issues are assessed: unexpected drug-drug 
interactions, pharmacokinetic interactions with ritonavir-boosted antiretroviral 
regimens, research in patients versus healthy volunteers, research in children, 
importance of GIQ, and ritonavir as a booster.
It can be concluded from this thesis, that more research is necessary to disentangle 
the complexity of possible drug-drug interactions of ritonavir-boosted antiretroviral 
regimens. When designing future trials, all pros and cons of performing trials in 
healthy subjects versus patients have to be considered, as well as the inclusion of 
women. It is also recommended to do more pharmacokinetic research in children 
to determine the optimal pediatric dosing regimens of antiretroviral drugs. 
Additionally, an important future role is assigned to the GIQ-concept because of its 
multidisciplinary aspects of combining virology and pharmacokinetics. Finally, an 
effort should be made to develop the ideal boosting agent with specific inhibition 
on cytochrome P450 3A4 enzymes and lack of adverse events.
Samenvatting
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HIV-infectie en AIDS
HIV is een afkorting voor humaan immunodeficiëntie virus. Dit virus infecteert o.a. 
CD4 cellen van het afweersysteem van een HIV-geïnfecteerde patiënt en kan zich 
in die cellen vermeerderen. Het afweersysteem verdedigt het lichaam tegen 
bacteriën, schimmels en virussen en zorgt ervoor dat mensen kunnen genezen van 
ziektes. HIV breekt dus het afweersysteem van HIV-geïnfecteerde patiënten af 
waardoor infecties gemakkelijker kunnen optreden (1). Naarmate de HIV-infectie 
erger wordt, zijn er meer virusdeeltjes in het lichaam aanwezig en kan het lichaam 
zich steeds minder goed verdedigen tegen bacteriën, schimmels en virussen. 
Het aantal virusdeeltjes in het bloed wordt weergegeven als viral load (= virale 
belasting). Uiteindelijk, als er veel virusdeeltjes in het bloed aanwezig zijn en het 
afweersysteem zwakker wordt, kan HIV leiden tot AIDS.
AIDS is een afkorting van Acquired Immune Deficiency Syndrome, ofwel Verworven 
Immuun Deficiëntie Syndroom. Bij patiënten met AIDS werkt het afweersysteem 
niet goed meer en kan het afweersysteem infecties niet meer tegenhouden. 
Mensen met AIDS krijgen dus ziektes als longontsteking en huidkanker, waaraan 
de patiënten zonder behandeling overlijden. De eerste gevallen van AIDS zijn 
beschreven bij homoseksuele mannen in de Verenigde Staten in 1981 (2;3). In 1983, 
werd HIV geïdentificeerd als een veroorzaker van AIDS (4;5).
Besmetting met HIV kan optreden na onbeschermde geslachtsgemeenschap, 
bloedtransfusie met HIV-geïnfecteerd bloed, intraveneus drugsgebruik met 
besmette naalden en door overdracht van moeder op kind tijdens de zwanger-
schap, bij de bevalling of bij het geven van borstvoeding.
Sinds de ontdekking van AIDS in 1981 zijn er wereldwijd 25 miljoen mensen 
overleden aan deze ziekte. Er is geschat dat er eind 2006 ongeveer 39,5 miljoen 
personen leefden die besmet waren met HIV. Verder zijn er in 2006 4,3 miljoen 
mensen geïnfecteerd geraakt met HIV en zijn er 2,9 miljoen patiënten overleden 
aan AIDS (6). De pandemie spreidt zich dus nog steeds uit en er is een duidelijke 
behoefte aan het wereldwijd optimaliseren en intensiveren van de preventie van het 
verspreiden van HIV en de behandeling ervan. Dit proefschrift handelt over 
de Klinische Farmacologie van ritonavir-gebooste antiretrovirale combinatietherapie 
in HIV-behandeling (Clinical pharmacology of ritonavir-boosted antiretroviral 
regimens in HIV-treatment) om de behandeling te optimaliseren.
Geneesmiddelen tegen HIV en AIDS
Er zijn verschillende soorten geneesmiddelen die bij de behandeling van HIV en 
AIDS kunnen worden ingezet. Deze geneesmiddelen worden antiretrovirale 
middelen genoemd. De behandeling van HIV en AIDS is erop gericht om het 
vermeerderen van de virusdeeltjes af te remmen en dus de viral load te verlagen.
Sinds 1987 is het eerste geneesmiddel tegen HIV/AIDS op de markt, zidovudine 
genaamd (7). Op dit moment zijn er 4 groepen van geneesmiddelen voor de 
behandeling van HIV en AIDS beschikbaar: nucleoside en nucleotide reverse 
transcriptase remmers, non-nucleoside reverse transcriptase remmers, protease-
remmers en fusieremmers. Geneesmiddelen uit deze groepen vallen het virus op 
verschillende manieren aan en zorgen op verschillende wijzen voor remming van 
de vermeerdering van virusdeeltjes.
Sinds het beschikbaar zijn van proteaseremmers worden HIV en AIDS altijd 
behandeld met combinatietherapie. Er wordt dan een combinatie van 3 genees-
middelen gegeven uit de verschillende groepen, die hierboven zijn beschreven. 
Meestal wordt gestart met twee nucleoside reverse transcriptaseremmers in 
combinatie met een non-nucleoside reverse transcriptaseremmer of een protease-
remmer.
Samenspel van patiënt, geneesmiddel en virus
Er zijn 3 factoren belangrijk om de HIV-therapie tot een succes te maken, namelijk 
de patiënt zelf, het geneesmiddel en het virus (8). Het resultaat van de behandeling 
hangt niet alleen af van de krachtigheid van het geneesmiddel, maar ook van het 
feit of het geneesmiddel na inname veel bijwerkingen geeft en tenslotte van de 
therapietrouw van de patiënt. 
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Er is geschat dat ongeveer 95% van alle anti-HIV geneesmiddelen moeten worden 
ingenomen om het virus voldoende te kunnen onderdrukken en dus effectief te zijn 
bij 80% van de patiënten (9-11). Dit houdt in dat slechts 5% van de doses mogen 
worden gemist of te laat mogen worden ingenomen, wat voor de patiënt moeilijk is. 
Therapietrouw wordt als net zo belangrijk beschouwd als de krachtigheid van de 
combinatietherapie van de anti-HIV geneesmiddelen. Het is daarom van groot 
belang om patiënten erop te wijzen dat zij hun geneesmiddelen dagelijks op de 
juiste wijze moeten innemen.
Een andere belangrijke factor om de therapie tot succes te maken is het anti-HIV 
geneesmiddel zelf en de hoeveelheid van het geneesmiddel dat in het bloed 
aanwezig is. Zelfs als de patiënt therapietrouw is en de anti-HIV geneesmiddelen 
op een juiste wijze inneemt, kunnen de bloedwaarden van de anti-HIV genees-
middelen verschillen tussen patiënten. De bloedwaarde van het geneesmiddel 
hangt namelijk af van verschillende patiëntkarakteristieken die ervoor zorgen hoe 
het geneesmiddel in het bloed wordt opgenomen, wordt verdeeld over de weefsels 
en daarna wordt uitgescheiden uit het lichaam. Dit wordt de farmacokinetiek van 
een geneesmiddel genoemd. 
Voor proteaseremmers zijn er target concentraties (bloedwaardes of bloedspiegels) 
(12) gedefinieerd waaraan de waarde voor de dalspiegel (de laagste bloedwaarde 
net voor inname van een volgende gift van het geneesmiddel) moet voldoen. 
In Nederland worden routinematig concentraties van anti-HIV geneesmiddelen 
bepaald, wat therapeutic drug monitoring (TDM) wordt genoemd. Als de bloed-
waardes niet voldoen aan de target waarde zal de dosering van de geneesmiddelen 
worden aangepast. Op deze wijze wordt TDM dus gebruikt om de behandeling met 
anti-HIV geneesmiddelen te optimaliseren (13).
Een laatste belangrijke factor is het virus zelf. Het risico bestaat dat HIV resistent 
kan raken voor bepaalde geneesmiddelen als het virus niet goed genoeg wordt 
onderdrukt, bijvoorbeeld bij een bloedwaarde onder de target concentratie. 
Het optreden van resistentie hangt samen met het ontstaan van mutaties in het 
virus. Als er bepaalde mutaties aanwezig zijn, reageert het virus niet meer goed op 
bepaalde geneesmiddelen, die dan in de toekomst niet meer kunnen worden 
gebruikt voor onderdrukking van de HIV-infectie. Hierdoor worden de behandel-
mogelijkheden voor een patiënt beperkt, aangezien er ook kruisresistentie bestaat 
tussen bepaalde anti-HIV geneesmiddelen uit dezelfde geneesmiddelengroep. 
Hierdoor kunnen andere geneesmiddelen uit dezelfde groep soms ook niet meer 
worden ingezet.
Ritonavir-gebooste HIV-behandeling als centraal thema 
van dit proefschrift
Dit proefschrift beschrijft onderzoek naar proteaseremmers en ritonavir in het 
bijzonder. Proteaseremmers hebben de afgelopen jaren sterk bijgedragen aan de 
behandeling van HIV en AIDS, hoewel de eerste onderzoeken, die zijn uitgevoerd 
naar het effect van proteaseremmers, een falen van de therapie lieten zien bij 40 
tot 60% van de patiënten (14). Het therapiefalen kan ten dele worden verklaard door 
een slechte therapietrouw en niet regelmatige inname van de proteaseremmers, 
wat veroorzaakt wordt door de farmacokinetische nadelen van de protease-
remmers. Proteaseremmers hebben een korte halfwaardetijd (= tijd die nodig is 
om de concentratie van een geneesmiddel in het bloed met 50% te verlagen) 
waardoor ze een aantal malen per dag moeten worden ingenomen om voldoende 
hoge en stabiele bloedspiegels te bereiken. Daarnaast betreft het vaak een groot 
aantal tabletten/capsules. Verder worden ze niet goed in het bloed opgenomen wat 
vaak sterk afhankelijk is van voedsel. De meeste proteaseremmers (saquinavir, 
nelfinavir, lopinavir (capsules), atazanavir, tipranavir (15) en darunavir (16)) moeten 
dan ook met een grote hoeveelheid (vetrijk) voedsel worden ingenomen. 
Andere factoren die subtherapeutische en dus onvoldoende hoge bloedwaardes 
van proteaseremmers kunnen veroorzaken zijn: de grote mate van metabolisering 
via het CYP450-enzymsysteem (met name via CYP3A4) en interacties met andere 
geneesmiddelen (14;17). Proteaseremmers hebben een smalle therapeutische 
breedte wat betreft bloedspiegels. Dit houdt in dat er slechts een klein verschil is 
tussen een te lage en ineffectieve bloedwaarde en een te hoge en toxische bloed-
waarde. Bijwerkingen en therapiefalen kunnen dan ook gemakkelijk optreden.
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Ritonavir als booster
Na het op de markt verschijnen van ritonavir werd het alleen in een hoge dosering 
van 600 mg twee keer per dag gebruikt. Het was echter de proteaseremmer met 
de meeste bijwerkingen zoals misselijkheid, diarree, verandering in smaak en 
paresthesie (stoornis in de gevoelswaarneming) (18;19). Lagere doses werden 
beter verdragen dan de geregistreerde en normaal gebruikte dosering.
Ritonavir is een sterke remmer van het enzym cytochroom P450 3A4 (CYP3A4), dat 
proteaseremmers afbreekt. Uit onderzoek blijkt dat ritonavir kan worden gebruikt in 
combinatie met andere proteaseremmers om de afbraak van deze protease-
remmers te beperken. Hierdoor worden de bloedwaardes van deze protease-
remmers verhoogd waardoor ze effectiever zijn (20). Ritonavir werkt in dit geval als 
een booster van de andere proteaseremmers. Een dosering van twee keer daags 
100 mg is de laagste dosering waarbij ritonavir werkzaam is als booster. 
Het gebruik van ritonavir (100 tot 200 mg een- tot tweemaal daags) om bloed-
spiegels van andere proteaseremmers te verhogen wordt nu standaard toegepast 
wanneer een proteaseremmer deel uitmaakt van de medicamenteuze behandeling 
van HIV/AIDS. De voordelen van het gebruik van ritonavir als booster zijn dat de 
dalspiegels van andere proteaseremmers worden verhoogd, de variabiliteit in 
bloedwaardes tussen patiënten afneemt en de halfwaardetijd toeneemt waardoor 
een- of tweemaal daags doseren mogelijk is en waardoor inname met voedsel 
minder belangrijk wordt. Hierdoor neemt het aantal in te nemen tabletten of 
capsules af. Tenslotte zou boosting ervoor kunnen zorgen dat het virus ook geremd 
kan worden als er sprake is van een minder grote gevoeligheid van het virus voor 
de geneesmiddelen (20). Nu worden de meeste proteaseremmers (saquinavir, 
indinavir, lopinavir, fosamprenavir, atazanavir, tipranavir and darunavir) in de 
dagelijkse praktijk gebruikt in combinatie met ritonavir.
Onderwerpen van dit proefschrift
In dit proefschrift wordt ingegaan op ritonavir en eenmaal daags doseren, op 
ritonavir en interacties met andere geneesmiddelen en op ritonavir en de 
ontwikkeling van resistentie.
1. Ritonavir en eenmaal daags doseren
Zoals hiervoor is beschreven zijn de nadelen van het gebruik van proteaseremmers 
de inname van een grote hoeveelheid tabletten of capsules en het twee- of zelfs 
driemaal daags doseren vanwege de korte halfwaardetijd, wat de therapietrouw 
niet bevordert. De complexiteit van de combinatietherapie en inname van een groot 
aantal tabletten/capsules speelt een grote rol bij de therapietrouw. Vereenvoudiging 
van de combinatietherapie naar een eenmaal daags regime zal de therapietrouw 
waarschijnlijk verbeteren. Uit meerdere onderzoeken bleek namelijk dat bij eenmaal 
daags doseren de therapietrouw verbeterde terwijl de effectiviteit van de therapie 
behouden bleef (21;22). 
Het eenmaal daags gebruik van lopinavir/ritonavir bij volwassenen is eerder onder-
zocht (23;24), het gebruik bij kinderen echter niet. In hoofdstuk 1 is daarom de 
farmacokinetiek van een eenmaal daagse dosering van lopinavir/ritonavir bij 
kinderen onderzocht. Hoofdstuk 2 beschrijft het virologische effect en de veilig-
heid van een eenmaal daags schema van lopinavir/ritonavir gedurende een 12 
maanden follow-up. In de hoofdstukken 1 en 2 is bepaald of het boosting effect 
van ritonavir voldoende is om bij een eenmaal daagse dosering voldoende 
blootstelling aan lopinavir/ritonavir te bewerkstelling gedurende een doseerinterval 
van 24 uur.
2. Ritonavir en interacties
Sinds het op de markt komen van proteaseremmers en het geven van combinatie-
therapie, is HIV-infectie veranderd van een dodelijke in een chronische ziekte 
resulterend in een daling van het aantal patiënten dat AIDS ontwikkelt of eraan 
overlijdt. HIV-geïnfecteerde patiënten blijven tegenwoordig langer in leven en de 
behandeling van co-morbiditeit (andere ziekten naast de HIV-infectie) en (lange 
termijn) bijwerkingen van de HIV-medicatie worden steeds belangrijker. 
Het behandelen van andere ziekten of bijwerkingen maakt de HIV-behandeling 
complex vanwege het optreden van mogelijke interacties (wisselwerking) tussen de 
HIV-medicatie en andere geneesmiddelen. Ziektebeelden zoals epilepsie (25;26), 
neuropatische pijn (27;28) en depressie (29) komen vaak voor bij HIV-geïnfecteerde 
patiënten en moeten worden behandeld. 
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HIV-geïnfecteerd patiënten hebben namelijk een verhoogde kans op de ontwikkeling 
van depressie vanwege sociale stigmatisatie, verlies van vrienden aan AIDS, 
gebrek aan sociale ondersteuning en andere factoren. Depressie komt bij 22-45% 
(29) van de HIV-geïnfecteerde patiënten voor; bij de niet HIV-geïnfecteerde 
populatie komt depressie echter bij 13-20% voor. Er worden dus veelvuldig anti-
depressiva voorgeschreven aan HIV-geïnfecteerde patiënten. Verder komt epilepsie 
vaak voor bij HIV-infectie, ofwel als een direct effect van HIV of bij een bepaalde 
infectie (25;26). Er wordt geschat dat 11% tot 17% van de patiënten aanvallen zal 
ontwikkelen. Verder komt neuropatische pijn ook relatief veel voor bij de HIV-
geïnfecteerde patiënten, namelijk ongeveer bij 10% tot 15%. Een voorbeeld van een 
bijwerking die vaak optreedt bij het gebruik van proteaseremmers is het optreden 
van verhoogde cholesterol waarden (hyperlipidemie) (30), wat een verhoging van 
de kans op een hartinfarct tot gevolg heeft (31).
Ritonavir is een sterke remmer van cytochroom P450 (CYP450) enzymen als het in 
een hoge dosis van 400-600 mg tweemaal daags wordt gedoseerd (18;19). Verder 
versnelt het dan waarschijnlijk ook de afbraak van geneesmiddelen die via 
glucuronidering worden gemetaboliseerd (32;33). Omdat ritonavir deze enzymen 
en glucuronidering beïnvloedt en zelf ook wordt afgebroken door CYP450 enzymen, 
geeft het veel interacties (wisselwerking) met andere geneesmiddelen. De meeste 
onderzoeken hebben echter de interacties van ritonavir in een hoge dosis 
bestudeerd, terwijl de lage dosis waarin ritonavir tegenwoordig wordt toegepast 
minder goed is onderzocht.
Gebaseerd op het bovenstaande, hebben we de mogelijke interacties tussen 
ritonavir in combinatie met een andere proteaseremmers en lamotrigine 
(hoofdstuk 4) en paroxetine (hoofdstuk 5) onderzocht. Deze geneesmiddelen 
worden respectievelijk gebruikt voor epilepsie/neurogene pijn en depressie.
We hebben de combinatie lopinavir/ritonavir en lamotrigine onderzocht omdat 
lamotrigine wordt omgezet door glucuronidering, met name in het afbraakproduct 
lamotrigine-2N-glucuronide (34). Zoals hierboven beschreven kan een hoge 
dosering ritonavir de afbraak van geneesmiddelen via glucuronidering versnellen, 
maar er zijn geen gegevens wat het effect van een lage dosis ritonavir is.
De reden voor het onderzoeken van de combinatie van fosamprenavir/ritonavir met 
paroxetine was dat de bijsluitertekst van Norvir® (ritonavir) (18) beschrijft dat het 
gelijktijdig gebruik van geneesmiddelen die worden afgebroken door CYP2D6 
(zoals paroxetine) niet gecombineerd mogen worden met ritonavir tenzij er een 
afweging is gemaakt tussen het risico op interacties en het beoogde effect van de 
combinatie. De combinatie van een lage dosis ritonavir met paroxetine was echter 
tot dusver nog niet onderzocht.
In hoofdstuk 3 wordt het lipidenverlagende effect van rosuvastatine bij HIV-
geïnfecteerde patiënten met hyperlipidemie onderzocht. We hebben ervoor 
gekozen om dit onderzoek uit te voeren omdat statines de cholesterol waarden 
kunnen verlagen. De meeste statines kunnen echter niet worden gebruikt in 
combinatie met proteaseremmers vanwege het optreden van interacties middels 
het CYP450-systeem. Rosuvastatine wordt bijna niet via deze enzymen afgebroken 
en een interactie tussen rosuvastatine en lopinavir/ritonavir werd dus ook niet 
verwacht. Het gelijktijdig gebruik van rosuvastatine en lopinavir/ritonavir was 
voordat dit onderzoek werd opgestart niet onderzocht.
3. Ritonavir en resistentie
Het ontstaan van resistentie tegen proteaseremmers wordt beschouwd als een 
geleidelijke verhoging van de geneesmiddelconcentratie die nodig is om het virus 
te remmen. De effectiviteit van proteaseremmers kan daarom afhangen van de 
bloedspiegel van het middel in relatie tot de mate van resistentie van het virus voor 
het desbetreffende geneesmiddel (35;36). Het toenemen van de aanwezigheid van 
resistentie en kruisresistentie van HIV voor proteaseremmers is een grote 
belemmering voor het succesvol onderdrukken van vermeerdering van het virus op 
de lange termijn (37-39).
Het concept van de inhibitiecoëfficiënt is recentelijk geïntroduceerd bij de 
behandeling van HIV-geïnfecteerde patiënten (35;40-43). Dit concept past het idee 
dat het ontstaan van resistentie een relatief begrip is toe. Bij het gebruik van dit 
concept wordt verondersteld dat een verhoogde bloedspiegel van een anti-HIV 
geneesmiddel resistentie te boven kan komen zolang de bloedspiegels nog 
klinisch aanvaardbaar zijn en geen bijwerkingen veroorzaken. De genotypische 
inhibitiecoëfficiënt (GIQ) wordt uitgedrukt als de ratio van de plasma dalspiegel van 
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de proteaseremmer en het aantal relevante mutaties en kan worden gebruikt als 
voorspeller van het effect van de HIV-behandeling (42;44;45). 
Hoofdstuk 6 beschrijft een onderzoek dat is uitgevoerd om de relatie tussen de 
GIQ van lopinavir en het virologische effect te bepalen en om een richtwaarde voor 
de GIQ op te stellen. In hoofdstuk 7 is het gebruik van de GIQ van fosamprenavir 
in de dagelijkse praktijk gevolgd en beschreven.
Resultaten uit dit proefschrift
Hieronder zijn per hoofdstuk de resultaten van de onderzoeken van dit proefschrift 
weergegeven.
Deel I: Ritonavir en eenmaal daags doseren
In hoofdstuk 1 werd het eenmaal daags doseren van lopinavir/ritonavir bij HIV-
geïnfecteerde kinderen onderzocht. HIV-geïnfecteerde kinderen die goed 
reageerden op een tweemaal daagse therapie en een viral load van minder dan 
50 kopieën/mL hadden, kregen lopinavir/ritonavir 460/115 mg/m2 eenmaal daags 
in combinatie met zidovudine en lamivudine toegediend. Bij alle kinderen is een 
24-uurs farmacokinetische curve afgenomen, wat inhoudt dat er voor inname van 
lopinavir/ritonavir bloed werd afgenomen en tevens 2, 4, 6, 8, 12, 18 en 24 uur 
na inname van de medicatie. De dalspiegels van lopinavir, afgenomen 24 uur na 
inname, moesten minimaal 1,0 mg/L zijn. Deze target bloedspiegel was gebaseerd 
op eerder onderzoek. Onze resultaten lieten zien dat een dosering van eenmaal 
daags 460/115 mg/m2 lopinavir/ritonavir bij kinderen leidt tot bloedwaardes die 
gemiddeld gelijk waren aan die van volwassenen die 800/200 mg lopinavir/ritonavir 
innamen. De variabiliteit in bloedspiegels was echter bij kinderen veel groter. Vijf 
van de 7 (71%) kinderen jonger dan 3,5 jaar hadden subtherapeutische dalspiegels 
lager dan 1,0 mg/L, vergeleken met 5/12 (42%) in de groep kinderen die ouder was 
dan 3,5 jaar. Er is dus meer onderzoek nodig, vooral in jonge kinderen, om te 
bepalen of een hogere dosis van lopinavir/ritonavir, eenmaal daags gedoseerd, 
nodig is om de targetwaarde voor de dalspiegel te bereiken.
Hoofdstuk 2 focust op het virologische effect en de veiligheid van eenmaal daags 
doseren van lopinavir/ritonavir in HIV-geïnfecteerde kinderen. Het beschrijft de 12 
maanden follow-up van de kinderen die 460/115 mg/m2 lopinavir/ritonavir kregen, 
zoals beschreven in hoofdstuk 1. Er werd geconcludeerd dat versimpeling van de 
therapie van tweemaal naar eenmaal daagse inname van lopinavir/ritonavir zorgt 
voor voldoende onderdrukking van het virus. Bij de meeste kinderen jonger dan 
3,5 jaar moest echter de dosering worden verhoogd naar eenmaal daags 600/150 
mg/m2 lopinavir/ritonavir om voldoende hoge plasmaspiegels te bereiken. Verder 
werd gevonden dat lopinavir/ritonavir drank of capsules met voldoende voedsel 
moesten worden ingenomen om adequate bloedspiegels te bereiken. Omdat er 
een grote variabiliteit in bloedspiegels werd waargenomen in dit onderzoek, is het 
periodiek bepalen van de bloedspiegels (TDM) aan te raden. Tenslotte werd 
het eenmaal daags toedienen van lopinavir/ritonavir goed getolereerd. Er traden 
geen ernstige bijwerkingen op.
Deel II: Ritonavir en wisselwerking met andere geneesmiddelen
Hoofdstuk 3 beschrijft het pilot-onderzoek naar de combinatie van lopinavir/
ritonavir en rosuvastatine in HIV-geïnfecteerde patiënten. Dit onderzoek is 
uitgevoerd omdat, zoals hierboven beschreven, door het gebruik van lopinavir/
ritonavir een verhoging van cholesterol (hyperlipidemie) kan optreden bij HIV-
geïnfecteerde patiënten. HIV-geïnfecteerde patiënten die lopinavir/ritonavir 
gebruikten en een nuchter totaal cholesterol van 6,2 mmol/L hadden werden 
tijdens dit onderzoek 12 weken behandeld met rosuvastatine. De dosering van 
rosuvastatine werd opgehoogd afhankelijk van de respons op de lipiden-
huishouding. In periode 1 (week 1-4) werd gestart met de inname van eenmaal 
daags 10 mg rosuvastatine. In periode 2 (week 4-8) werd de rosuvastatine dosering 
opgehoogd naar 20 mg, als niet aan alle van de volgende vier criteria werd 
voldaan: totaal cholesterol <5,0 mmol/L, LDL-cholesterol <2,6 mmol/L, HDL-
cholesterol >1,0 mmol/L en triglyceriden <2,0 mmol/L. Aan het begin van periode 3 
(week 8-12) werden de waarden van de lipiden wederom beoordeeld. Als de 
waarden niet voldeden, werd de dosering van rosuvastatine verhoogd tot 40 mg. 
Als de streefwaarden wel bereikt waren, bleef de dosering gehandhaafd. Tijdens 
week 0, 4, 8 en 12 werden dalspiegels afgenomen van lopinavir/ritonavir en 
rosuvastatine. Uit dit onderzoek bleek dat rosuvastatine een effectieve statine is in 
HIV-geïnfecteerde patiënten met hyperlipidemie. Lopinavir/ritonavir bloedspiegels 
werden niet beïnvloed door rosuvastatine, terwijl we onverwachts 1,6-keer hogere 
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dalspiegels van rosuvastatine vonden vergeleken met gegevens bij gezonde 
vrijwilligers. Er werd geconcludeerd dat er meer onderzoek zal moeten plaats-
vinden om de farmacokinetiek en het effect van rosuvastatine en de veiligheid van 
de combinatie van rosuvastatine met lopinavir/ritonavir volledig in kaart te brengen. 
Tot die tijd moet de combinatie van rosuvastatine en lopinavir/ritonavir met voor-
zichtigheid worden gebruikt.
In hoofdstuk 4, werd het effect van lopinavir/ritonavir op de bloedspiegels van het 
anti-epilepticum lamotrigine en het belangrijkste afbraakproduct van lamotrigine, 
lamotrigine-2N-glucuronide, bepaald. Vierentwintig gezonde personen deden mee 
aan dit onderzoek en kregen lamotrigine (100mg tweemaal daags) in combinatie 
met lopinavir/ritonavir 400/100mg tweemaal daags. Afhankelijk van de verlaging 
van de dalspiegels van lamotrigine, werd het onderzoek ofwel gestopt of werd een 
dosisverhoging van lamotrigine toegepast. De resultaten van dit onderzoek lieten 
zien dat lopinavir/ritonavir de blootstelling aan lamotrigine verlaagd met 50%, waar-
schijnlijk door versnelling van de glucuronidering, wat het mechanisme is waardoor 
lamotrigine wordt gemetaboliseerd. Een dosisverhoging van 200% van de initiële 
lamotrigine dosis was nodig om gelijkwaardige bloedspiegels van lamotrigine te 
bereiken. Verder leek lamotrigine geen effect te hebben op de farmacokinetiek van 
lopinavir/ritonavir.
In hoofdstuk 5 werd de combinatie van het gebruik van het antidepressivum 
paroxetine en fosamprenavir/ritonavir onderzocht in gezonde vrijwilligers die 
paroxetine 20 mg eenmaal daags alleen of in combinatie met fosamprenavir/
ritonavir 700/100 mg tweemaal daags innamen. Fosamprenavir/ritonavir verlaagde 
de paroxetine blootstelling met 55%. Dit effect kan ten dele worden verklaard door 
eiwitverdringing van paroxetine. Naar onze mening, is deze interactie klinisch 
relevant en kan titratie naar een hogere dosis van paroxetine nodig zijn om 
voldoende effect van paroxetine te bereiken bij patiënten met een depressie.
Deel III: Ritonavir en resistentie
Uit de resultaten van hoofdstuk 6 blijkt dat de genotypische inhibitiecoëfficiënt 
(GIQ) en het aantal mutaties het effect van de behandeling met lopinavir/ritonavir 
kunnen voorspellen. Voor 95 HIV-geïnfecteerde patiënten die eerder op een 
proteaseremmer hadden gefaald, werd de GIQ (plasma dalspiegel / aantal 
mutaties) berekend voor lopinavir. De voorspellende waarde voor het effect van de 
HIV-behandeling van de GIQ was gelijk aan die van het aantal mutaties. Het is 
echter zo dat de GIQ te veranderen is door dosisverhoging van lopinavir (resulterend 
in hogere bloedspiegels en een hogere GIQ) en het aantal mutaties daarentegen 
echter niet.
Hoofdstuk 7 beschrijft het gebruik van de GIQ in de dagelijks praktijk bij HIV-
geïnfecteerde patiënten die eerder op proteaseremmers therapiefalen lieten zien en 
startten met het gebruik van fosamprenavir/ritonavir. In dit hoofdstuk worden de 
casussen beschreven van 6 patiënten. Na bepaling van de bloedspiegel van 
fosamprenavir werd de GIQ (dalspiegel van amprenavir in ng/mL / aantal voor 
amprenavir relevante mutaties) berekend. Als de GIQ lager was dan 750, werd 
dosisverhoging geadviseerd. In dit hoofdstuk worden de relatie tussen de GIQ en 
de effectiviteit van de behandeling, problemen rond de dosisverhoging van fosam-
prenavir/ritonavir en de interactie tussen lopinavir/ritonavir en fosamprenavir 
besproken.
Algemene discussie
Het proefschrift wordt afgesloten met een discussie over onverwachte interacties, 
interacties van ritonavir met andere geneesmiddelen (hoge versus lage dosering 
ritonavir), onderzoek met patiënten versus gezonde vrijwilligers, onderzoek met 
kinderen, het belang van de GIQ en tenslotte het gebruik van ritonavir als booster.
Uit dit proefschrift komt naar voren dat er meer onderzoek nodig is om de 
complexiteit van mogelijke interacties met ritonavir-bevattende HIV-therapie te 
ontrafelen. Bij het ontwerpen van toekomstige onderzoeken, moeten alle voor- en 
nadelen van het uitvoeren van onderzoek in gezonde vrijwilligers versus patiënten 
worden afgewogen, net als het includeren van vrouwen in de onderzoekspopulatie. 
Er wordt aangeraden om meer farmacokinetisch onderzoek bij kinderen uit te 
voeren om de optimale dosering van antiretrovirale geneesmiddelen voor deze 
patiëntengroep te bepalen. Verder wordt een belangrijke rol toegekend aan het GIQ-
concept vanwege het combineren van kennis van verschillende disciplines, zoals 
virologie en farmacokinetiek. Tenslotte wordt gesuggereerd om de ideale booster te 
ontwikkelen met specifieke remming van CYP3A4 en afwezigheid van bijwerkingen.
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Dit was het dan… de laatste woorden kunnen op papier worden gezet. De tijd is 
omgevlogen! Alweer zo’n 5 1/2 jaar geleden ben ik begonnen met de opleiding tot 
ziekenhuisapotheker bij de afdeling Apotheek/Klinische Farmacie van het 
UMC St Radboud. Een jaar later kwam voor mij de mogelijkheid om de opleiding 
te combineren met promotieonderzoek waar al lang mijn interesse naar uitging. 
Op sommige momenten was het combineren van onderzoek en opleiding flink 
aanpoten, maar het is het zeker waard geweest en ik heb er absoluut van genoten!
Het uitvoeren van het onderzoek en schrijven van het proefschrift was niet mogelijk 
geweest zonder hulp van velen. Hieronder wil ik een aantal personen specifiek 
bedanken voor hun bijdrage.
De onderzoeken hadden niet kunnen plaatsvinden zonder deelname van de patiënten 
en vrijwilligers. Ik wil hen dan ook als eerste hartelijk danken voor hun deelname!
Prof. dr. Hekster, promotor, beste Chiel, vanaf het begin dat ik gestart ben met de 
opleiding tot ziekenhuisapotheker heb je me als mijn opleider op mijn gemak 
gesteld. Jouw continue aandacht voor het gevoel van mensen en de communicatie 
tussen personen vind ik erg bijzonder. Ik heb hierdoor veel over mezelf geleerd en 
ook hoe ik anderen wil en kan begeleiden. Voor wat betreft het onderzoek was je 
steeds op de achtergrond aanwezig en was je altijd bereid om de onderzoeks-
voorstellen en manuscripten kritisch en uitgebreid te beoordelen. Dank voor dit alles!
Dr. Burger, copromotor, beste David, ik wil je bedanken voor de fantastische 
begeleiding die je me hebt gegeven. Jouw deur stond altijd voor me open en ik heb 
je manier van begeleiden altijd als bijzonder prettig ervaren. Je hebt me vrijgelaten 
om me als onderzoeker te ontwikkelen, maar stond me altijd met raad en daad bij. 
Ik hoop nog lang met je mogen samenwerken en hopelijk in de toekomst ook nog 
onderzoek met je te doen. Verder heb je me natuurlijk enthousiast gemaakt voor 
NEC, waardoor ik toch regelmatig met jou op de tribune zit met een rood/zwart/
groene pruik!
Dr. Koopmans, copromotor, beste Peter, jij was als betrokken arts de link met de 
kliniek en dus met de patiënten en vrijwilligers. Jij keek steeds met een klinische 
blik naar de onderzoeksvoorstellen en manuscripten, waardoor goede discussies 
ontstonden en de stukken werden verbeterd. Verder kijk ik met plezier terug naar 
de jaarlijks terugkerende barbecue bij jou thuis. Bedankt dat je mijn co-promotor 
wilde zijn!
Oud-collega HIV-onderzoekers: Rob, Alina, Charles en Jackie, jullie gingen mij 
voor in het promotietraject en ik heb van al jullie tips en ervaringen gebruik mogen 
maken. Dank voor de gezelligheid! Rob en Charles, ik wil jullie veel succes wensen 
met de verdere ontwikkeling van jullie nieuwe onderzoeken! Alina en Jackie, jullie zijn 
niet verder gegaan met onderzoek binnen onze afdeling of in de HIV-wereld, maar 
we hebben toch contact gehouden en ik hoop dat dit in de toekomst ook zo blijft!
Collega-promovendi: Rafaella, Hanneke, Roger en Matthijs, ik wil jullie veel succes 
wensen met het (afronden van het) onderzoek en ik hoop dat jullie er net zoveel van 
zullen genieten als ik dat heb gedaan. We komen elkaar nog wel tegen tijdens de 
wekelijkse HIV-koffie (dat blijft voor mij toch echt de juiste naam)!
Remco de Jong, afdelingshoofd Apotheek/Klinische Farmacie en Ellen Frankfort, 
hoofd Ziekenhuisapotheek, jullie hebben mij, samen met de staf, de mogelijkheid 
geboden om naast de opleiding tot ziekenhuisapotheker te starten met onderzoek 
en het ZAPIKO-traject. Hierdoor heb ik me (en mijn time-management) verder kun-
nen ontwikkelen en mijn interesse in het onderzoek kunnen verdiepen. Ik ben erg 
blij dat mij deze mogelijkheid is geboden!
De andere ziekenhuisapothekers en ZAPIO’s wil ik bedanken voor hun flexibiliteit 
en voor het begrip dat ik steeds kreeg tijdens de switch tussen de opleiding en het 
onderzoek.
De analisten van het Laboratorium Klinische Farmacie ben ik veel dank verschul-
digd voor het uitvoeren van de vele metingen. Ik heb berekend hoeveel monsters 
gemeten zijn voor de verschillende onderzoeken en dat zijn er maar liefst ongeveer 
2500! Verder wil ik Marga, Noor en Corrien specifiek bedanken voor het opzetten 
van de analysemethoden voor de bepaling van respectievelijk lamotrigine, 
lamotrigine-2N-glucuronide en paroxetine. 
Alle andere collega’s van AKF wil ik bedanken voor de prettige samenwerking van 
de afgelopen jaren en de interesse in mijn promotietraject.
De HIV-consulenten, infectiologen (i.o.) en de virologen van het UMC St Radboud 
wil ik bedanken voor de overdracht van hun kennis en voor de gezelligheid tijdens 
de patiëntenbesprekingen en vergaderingen.
Marjolein Bosch, HIV-consulente, wij hebben tijdens het onderzoek in Keulen het 
nuttige met het aangename gecombineerd, wat erg gezellig was (wat een wereld-
stad is het, hè?). Ik hoop dat we de lunches en borrels er ook in houden!
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De medewerkers van het Clinical Research Center Nijmegen (waar ik menig uurtje 
tijdens de vrijwilligersstudies heb doorgebracht) wil ik bedanken voor hun hulp bij 
het uitvoeren van het onderzoek bij de gezonde vrijwilligers.
Lara Dawood, stagiaire Farmacie van de Universiteit Utrecht, wil ik bedanken voor 
haar inzet tijdens het LOLA-onderzoek, dat we ook het LARA-onderzoek 
(The effect of LopinAvir/Ritonavir on the pharmacokinetics of lAmotrigine in healthy 
subjects) hadden kunnen noemen…
Het onderzoek was niet mogelijk geweest zonder de prettige samenwerking met de 
volgende disciplines: de infectiologen en HIV-consulenten van het Sophia 
Kinderziekenhuis, het LUMC, het AMC en het St Elisabeth Ziekenhuis.
In het bijzonder wil ik Gwenda Verweel (arts Sophia Kinderziekenhuis) en Jolanda 
Hoefnagel (arts-assistent afdeling Medische Microbiologie UMC St Radboud) 
bedanken voor het opzetten en uitvoeren van de onderzoeken respectievelijk met 
kinderen en de GIQs. Jullie hebben mijn kennis van beide vakgebieden vergroot! 
Bedankt voor de goede samenwerking!
Die Kollegen aus Köln und Bonn, möchte ich bedanken für die Zusammenarbeit 
und Gastfreundschaft. Ich danke Ihnen für die Beteiligung an die Rosalka Studie. 
Ich habe mich immer gefreut auf die BONUS-meetings!
Verder wil ik de leden van de manuscriptcommissie, Prof. dr. Van der Meer, 
Prof. dr. Egberts, en dr. Kroon, bedanken voor het bestuderen en beoordelen van 
dit proefschrift.
Familie en vrienden, ik wil jullie bedanken voor de interesse in mijn werk en 
promotietraject en voor de gezelligheid en afleiding waarvoor jullie in de afgelopen 
jaren hebben gezorgd.
Hanneke en Audrey wil ik alvast bedanken voor het feit dat ze mijn paranimfen 
willen zijn.
Hanneke, we kennen elkaar al vanuit Utrecht, waar we huisgenoten waren. Ik ben je op 
de voet gevolgd naar Nijmegen en nu zijn we zelfs straatgenoten in Malden. Je bent 
een goede vriendin en ik hoop dat we elkaar in de toekomst ook blijven volgen.
Audrey, voor mij ben je een goede collega waar het zowel op zakelijk als op 
persoonlijk vlak goed mee klikt. Verder wordt het nu toch echt eens tijd om die 
meeting in “Paris” te gaan houden! En laten we de feestjes en concerten van 
Jan S. erin houden…
Papa en mama, zolang als ik me kan herinneren hebben jullie mij aangemoedigd 
in mijn studie en werk, me gesteund in mijn beslissingen en altijd voor me klaar 
gestaan. Bedankt hiervoor!
Armand, je bent voor mij de rots in de branding geweest en degene die me afremde 
als ik het echt te bont maakte met de lange werktijden. Ik kon het toen niet altijd 
waarderen, maar ben je er achteraf zeker dankbaar voor en ook voor de steun die 
je me steeds hebt gegeven. Jij was er voor mij om alles met een goede dosis 
humor af en toe eens flink te relativeren. Nu is dit hoofdstuk af en gaan we op voor 
een nieuw avontuur en een ander groot feest…
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Manon Jantine van der Lee werd geboren op 17 mei 1976 te Utrecht. Ze groeide op in 
Maarssen en behaalde in 1994 het VWO diploma aan het Christelijk Gymnasium te 
Utrecht. Aansluitend werd begonnen met de studie Farmaceutische Wetenschappen 
aan de Universiteit Utrecht, alwaar in november 1999 het doctoraal-examen en in 
mei 2002 het apothekers-examen werden behaald. In juli 2002 begon ze met de 
opleiding tot ziekenhuisapotheker bij de afdeling Apotheek/Klinische Farmacie van 
het UMC St Radboud te Nijmegen. Vanaf juli 2003 werd de opleiding tot ziekenhuis-
apotheker, die eind december 2007 zal worden afgerond, gecombineerd met 
promotieonderzoek.
Manon van der Lee is vriendin van en samenwonend met Armand van Oosterwijck.

